The role of the killer immunoglobulin-like receptor in haematological malignancies and stem cell transplantation by Gabriel, Ian
1 
 
 
 
 
 
 
The role of the killer immunoglobulin-like receptor in 
haematological malignancies and stem cell transplantation 
 
 
 
Thesis of PhD 
August 2012 
 
 
 
Dr Ian H Gabriel MB BS BSc (Hons) MRCP (UK) FRCPath  
Department of Investigative Science; Haematology 
Imperial College, London, United Kingdom 
 
 
 
 
 
Supervisor   Professor Katayoun Rezvani  MBBS, PhD, FRCPath 
              Co-supervisor        Professor Letizia Foroni   MD, PhD, FRCPath 
 
 
2 
 
Contents 
       Page  
 
Abstract         14  
Dedication        15  
Declaration        16 
Abbreviations         17 - 21 
Chapter 1 Introduction       22  
1.1  Natural Killer Cells       22– 25 
1.2   Killer Immunoglobulin Receptors     25 – 27 
1.2.1     Killer Immunoglobulin Receptors and T-cells   27 – 28 
 
1.3  Missing-Self and Self-Tolerance     28 – 29 
1.3.1  NK cell Licensing and Self-Tolerance     30 – 31 
 
1.4  Killer Immunoglobulin haplotype     33 –34 
 
1.5  Non-KIR NK receptors      35 – 36 
 
1.6  Killer Immunoglobulin Receptors and Human Disease  36 – 37 
1.6.1  NK cells and malignancy       37 – 38 
1.6.2  Killer Immunoglobulin Receptors and malignancy   38 – 40 
1.6.3  Killer Immunoglobulin Receptors and  
haematological tumours      40 – 42 
1.6.4  NK cells and treatment outcome in  
haematological malignancies     42 – 44 
 
1.7  Chronic Myeloid Leukaemia      44 – 45 
1.7.1  The role of NK cells in Chronic Myeloid Leukaemia   45 – 51 
 
1.8  Haematopoietic Stem cell Transplantation    51 – 53 
3 
 
 
1.9  NK cells and Autologous Stem cell Transplantation (ASCT) 53 
1.9.1  Natural Killer cells and ASCT      54 
1.9.2  Absolute lymphocyte count and ASCT outcome   55 – 56 
1.9.3   KIR-ligand mismatch in ASCT      56 
 
1.10 NK cells and Allogeneic Stem Cell Transplant (allo-SCT)  57 – 58 
1.10.1  Haplo-identical Allogeneic Stem Cell Transplant   58– 61 
1.10.2  Killer Immunoglobulin Receptors and unrelated allo-SCT  61 – 63 
1.10.3  KIR haplotype and allogeneic stem cell transplant   63 
1.10.4  Killer Immunoglobulin Receptors and reduced  
intensity allo-SCT       65 – 66 
1.10.5  Breaking of self tolerance following all-SCT    66 
 
1.11  The role of NK cells in graft versus host disease   67 – 70 
 
1.12  Multiple Myeloma       71 – 72 
 
1.13  Killer Immunoglobulin Receptors and Infection   72 
1.13.1  Viral infections       72 
1.13.2  Human Immunodeficiency virus     72 – 75 
1.13.3  Hepatitis        76 – 77 
1.13.4  Cytalomegalovirus       77 
1.13.5 Other viral infections       78 
1.13.6  Killer Immunoglobulin Receptors and non-viral infections  78 – 79 
 
1.14  NK cells and Bacteria       79 – 80 
1.14.1  Killer Immunoglobulin Receptors and bacterial infection  81 – 84 
 
Hypothesis         85 
 
Chapter 2 Materials and Methods      86 
4 
 
2.1 Sample Collection       86 – 88 
2.2 DNA Concentration Determination     88 – 89 
2.3 Killer Immunoglobulin Receptor Genotyping    89 – 90 
2.4 KIR Haplotype Determination      91 
2.5 HLA Typing        92 – 93 
2.6 Processing, freezing and thawing of PBMC    94 
2.6.1 Isolation and enumeration of PBMC     94 
2.6.2 Cell Freezing        95 
2.6.3 Cell Thawing        95 
2.7 Natural Killer cell surface phenotyping     95 – 96 
2.8 Intracellular Cytokine staining      96 – 98 
2.9 Heat Shock Protein stimulation of PBMC    98 -  99–  
2.10 Natural Killer Cell expansion and selection    101 
2.10.1 Natural Killer Cell expansion      101 – 102 
2.10.2 Purification of NK cells from PBMC     102 
2.10.3 Statistics 
 
Chapter 3 Killer Immunoglobulin-like Receptors and Chronic myeloid Leukaemia   
         105  
 
3.1 Introduction        105 – 106 
3.2 Current Management of CML      107 – 109 
3.3 The CML Initiating or Leukaemia Stem cell    110 – 111 
3.4 Patient characteristics and treatment     112– 113 
3.4.1 Discovery Sample: Imperial Cohort                                                112 – 114 
3.4.2 Validation sample        114 
 
3.5 Statistical Methods                                                                               115 
 
        
3.6.1 KIR genotype and CCyR, PFS and OS     116 – 121 
 
5 
 
3.7 Validation Study        121 – 123 
 
3.8 Influence of KIR2DS1 and HLA-C on CCyR    123 – 124 
 
3.9 Discussion        125 – 130 
 
Chapter 4 Killer Immunoglobulin-like Receptors and  
Autologous Stem cell transplantation     131 
4.1 Introduction        131 – 135 
4.2 Results        136 
4.2.1 Patient characteristics              136 
4.2.2 Cytogenetics        137 
4.2.3 Serum Markers        137 
4.2.4 Transplant Characteristics      138 
4.2.5 KIR genotypes and PFS             139 – 150 
 
 
4.3 Discussion                150 – 157 
 
Chapter 5 Killer Immunoglobulin-like Receptors and graft versus host disease   
         158  
 
5.1.1 Acute graft versus host disease     158– 160 
5.1.2 Prophylaxis of GvHD       160 – 163 
 
5.2 The role of KIR in acute graft versus host disease  163 – 164 
5.2.1.Patient characteristics       164 
 
5.3 Results         165 
 
6 
 
5.4 Graft Versus Host Disease Pathophysiology    171 - 173 
 
5.5  KIR2DS2/DL2 expression on lymphocyte subsets   173 – 178 
 
 
5.6 Tumour necrosis factor-alpha and acute GvHD    179 – 181 
5.6.1 Results        181 – 187 
 
5.7 Interferon and GvHD Pathogenesis     188 – 189 
5.7.1 Results         189 – 197 
 
5.8 Interleukin- 2 and Acute Graft versus Host Disease   197 
5.8.1 Results         198 – 201 
5.8.2 IL-2 and KIR Discussion       201 
5.8.2.1 Regulatory T-cells      202 
5.8.2.2 Interleukin-2 and T-regs     202 
5.8.2.3 Regulatory T-cells and Acute  
Graft versus Host Disease      203 – 204 
5.8.3 IL-2 Conclusion        204 – 205 
 
5.9 MIP1 proteins and GvHD Pathogenesis     206 – 208 
5.9.1 Results         208 – 215 
5.9.2 Conclusion        215 – 216 
 
5.10 Heat shock protein and GvHD      217 
5.10.1 Results         218 – 224 
5.10.2 Conclusion        224 
 
5.11 Chapter 5 Conclusion       225 – 228 
Chapter 6 Discussion        229 
Acknowledgements        239 
References         240 - 309 
7 
 
Figures and Tables  
 
          Pages  
   
Figures  
Figure 1.1 The balance between inhibitory and activatory KIR determines the   
           32 
overall cytotoxic response.  
 
Figure 1.2: The membrane bound killer Immunoglobulin like receptors (KIR).   35  
 
Figure 1.3: Schematic view of the KIR haplotypes A and B and the    64 
centromeric and telomeric motifs.  
 
Figure 2.1: A. Example of a photograph of gel electrophoresis of PCR for KIRs  90-91    
     B.KIR typing worksheet from kit.  
 
Figure 2.2: Simulation of peripheral blood NK cells with incremental   99  
doses of heat shock protein 60 (HSP-60) and IFN-  expression.  
 
Figure 2.3: Example of NK cell following Selection using Miltenyi NK   103 
negative selection cocktail and magnetic beads.  
 
Figure 3.1. Schematic representation of the randomisation of patients entered into the 
multi-centre STI571 Prospective International Randomised Trial (SPIRIT-1).  114 
 
Figure 3.2. The 2-year probabilities of CCyR and OS according to KIR2DS1   119 
genotype in patients with CML in chronic phase treated with Imatinib as  
first line therapy.  
 
Figure 3.3. The 2-year probabilities of CCyR and OS according to the KIR2DS1  123-124 
genotype in the CML validation sample.  
8 
 
 
Figure 3.4 Association between KIR2DS1/KIR2DL1 and HLA-C genotype and  125   
the 2-year probability of Complete cytogenetic response.  
 
Figure 4.1 The presence of KIR3DS1 shortens time to progression following ASCT 143  
for myeloma in patients with good risk disease.  
 
Figure 4.2. The importance of HLA-Bw4 status in good risk KIR3DS1+ patients  146 
undergoing ASCT for myeloma.  
 
Figure 4.3: Proposed explanation for differing PFS in myeloma patients   153 
undergoing ASCT based on HLA-Bw4 genotype.  
 
Figure 4.4: The proposed effector functions of an unopposed KIR3DS1   155 
signaling pathway.  
 
Figure 5.1: Identification of lymphocyte subsets by differential surface staining  163  
with anti CD56 and CD3 monoclonal antibodies.  
 
Figure 5.2: Example of KIR2DS2/DL2 expression on lymphocyte subsets.   175  
 
Figure 5.3: KIR2DS2/DL2 expression in CD8+ and CD4+ T-cell subsets.   177  
 
Figure 5.4: (A) NK cells are divided into two distinct subsets based on expression  178  
of CD56 (i) high (CD56 high) or (i) low (CD56 dim).  
(B) Example of differential expression of KIR2DS2/DL2 within CD56 bright  
and CD56 dim NK subsets.  
 
Figure 5.5: The proposed pathophysiology of acute graft versus host disease  172 
 
Figure 5.6: Intracellular expression of TNF-α in T-cells following stimulation  182  
with PMA and Ionomycin according to KIR2DS2/DL2 expression status.  
9 
 
 
Figure 5.7: The percentages of T-cells expressing intracellular TNF-α in   184  
healthy controls according to KIR2DS2/DL2 surface expression status.  
 
Figure 5.8: Intracellular expression of TNF-α in NK-cells following stimulation  185  
with PMA and Ionomycin according to KIR2DS2/DL2 expression status.  
 
Figure 5.9: The percentages of NK-cells expressing intracellular TNF-α in   186  
healthy controls according to KIR2DS2/DL2 surface expression status.  
 
Figure 5.10: Intracellular expression of IFN-  in T-cells following stimulation  163  
with PMA and Ionomycin according to KIR2DS2/DL2 expression status.  
 
Figure 5.11: The percentages of T-cells expressing intracellular TNF-α in   192 
healthy controls according to KIR2DS2/DL2 surface expression status.  
 
Figure 5.12: Intracellular expression of IFN-  in NK-cells following stimulation  193  
with PMA and Ionomycin according to KIR2DS2/DL2 expression status.  
 
Figure 5.13: The percentages of NK-cells expressing intracellular IFN-  in   194  
healthy controls according to KIR2DS2/DL2 surface expression status. 
 
Figure 5.14: Interleukin-2 expression of peripheral blood mononuclear   198  
cells following stimulation with PMA and Ionomycin. IL-2 is only expressed  
by the CD3+ fraction.  
 
Figure 5.15: Intracellular expression of interleukin-2 in T-cells following   199 
stimulation  with PMA and Ionomycin.  
 
Figure 5.16: The percentage of IL-2 production in T-cells of healthy controls  200 
according to KIR2DS2/DL2 surface expression status 
 
10 
 
Figure 5.17: Intracellular expression of MIP-1  in T-cells following stimulation  209  
with PMA and Ionomycin according to KIR2DS2/DL2 expression status.  
 
Figure 5.18: The percentages of T-cells expressing intracellular MIP-1  in   210  
healthy controls according to KIR2DS2/DL2 surface expression status.  
 
Figure 5.19: Example of T-cell MIP-1  baseline expression (unstimulated) in  211 
 a healthy volunteer control.  
 
Figure 5.20: Example of MIP-1  expression in NK cells of a healthy volunteer 212 
following stimulation with PMA and Ionomycin according to KIR2DS2/DL2  
surface expression status.  
 
Figure 5.21: Intracellular expression of MIP-1  in T-cells following stimulation  214 
 with PMA and Ionomycin according to KIR2DS2/DL2 expression status.  
 
Figure 5.22: Comparison of the percentage MIP-1  expression between the  214 
KIR2DS2/DL2 positive and negative T-cells within healthy volunteers.  
 
Figure 5.23: T-cells negative for CD28 express significantly less KIR2DS2/DL2/  222 
 than CD28null T-cells 
 
Figure 5.24: Intracellular expression of IFN-  in T-cells following stimulation  224 
 with heat shock protein 60KDa (HSP-60) in a KIR2DS2/DL2 positive healthy control.  
 
Figure 6.1. Example of KIR2DS1 NK expansion in a patient with CML with suboptimal reponse 
to TKI therapy.  
 
 
 
 
11 
 
 
 
Tables  
 
Table 1: The Killer Immunoglobulin receptors (KIR) and their known   27 
HLA Class Ia ligands  
 
Table 2.1: Monoclonal antibodies (Mab) used in both surface and    100 
intracellular cytokine analysis.. 
 
Table 3.1: The Leukaemia.Net criteria for defining advanced phase CML   105 
 
Table 3.2: The European Leukameia.Net definitions of optimal, sub-optimal  107 
and treatment failure following instigation of Imatinib mesylate therapy in patients  
with chronic myeloid leukaemia in chronic phase  
 
Table 3.3: Characteristics of patients with chronic myeloid leukaemia who  113 
received 400mg Imatinib mesylate as first line treatment (discovery sample). 
 
Table 3.4: Association between individual KIRs and achievement of CCyR,   117 
progression free survival and overall survival at 2 years on univariate analysis.  
 
Table 3.5: The relative risks of non-achievement of CCyR or disease   121 
progression on multivariate analysis. 
 
Table 4.1: Patient Characteristics of multiple myeloma patients undergoing  139 
autologous stem cell transplantation. 
 
Table 4.2: Association between individual KIRs and progression-free survival on  141 
univariate analysis in multiple myeloma patients undergoing autologous stem cell 
transplantation. 
 
12 
 
Table 4.3: Multivariate analysis of factors associated with PFS after ASCT for  145 
myeloma       
 
Table 4.4: Association between KIR3DS1, KIR3DL1, and HLA-Bw4 on PFS following ASCT for 
multiple myeloma          149 
 
Table 5.1: The consensus group staging and grading of acute GvHD following  allogeneic stem 
cell transplantation. (Prezpiorka et al Bone Marrow Transplant 1994).    164 
 
Table 5.2: The frequencies of the killer immunoglobulin-like receptor genes in the KIR 
repertoires of donors of peripheral blood stem cells for patients transplanted for chronic 
myeloid leukaemia in chronic phase.        169 
 
Table 5.3: KIR2DL2/DS2 status of patients with CML in CP who developed    170 
 acute GvHD following sibling allogeneic stem cell transplantation 
 
Table 5.4: A. KIR2DL2/DS2 expression in lymphocyte subsets in healthy volunteer 176 
controls  
    B shows the percentages of CD8 and CD4 T-cell subsets with KIR2D expression.  
 
Table 5.5: The percentages of T-cells expressing intracellular TNF-α in healthy   184 
controls according to KIR2DS2/DL2 surface expression status.  
 
Table 5.6: The percentages of NK-cells expressing intracellular TNF-α in    186  
healthy controls according to KIR2DS2/DL2 surface expression status.  
 
Table 5.7: The percentages of T-cells expressing intracellular IFN-  in    193 
healthy controls according to KIR2DS2/DL2 surface expression status.  
 
Table 5.8: The percentages of NK-cells expressing intracellular IFN-  in    194 
 healthy controls according to KIR2DS2/DL2 surface expression status.  
 
13 
 
Table 5.9: The percentage of IL-2 production in T-cells following stimulation   200 
with PMA and Ionomycin according to KIR2DS2/DL2 surface expression status.   
 
Table 5.10: The percentages of T-cells expressing intracellular MIP-1  in    210 
 healthy controls according to KIR2DS2/DL2 surface expression status.  
 
Table 5.11: The percentage of MIP-1  expression in NK cells following stimulation  213 
with PMA and Ionomycin, according to KIR2DS2/DL2 surface expression status.  
 
Table 5.12: The percentage of both CD4+ and CD8+ T-cells co-expressing CD28   222 
and which are CD28null were determined using surface staining. In both subsets  
the percentage of cells also surface positive for KIR2DS2/DL2 was determined.  
 
Table 5.13  Summary of the differential cytokine production of both KIR2DS2 positive and  
negative T-cell subsets .          217 
 
 
 
 
 
 
 
 
 
 
14 
 
 
 
Abstract  
 
 
 
Natural killer cells (NK) cells are marrow-derived cytotoxic lymphocytes, representing 5-18% 
of human blood mononuclear cells. NK cells are an important component of the innate 
immune system in humans playing important roles in both the elimination and control of 
tumour metastases and leukaemia. NK activity against target cells is determined, by the net 
balance of the transmitted intracellular signals from both activating (pro-cytotoxic) and 
inhibitory (anti-cytotoxicity) cell surface receptors. One major class of such receptor is the 
Killer immunoglobulin-like receptors (KIRs), which were investigated in detail in this study.  
 
Using KIR genotype and HLA typing, I found that the KIR2DS1 positive genotype was an 
independent predictor for failure to achieve complete cytogenetic response (CCyR) and for 
inferior progression-free survival (PFS) in patients with chronic myeloid leukaemia in first 
chronic phase disease (CML-CP) treated with tyrosine kinase inhibitors. This was validated in 
a further 174 CML-CP patients and demonstrated therefore that KIR-HLA immunogenetics is 
a novel prognostic tool for patients with CML in CP. Following this finding, I hypothesised 
that as KIR-HLA genotype can predict for outcome in haematological malignancy, then their 
influence might be greatest at a time of relative NK cell predominance, such as in the 
immediate post transplant setting. I therefore went on to investigate and demonstrate in 
the malignancy multiple myeloma (MM), that KIR3DS1 positivity may identify patients at 
greater risk of progression after an autologous stem cell transplant, and further that there 
was a significant association of the KIR2DS2/DL2 genotype with acute graft-versus host 
disease (aGVHD) following allogeneic stem cell transplant. I finally demonstrate that the 
association of KIR2DS2/DL2 with GvHD is likely due to the demonstration that KIR2DS2/DL2 
expressing cells have a significantly greater capacity for the production of IFN-  and TNF- , 
which are directly associated with aGvHD with a relative reduction in IL-2 production which 
is important for regulatory T-cell development.  
 
In conclusion my data show that KIR genotype predicts both the response to targeted 
therapy in CML, that the role of KIR is also important in disease control during 
haematopoeitic reconstitution following transplant and that certain KIR molecules associate 
with increased incidence and severity of aGvHD and this may be mediated by the increased 
propensity to produce TNF-α, IFN-γ, MIP1- , and MIP-1  and a reduction in IL-2.  
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Chapter 1 Introduction   
 
 
1.1 Natural Killer Cells 
Natural killer cells (NK) cells are marrow derived cytotoxic lymphocytes, representing 
between 5 to 18% of human peripheral blood mononuclear cells (PBMC) (Gregoire 2007)1. 
NK cells can be broadly defined phenotypically by the surface expression of CD56 (Neural 
Cell Adhesion Molecule: N-CAM) and the lack of CD3 expression (CD56+, CD3-), and have 
the morphology of large granular lymphocytes (LGL)2, -4. The NK cell subset represents an 
important component of the innate immune system in humans5. Indeed NK cells play a 
crucial first line defence role in the early control of viral infection and in immuno-
surveillance for malignant tumour cells2.  
Consistent with their role as an important mediator of innate immunity, NK cells are widely 
distributed in both lymphoid and non-lymphoid tissues2, 6. Furthermore, NK cells can 
uniquely infiltrate the uterus and have an important role in the development and protection 
of the embryo and foetus (Moffet-King 2002)7. NK cell deficiency is associated with 
overwhelming and fatal infections in childhood8. 
Natural Killer cell effector function is achieved through a variety of mechanisms analogous 
to cytotoxic CD8+ T-lymphocytes. These including the directed exocytosis of secretory 
lysosomes containing lytic proteins (including Perforin and GranzymeB) which results in 
cytolysis of target cells, and Fas ligand (CD95L) which results in activation of the death 
receptor pathways and subsequent cell death, or through the release of cytokines (CK)9-11. 
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Activated NK cells produce TNF-  resulting in promotion of a pro-inflammatory cytokine 
cascade, and IFN- , which is important in shaping the immune response. NK derived IFN-  
promotes T-helper 1 (Th1) cell differentiation, leads to up-regulation of antigen presenting 
cell (APC) MHC class-I expression and cytokine production, activates macrophage killing of 
intracellular pathogens, and has anti-viral and tumour growth effects12-15. In addition NK 
cells express CD16 (Fc RIIIA, the low-affinity IgG Fc receptor) (co-expressed on CD56dim 
cells, see below), which binds the Fc constant region of immunoglobulin when bound to the 
cell surface. This interaction results in NK degranulation and thus antibody-dependent 
cellular cytotoxicity (ADCC)16. NK cells have also been shown to further influence the 
immune response by limiting the expansion and function of CD4+, CD25+ FoxP3+ T-
regulatory cells (T-regs)17.  
NK cells can be broadly divided into two distinct subsets, based on the intensity of CD56 
surface expression. The majority of human NK cells express surface CD56 with low intensity 
(CD56 dim) and represent 90% of peripheral blood (PB) and splenic NK cells, whereas CD56 
high expressing NK cells (CD56 Bright) are predominately nodal in distribution (Vivier 
2008)18-20. Evidence suggests that CD56 expression intensity correlates with cytotoxic 
function. CD56 bright cells have been shown to be more potent producers of cytokines, 
which occurs within minutes of activation, and have potent immunoregulatory properties, 
but conversely have less cytotoxic function with reduced capability to kill tumour cells as 
compared to the more predominant CD56dim, CD16+ subset2. These functions are however, 
not strictly confined to each respective subset and a certain degree of functional overlap 
exists. It is believed that NK cell development occurs in the secondary lymphoid tissue and 
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that the CD56 dim subset is derived from the CD56 bright. When determining function of NK 
cells, a comparison between these two important populations should be sought.  
Although NK cells share common killing mechanisms with CD8+ T-cells, their activity is 
controlled by a limited repertoire of germ-line encoded receptors that do not undergo 
somatic recombination. Therefore, unlike cytotoxic T-cells (or B-lymphocytes), NK cells do 
not exhibit the antigen specificity, nor require the prior stimulation by exposure to major 
histocompatibility complex (MHC) expressed antigen, for functional competence21. NK cells 
requirement for clonal expansion, or antibody recognition. Whilst this places NK cells as the 
first line of defence, this immediate response capacity could present a danger to healthy 
cells in the event of inappropriate NK cell activation. Therefore, despite this non-MHC 
restriction, the cytotoxic activity of NK cells is tightly regulated allowing them to distinguish 
between healthy autologous cells and virally infected, transformed (target), or allogeneic 
cells16, 22, 23.  
 
The NK cell detection system includes a variety of cell surface receptors. These include 
activating and inhibitory receptors, the engagement of which with their cognate ligands 
results in transmission of downstream pro-cytotoxic signals or signals, which inhibit 
cytotoxic function respectively. The overall balance between these positive and negative 
signals regulates NK cell activity. Thus, the integration of antagonistic pathways upon 
interaction with neighbouring cells governs the dynamic equilibrium regulating NK cell 
activation and dictates whether or not NK cells are activated to kill target cells; this is known 
as the ‘dynamic equilibrium concept’ (Vivier 2004)23.  
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NK cells, which rely on missing or modulated class I expression for activation, utilize a 
complex recognition system involving multiple positive and negative signalling receptors. 
Two structurally distinct receptor families are expressed by human NK cells, the killer 
immunoglobulin-like receptors (KIRs) of the immunoglobulin superfamily and the C- type 
lectin-like receptors. 
 
1.2 Killer Immunoglobulin Receptors 
The Killer immunoglobulin-like receptors (KIRs) represent a major class of NK surface 
receptor. KIRs also found expressed on a subset of T-cells and NK-T cells. They include both 
inhibitory (iKIR) and activating (aKIR) receptors which when bound to their cognate ligand 
result in the generation of negative or positive signals respectively for the triggering of 
cytotoxic responses.  
 
The KIR gene cluster is located on chromosome 19q34 and shows extreme polymorphism 
and structural diversity. To date 17 distinct KIR gene loci have been identified, which vary 
with respect to their presence or absence on different KIR haplotypes (see below), creating 
considerable diversity in the number or KIR phenotypes observed within a population. Allelic 
polymorphism at individual KIR genes also exists, further contributing to the level of KIR 
diversity observed (Middleton 2005)24-26. The ability of NK cells to kill targets appears to be 
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at least partly dependent upon the outcome of these counter-balancing signals generated 
by KIRs.  
The known ligands for KIR molecules are shown in Table 1. The killer immunoglobulin-like 
receptors recognize classical class I HLA molecules: HLA-A, HLA-B, and HLA-C proteins. An 
intact HLA class I trimer, composed of heavy chain, β2-microglobulin, and peptide, is 
required for KIR recognition. KIRs with long cytoplasmic tails are inhibitory, based on the 
presence of immunoreceptor tyrosine-based inhibition motifs (ITIM) in their cytoplasmic 
domains. KIRs with short tails interact with adaptor molecules such as DAP-12 (DNAX 
activation protein), which contain immunoreceptor tyrosine-based activation motifs (ITAM) 
and transmit activating signals (Lanier 1998)27. The ligands for inhibitory KIR (sub-families 
KIR2DL and KIR3DL) are well characterised whereas little is known about those for the 
corresponding aKIR although some have been shown to bind weakly to the same class I 
determinants (Table 1.1)  
Members of the KIR2DL receptor family recognise HLA-C proteins. All HLA-C proteins 
possess either: (1) Ser residue at position 77 and an Asn residue at position 80 of the heavy 
chain (the group 1 Cw molecules) or (2) have an Asn residue at 77 and a Lys residue at 80 
(group 2 Cw molecules). It is these polymorphisms that are recognised by the different 
KIR2DL isoforms: KIR2DL2/3 recognise group 1 molecules whereas KIR2DL1 recognises 
group 2. (Parham 2005)28 Studies suggest that HLA-G may serve as a ligand for KIR2DL4. 
With regard to the KIR3D subfamily, KIR3DL1 has been shown to react with HLA-B and 
certain HLA-A proteins, which possess the Bw4 serological epitope (defined by residues 77–
83 in the α1 domain). The presumed ligand for the activating KIR3DS1 is also HLA-Bw429. 
KIR3DL2 has been shown to recognize certain HLA-A ligands although the precise specificity 
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of the latter has not been defined.  The non-classical HLA-E binds to the non-KIR 
CD94/NKG2A receptor25.  
As these two gene clusters (KIR and HLA) segregate independently, it is crucial to consider 
combinations of HLA and KIRs with regard to NK effect, in addition to considering KIR alone.  
 
 
Table 1.1 The Killer Immunoglobulin receptors (KIR) and their known HLA ligands  
 
 
*  
 
 
 
 
 
 
 
CD94/NKG2A, a C-lectin type receptor binds the non-classical (HLA-class Ib) ligand 
HLA-E  
 
 
1.2.1 Killer Immunoglobulin Receptors and T-cells 
 
In addition to their expression on NK cells, KIR molecules as mentioned have also been 
demonstrated on a fraction on T-cells (Mingari 1998)29 including both TCR + and TCR + 
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subsets (Moretta 1990)30. All inhibitory KIR molecules have been demonstrated on T-cells 
with the majority of expression seen on CD8+ as compared to CD4+ lymphocytes. iKIR 
expression is particularly seen on CD8+ cells with a memory phenotype, and cross linking of 
such receptors leads to an inhibition of cytotoxic T-cell function (Ferrini 1994)31.  KIR 
expression on T-cells may also be influenced by certain cytokines (Correia 2011)32. It is 
hypothesised that this T-cell expression of iKIR may have a homeostatic role similar to that 
of NK cell expressed iKIR in preventing cross-reaction with self-antigen by generating a 
strong inhibitory signal. More recently, CD8+ T-cells have been demonstrated to express NK 
activating receptors suggesting that a balance of receptor signals similar to NK cells is also 
important in modulating T-cell function. 
 
1.3 Missing-self and self Tolerance 
In the normal homeostatic condition, NK cells are quiescent (non-activated), in order to 
prevent autoimmune activity this is ‘self tolerance’. Human NK cells inhibitory receptors 
recognize MHC class I molecules as cognate ligands present on virtually every cell in the 
body.  Self-tolerance is thought to be maintained by this inhibitory KIR recognition of ‘self’ 
HLA ligand on virtually every cell in the body. The iKIR–MHC ligand interaction is thought to 
be central to homeostasis generating strong downstream signals once engaged with 
classical MHC class I, preventing the NK overall balance favouring activation. Such inhibitory 
KIR signals to the NK cell dominate over any activating signal and prevent NK effector 
function. To ensure this phenomenon, every NK cell with killing capacity has an inhibitory 
receptor that recognizes as least one of the MHC class I gene products on the cell’s surface 
33-35.  
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In certain circumstances, such as viral infection (for example cytomegalovirus; CMV, or the 
human immunodeficiency virus; HIV) or following malignant transformation, changes in NK 
ligand expression leads to disruption of this balance. These changes favour an overall 
activation of cytotoxic responses (Figure 1.1). These changes may include (1) increased 
activating receptor-ligand binding, due to recognition of viral determinants such as CMV 
encoded ligands or haemagglutinins derived from influenza (or Para-influenza) viruses, the 
over-expression of self molecules at times of stress, such as DNA damage response 
molecules which are natural ligands for activating receptors (Raulet 2009)36, or the 
expression of tumour specific antigens, (such as B7-H6 protein up-regulated on acute 
leukaemia (myeloid and lymphoblastic), melanoma and lymphoma cells which specifically 
binds the activating receptor NKp30) (Brandt 2009)37  (2) Inhibitory ligand down-regulation; 
MHC class I expression may be reduced or absent in certain tumours (Karre 1986)38 resulting 
in significantly enhanced NK cell sensitivity. In the latter situation, where there is lack of the 
MHC ligand ‘missing self’ there is loss of these strong inhibitory signals, which is thought to 
be the basis of NK reactivity and the allo-reactive anti-leukaemia effect seen after KIR 
mismatched allo-SCT (below).   
 
A more contemporary view held is that NK cells survey both for cells with missing self but 
those over expressing ligands for aKIR.  As many tumours down-regulate MHC molecules as 
an evolved mechanism to evade T-cell mediated killing, this ‘missing self’ reactivity is 
important.   
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1.3.1 NK cell Licensing and self-tolerance  
 
The KIR-MHC ligand interaction is more complex than simply a generation of positive or 
negative downstream effect. KIR-HLA class I interaction is the foundation for NK effector 
function and self-tolerance. Early during NK development, NK cells expressing inhibitory KIR 
(iKIR) for self HLA-class I molecules, are preferentially endowed with functional competence 
and effector function. Conversely, NK expressing iKIR (which are part of the individual’s 
inherited KIR repertoire) for which there is no cognate ligand normally expressed in that 
individual, are rendered hypo-responsive. This education process during NK cell 
development, results in the ability of NK cells populations to mount strong protective 
effector responses upon sensing a lack of ‘self (ligand) HLA-class I.  
 
This ‘missing ligand’ effect, which may occur following HLA down regulation or modulation, 
or from the introduction of HLA disparate allogeneic cells (in the context of stem cell 
transplant), leads to loss of the strong inhibitory signals and an overall NK signal balance 
favouring strong cellular activation. Conversely, where iKIR for non-self (iKIR expressed on 
the NK surface but whose cognate ligand is not part of the HLA genotype of the individual 
and therefore not normally expressed) molecules sense their ‘missing’ ligand (which is the 
normal state) no such strong inflammatory response (against normal tissue) is generated. 
Such KIR expressing cells are hypo-responsive and as such have been educated to be self-
tolerant. This mechanism thus prevents against deleterious constitutive systemic 
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inflammation. (Yu 2007, Yawata 2008)39, 40. Therefore, it can be seen that NK cells may 
exhibit both self-tolerance and missing-self mechanisms.  
 
 
 
 
This NK cell ‘licensing’ for function, appears to be dependent on their inhibitory rather than 
their activatory receptors. Yokayama and colleagues (2005)41 demonstrated in mice that 
Ly49 (killer cell lectin-like receptor subfamily A member 1, a murine NK receptor functionally 
akin to human KIR) is required for MHC interaction and endowment of function. MHC 
deficient mice were shown to have no competent NK cells when subsequently exposed to 
cells with missing self. Furthermore, they demonstrated that the signal generated by the 
iKIR-MHC interaction is transmitted via the ITIM containing inhibitory cytoplasmic receptor 
tail, as deletion or mutation of ITIM motifs resulted in non-functional NK cells. The exact 
process by which this NK education occurs is not fully elucidated but it does not appear to 
involve the same pathway molecules that are engaged for an inhibitory effect.  
 
Interestingly even in NK cells expressing more than one iKIR for self-HLA epitopes, the 
presence of only 1 cognate (self) ligand is able to render the NK cell non-functional (Yu 
2007)39 demonstrating the importance of the KIR-MHC inhibitory axis to prevent auto-
immunity.  
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Figure 1.1 A. In healthy individuals negative signals preventing cellular activation are 
mediated by the strong interactions between inhibitory KIR with MHC class I molecules, 
over-riding pro-cytotoxic signals. B. In the disease state, down-regulation of MHC class-1 
molecules (i) and / or up-regulation of activating receptors (ii) can occur, leading to a 
change in the signal balance favouring cytotoxicity. 
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1.4 KIR Haplotype 
 
Individuals with diverse KIR haplotypes can be broadly divided into two biologically distinct 
groups, haplotype A and haplotype B (also known as Bx). Group A haplotype individuals 
have a low variation in gene content with a fixed number of genes encoding for iKIR with the 
exception of the activating receptor KIR2DS4. Group B haplotype individuals have variable 
gene content (with the presence of two to five activating receptors) including at least one of 
the following genes, KIR2DL5B, 2DS1, 2DS2, 2DS3, 2DS5 or 3DS1. Haplotype A genes have 
extensive allelic variability, whereas the haplotype B genes are less polymorphic. The genes 
(framework genes) KIR2DL4, 3DL2 and 3DL3 have been shown to be present on all 
haplotypes with rare exceptions (Middleton 2005)24. Strong linkage disequilibrium (LD) 
exists between a number of the KIR genes. Linkage disequilibrium describes the non-random 
association of alleles at two or more loci (not necessarily on the same chromosome). As this 
effect is found between a number of different KIR genes, it needs to be borne in mind when 
undertaking genotype association studies. The KIR genes in LD with one another are 
described below in the context of the recently described centromeric and telomeric regions 
of the KIR locus (page 44).  
  
Despite the presence of certain KIR genes/alleles in an individual’s genome, not all NK cells 
are identical in terms of KIR (or non-KIR receptor) expression. Each NK cell only expresses a 
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fraction of the available KIRs (Valiante 1997)35. This is thought to be subsequent to KIR gene 
silencing through processes such as DNA methylation (Chan 2003, Santourlidis 2002)42, 43. 
Therefore, within individuals, different NK clones exist expressing different cell surface 
receptors, including KIR, in differing combinations (Valiante 1997,Bashirova 2006)35,44. It can 
therefore be seen, that even within individuals, a diverse NK repertoire exists. Furthermore, 
this receptor expression (including KIR) of different NK clones is maintained with 
subsequent cell divisions, with each sub-population expressing a specific array of receptors, 
which may respond differently to diverse targets (Ljunggren 1990, Lanier 2005 Valiante 
1997 Chan 2005, Miller 2001)33-35, 42,45. It is conceivable therefore, that these differing NK 
sub-populations also have divergent responses to tumours and microbes dependent upon 
receptor expression and their engagement with different ligands.  
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Fig 1.2:  The membrane bound killer Immunoglobulin like receptors (KIR).  Activating 
receptors (short cytoplasmic domain) are denoted in red and inhibitory receptors (long 
intra-cytoplasmic domain) in blue.  
 
The immuno-polymorphism database www.ebi.ac.uk/ipd/kir/introduction.html 
 
 
1.5 Non-KIR NK receptors 
 
In addition to KIR, human NK cells express non-KIR surface receptors with both activating 
and inhibitory function. These receptors include the natural cytotoxicity receptors (NCRs) 
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NKp30, NKp44, and NKp46 and the C-type lectin receptors NKG2A (inhibitory) and NKG2C 
and NKG2D (activating), which have now been fully characterised in humans. In addition, a 
number of other receptors have been shown to be expressed on the surface of human NK 
cells: LAIR, a receptor structurally related to KIR when cross linked lead to reduction in 
killing of K562 (an MHC deficient cell line derived from a patient with an erythroblastic 
transformation of chronic myeloid leukaemia) (Meyaard 2009)46, Another inhibitory 
receptor is CD85j which recognises multiple class I alleles including HLA-G. Soluble HLA-G 
(which is also recognised by KIR2DL4) has been demonstrated to be up regulated in a 
number of tumour types and this up-regulation is believed to be a mechanism of tumour 
escape. CD160 is a known activating receptor, which together with its co-activating 
molecule CD2, interacts with HLA-C (Leleu 2009)47.  Signalling lymphocyte activation 
molecule (SLAM) and its related receptors (SLAM family 6): CD2-like receptor activating 
cytokine cells (CRACC), NK, T and B cell antigen-A (NTB-A) (CD150) and 2B4 (CD244), are all 
believed to be involved in triggering cytotoxicity, as is DNAX accessory molecule-1 (DNAM-1) 
(CD266). Interestingly, the NK activating receptor NKG2D is also expressed on a subset of 
CD4+ T-cells. Such cells are believed to have a regulatory function, which might in part be 
due to secretion of IL-10 and TGF-β.  
 
 
1.6. KIR and Human Disease  
 
Different inherited KIR repertoires alone, or in association with the presence or absence of 
HLA genes have been associated with disease in humans. Individual and groups of KIR genes 
have been associated with an increased susceptibility to infection, the development of auto-
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immune diseases such as insulin dependent diabetes mellitus (IDDM) rheumatoid arthritis, 
and Beçhet’s disease, and with an increased risk of malignant disease (both solid tumours 
and haematological cancers), NK cell pro-inflammatory responses against ‘stressed’ 
endothelial cells have also been shown to be important in the pathogenesis of 
atherosclerotic plaques resulting in acute coronary syndrome (ACS), a huge public health 
problem in Western populations.   
 
1.6.1 NK cells and Malignancy  
 
NK cells play an important role in the innate immune responses against cancer. NK cells in 
particular are crucial in the elimination and control of tumour metastases. Murine models 
have also demonstrated a very important role for NK cells in eradicating small tumour grafts 
and spontaneously arising tumours, although they are less efficient at killing large solid 
tumour masses (Stojanovic 2010) 48. NK anti-tumour activity has been demonstrated against 
a number of cancer cell lines including ovarian carcinoma (Carlsten 2007)49, neuroblastoma  
(Castriconi 2004)50 and more recently myeloma (El-Sherbiny 2007)51.  Tumour infiltration by 
NK cells is associated with a favourable outcome for a variety of tumour types. The extent of 
intra-tumoural NK infiltration has been used as a prognostic marker in colonic, gastric, and 
squamous cell lung carcinoma (Coca 2000, Ishigami 2000 and Villegas 2002)52-55. Such 
infiltrating NK cells are associated with reduced metastasis, reduced lymphatic and venous 
invasion, and reduced tumour angiogenesis (Ishigami 2000)54. NK derived IFN-  is thought to 
be responsible both for this reduction in tumour angiogenesis and for increased antigen 
presenting cell (APC) maturation and antigen presentation.  
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NK cells have multiple effects on other immune effector cells within the tumour 
microenvironment. It is accepted, that in addition to APC maturation, which promotes anti-
tumour responses, IFN-  secreted from NK cells can also prevent macrophage differentiation 
into immature APCs. This is a protective anti-neoplastic effect as these early APCs, have 
been shown to be recruited by the tumour environment inducing T-cell suppression and 
tumour angiogenesis (Wei and Zou 2005)56 thus promoting tumour growth.  
 
The interaction between NK cells and malignant cells is complex. Tumour cells have been 
demonstrated to have evolved strategies for immune (NK) avoidance, such as the down-
regulation of activating receptor ligands (Costello 2002)57 or the shedding of ‘decoy’ ligands, 
resulting in immune modulation (Salih 2002)58. Furthermore, the tumour microenvironment 
may modulate NK receptor expression itself, resulting in a decrease of cell surface activating 
receptors (Costello 2002)57.  
 
NK cell effector function abnormalities have been shown to be associated with an increased 
risk of tumour formation, including the development of lung and liver cancers (Sibbitt 1984 
and Taketomi 1998)59, 60.  A large longitudinal study of over 3000 Japanese subjects revealed 
impaired NK cytotoxicity (as assayed by killing of the K562 MHC deficient cell line) in 
individuals who then subsequently developed tumours (Imai Lancet 2000)61. Confirmatory 
evidence that NK cells, and importantly NK surface receptors, are crucial for tumour control 
is the demonstration that NKG2D and NKp46 (NK-NCR) deficient mice have enhanced 
tumour growth (Guerra 2008)62.   
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1.6.2 Killer Immunoglobulin Receptors and Malignancy 
 
To date, the majority of work on the role of NK receptors in malignancy has concentrated on 
the natural cytotoxicity receptors (NCR). There is emerging evidence for a role for KIR-HLA 
interactions in the control of tumours in humans. The role of KIRs and the development of 
malignancy is an interesting and evolving area of research.  
 
A number of studies have shown that an individual’s KIR repertoire may confer protection 
against the development of a number of tumours including cervical carcinoma, breast 
hepatocellular carcinoma and Hodgkin’s disease (HD). Conversely, other investigators have 
demonstrated that certain KIR genes may confer a susceptibility to malignant disease. The 
presence of individual KIR genes (+/- HLA-ligand) have been associated with cervical 
carcinoma (Carrington)63, breast cancer (Ozturk 2011)64, malignant melanoma, non-small 
cell lung carcinoma (Omar 2010)65,66. The aggregate number of activating KIR genes (≥ 5) in 
an individual’s repertoire has also been linked to the development of nasopharyngeal 
carcinoma (NPC) (Butsch Kovacic 2005)67. 
 
As mentioned, CD56dim NK cells are thought highly important anti-tumour effectors in 
humans. Recently, CD57 has been shown to be preferentially expressed by CD56dim NK cells 
and correlated with high KIR expression (with reduced expression of NKp46 and NKG2D). 
CD57+ NK cells (Bjorkstrom, Lopez-Verges 2010)68, 69were seen to be potent IFN-  producers 
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and cytotoxic against targets. It has been suggested that such cells may be more potent 
anti-tumour effectors.  
 
With well characterised associations with tumours such as cervical carcinoma (highly 
associated with human papilloma virus), nasopharyngeal carcinoma (associated with Epstein 
Barr virus; EBV) and Hodgkin’s disease (associated with EBV), it appears that NK cells play an 
especially important role in outcome in viral-related malignancies.   
 
1.6.3 KIR and haematological tumours 
 
Evidence for a role of KIR in haematological tumours is predominately seen in the setting of 
allo-SCT, although a growing body of evidence suggests its importance outside of the 
transplant setting.  
 
A number of studies have suggested a role for KIR immunogenetics in determining risk of 
leukaemogenesis. In the largest study to date (>250 patients with leukaemia) Zhang and 
colleagues revealed an over-representation of KIR2DS4 in chronic myeloid leukaemia (CML) 
and an under-representation of KIR2DS3 in acute lymphoblastic leukaemia (ALL)70. These 
data conflict with a previous smaller study suggesting that the presence of intact 
(functional) KIR2DS4 alleles (described elsewhere) are reduced in CML compared to normal 
controls (Giebel 2008)71 whereas no difference was noted for the variant (non-functional) 
KIR2DS4*003 allele (also known as KIR1-D). The former study however did not distinguish 
between KIR2DS4 allele types. Another KIR, KIR2DL2 has been shown in a different to 
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protect against the development of CML, but only in the presence of its ligand, HLA-C1 as 
compared with normal controls (Middleton 2009)72.  
 
Data also suggests that increasing numbers of inhibitory KIR within an individual’s KIR 
repertoire are associated with an increased risk of leukaemia development. Verheyden 
(2004)73 compared 96 patients with leukaemia to 148 healthy individuals with respect to the 
three major KIR phenotypes (Urhberg)74: AA (containing KIRs 2DL1 and 2DL3), AB (2DL1, 
2DL3, and 2DL2), and BB (2DL2). Genotype AB can be seen to contain more iKIRs, this 
(broad) phenotype was noted to be significantly increased in frequency in patients as 
compared to controls, suggesting increased overall inhibitory capacity was associated with a 
decreased capability to kill malignant cells. Phenotypes AB and AA can be seen to differ with 
respect to the presence of KIR2DL2. This led the authors to suggest a prominent role for this 
gene and its protein (receptor) in leukaemic escape. However, no difference was seen 
between the two groups with respect to phenotype BB.  This overall balance hypothesis is 
more plausible as in sub-analysis, the authors also noted specific AB phenotypes (AB1 and 
AB9) to be associated with increased leukaemic risk (AML and CML respectively), both these 
specific phenotypes contain only a few (1 - 2) activating receptors as compared to others.  
 
Until recently, data on KIR genotype and leukaemia rates have only been reported in adults. 
Emerging data suggests that certain activating KIR may be associated with a reduced 
susceptibility to childhood pre B-ALL, the most common form of leukaemia in children. In a 
large study by Alamalte et al  (2011)75 the presence of the activating KIR genes 2DS1 2DS2 
and 2DS3 in an infant’s KIR repertoire conferred protection against pre B-ALL, as did 
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increasing numbers of activating KIR. Moreover KIR2DS2 was found to confer protection 
from T lineage childhood ALL. 
 
Leukaemic blasts (AML, ALL, and CLL) have been shown to down-regulate class I MHC in an 
attempt to avoid T-lymphocyte attack (Brouwer 2002, Demanet 2003, Vollmer 2003, 
Verheyen 2009)76-79.  This decreased expression may make cells more at risk to NK mediated 
attack.  
 
With regard to the role of the KIR genotype in lymphoma, there is to date a paucity of data. 
Besson et al (2007)80 demonstrated a protective effect of KIR3DS1 and KIR2DS1 in Hodgkin’s 
disease. This effect was greatest in HD cases shown to be driven by the Epstein Barr virus 
(EBV). EBV is an oncogenic virus, which in the lytic phase renders the infected B-cell 
susceptible to NK lysis by the down regulation of iKIR ligands and an up-regulation of 
activating receptors (NKG2D and NCAM-1) (Pappworth 2007)81. As described above, the NK 
response to EBV infected cells has been associated with chronic inflammation and 
nasopharyngeal carcinoma in individuals with >5 activating KIR genes (Butsch Kovacic 
2005)67.  
 
 
1.6.4 NK cells and treatment outcome in haematological malignancies  
 
Natural killer cells in addition to their role in tumour control in the context of SCT (see 
below) may also be very important for the optimisation of standard therapies currently used 
in the treatment of certain haematological malignancies. NK cells can mediate direct tumour 
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cell lysis, via an antibody dependent cytotoxic (ADCC) activity2. Surface CD16 or FcRγIIIa 
expressed on 90% on peripheral NK cells (CD56dim population) is a low affinity receptor for 
the Fc component of Immunoglobulin subtype G (IgG)82. As such, NK cells in part are 
responsible for the function of anti-tumour monoclonal antibodies.  
 
Rituximab® (Roche; Basel Switzerland) is a synthetic chimeric mouse-human IgG1 antibody 
directed against surface CD20. CD20 is expressed on B-lymphocytes from early pre-B cells 
through to differentiation to mature lymphocytes. The addition of Rituximab® to 
conventional chemotherapeutic regimens has lead to dramatic improvements in response 
rates for NHL and DLBCL (Marcus 2005, Coiffier 2002/2009)83-85.  Whilst this treatment 
results in a number of anti-tumour mechanisms, its effect appears in part to be influenced 
by NK cells, indeed elevated NK cell numbers are associated with improved responses to 
Rituximab® (Janakiraman 1998)86. This could potentially also be important in the post 
transplant setting where anti-CD20 is used both for maintenance therapy and also in the 
treatment of post-transplant lymphoproliferative disease (PTLD).  
 
Polymorphisms in FcRγIIIa such as a substitution at position 158, (valine for phenylalanine 
substitution) has been shown to improve response to Rituximab® as a result of both 
increased CD16 transcript number and surface density, and an increased affinity for 
Rituximab®. Modified FcRγIIIa with greater affinity for anti-CD20 has also been shown to 
result in increased ADCC in CLL (Le Gariff-Tavernier 2011)87.  
 
The efficacy of ADCC mediated action of NK cells maybe affected by KIR-HLA interactions.  
The anti-tumour effect of Rituximab® against B-lymphoma cell lines has been shown to be 
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attenuated following KIR molecule activation (by ligation using anti-KIR antibody) or 
increased the shielding of HLA (generating a missing-ligand event). These data suggest that 
strong inhibitory signals via KIR may dampen down the ADCC of NK cells (Borgerding 2010). 
It is possible that different KIR molecules play divergent roles in modulating the efficacy of 
certain monoclonal antibody therapies. To date there are no studies looking at individual 
KIR molecules and disease response to Mab. However, with an ever-expanding 
armourmentarium of such Mabs available for an increasing number of varieties of tumour 
types (haematological and non-haematological), KIR-HLA immunogenetics could possibly be 
important predictors of treatment response.      
 
This also implies, that discrete NK populations maybe important for tumours treated with 
Mab and suggests that drugs modulating the action of KIR might synergise with such 
therapies. As NK cells are the predominant post-transplant subset certain Mab may be 
useful in the eradication of MRD.  
 
1.7 Chronic Myeloid Leukaemia  
 
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder resulting from the 
malignant transformation of a single haematopoietic stem cell. Clonal myeloid precursors 
proliferate and differentiate displacing normal haematopoietic elements in the bone 
marrow and peripheral blood. The malignant cells are characterised by the presence of the 
Philadelphia (Ph) chromosome, a chromosomal abnormality resulting from a reciprocal 
translocation, between chromosomes 9 and 22; t(9;22) (q34.1;q11.2) leading to 
translocation of the ABL-1 gene within the BCR (breakpoint cluster region) gene. The fusion 
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gene product is a constitutively activated tyrosine kinase, which activates downstream 
intracellular signalling pathways leading to clonal myeloproliferation. CML has three distinct 
disease phases; chronic (CP), accelerated (AP), and blastic phase/crisis (BP). BP being 
analogous to acute leukaemia. Patients in CP are often asymptomatic at presentation and 
may remain in CP for 6-12 years before progression. The median survival of untreated CP 
patients is approximately 5 years89.  
 
The treatment of CML (discussed further in chapter 3) has been revolutionised in the last 10 
years by the introduction of the tyrosine kinase inhibitor (TKI) Imatinib (IM)  (Gleevec; 
Novartis Basel, Switzerland). IM administration has resulted in excellent disease responses 
and has reduced the number of patients requiring allo-SCT (see later).   
 
 
1.7.1 Role of NK cells in CML 
 
NK cells are important mediators of graft versus leukaemia (GvL) responses after allo-SCT for 
CML (see below). In-vitro evidence suggests NK cells can suppress primitive CML progenitors 
in long-term culture (Cervantes 1996). This cytotoxicity is thought to be specific to the CML 
(Ph+) CD34+ cell, and occurs without the requirement for KIR-Ligand incompatibility 
(Sconocchia 2005)90. This study compared CD34+ cell killing by NK cells, and showed that 
HLA-matched donor NK cells were more effective than those from KIR mismatched family 
donors. The authors suggested that this results from an inoperative KIR inhibitory effect or 
from the counteraction by other pro-cytotoxic CML-NK interactions. They then 
demonstrated that NK killing was confined to Ph+ CD34 cells as opposed to Ph- cells, and 
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that this was due to over-expression of MICA/B the ligands for NKG2D by the malignant cell 
suggesting a role for this NCR. 
 
Yong and colleagues (2009)91 demonstrated that NK cells are capable of killing cycling CML 
progenitor cells and importantly, dependant on the conditions, may exert cytotoxic activity 
against primitive quiescent CD34+ Philadelphia (Ph) positive cells. In this study, exposure of 
these cells to Bortezomib (a proteasome inhibitor used in treatment of other 
haematological malignancies) lead to up-regulation of the TRAIL receptor DR4 (TRAIL-R1) 
increasing their sensitivity to NK-expressed TRAIL mediated apoptosis.  These data, suggest 
that NK cells may also play a central role in the natural history of CML, and that NK 
responses may be important in maximising treatment responses.  Although these data 
suggest the importance of the NKG2D-MICA/B and TRAIL-ligand interactions, KIR-HLA 
interactions are still likely to be very important in-vivo. In the study by Sconnochia et al90, 
acid stripping of HLA resulted in a strong KIR mismatch effect. Furthermore, as molecules 
such MICA and MICB are shed from tumour cells into the plasma, as a mechanism of tumour 
NK cytotoxicity evasion, (Raffaghello 2004) this may result in the KIR-HLA interaction at the 
cell surface as critical for response.  
 
It is possible that NK cells may also influence responses to directed CML therapies. Imatinib 
(STI571) can be used with remarkable effect in the treatment of CML. It binds with high 
affinity to the inactive form of certain tyrosine kinases inhibiting auto-phosphorylation and 
enzyme activation. IM has a limited target repertoire, which includes BCR-ABL fusion protein 
in CML cells, mast/stem cell growth factor receptor (cKIT; CD117) and platelet derived 
growth factor receptor (PDGF-R)93. More recently, IM has been demonstrated to also inhibit 
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ARG kinase (Okuda 2010)94. IM is highly active against the p120 BCR-ABL protein (Druker 
1996)95. This inhibition of auto-phosphorylation is closely related to IM’s anti-proliferative 
activity in CML, leading to apoptosis of BCR-ABL+ cell lines and the killing of primary CML 
and Ph+ ALL cell lines with significant clinical effect (above). This effect is in part due to a 
profound down-stream impact on STAT-5 activation by BCR-ABL with a subsequent 
reduction in downstream signals including, BCL-XL an anti-apoptotic protein (Silaber 2000, 
Reviewed in Capdeville 2002)96 and CRAKL, an adaptor molecule which activates the RAS 
and Jun kinases (Oda 1994)97. It is well documented that IM has also inhibitory effects on T-
cells by reducing both proliferation and activation (Cwynaski 2004, Dietz 2004, Seggewiss 
2005)98 - 100. To date the effects of Imatinib on NK cells are less well characterised.    
 
 
Studies of Imatinib on NK cells have been conflicting. Salih demonstrated that IM reduces 
MICA and MICB (ligands for activating receptor NKG2D) on CML cells resulting in reduced NK 
IFN-  production101. However, this effect did not translate into inferior cytotoxicity when 
assayed for K562 killing. Further data on the effect of IM and NK cells come from studies of 
gastrointestinal (GI) stromal tumour or GIST, a rare type of sarcoma found in the digestive 
system, most often in the wall of the stomach. GIST is characterised by cKIT mutations in 
>85% of cases, and responds to IM. Ménard et al 102, in a phase I study on GIST 
(demonstrated improved IFN-  production in 34/56 IM treated patients and that this 
response was highly prognostic for improved outcome. They also demonstrated improved 
expression levels of the activating receptor NKp30 and improved responsiveness to IL-2 
therapy. This study unfortunately did not evaluate MICA and B levels or NKG2D.  
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Other data, suggest that IM also influences NK activity by acting on the DC to promote NK 
activation and anti-tumour activity. Interestingly, IM also has an effect in wild type cKIT 
(non-mutated) GISTs, suggestive of a second mode of anti-tumour action other than cKIT 
inhibition. IM increases NK IFN-  production, but only when in co-culture with DCs (Borg 
2004)103 suggesting the drug induced favourable DC-NK interactions. Furthermore, IM has 
been demonstrated to have in–vivo anti-tumour activity, via NK cells, in murine models 
inoculated with tumour cell lines including melanoma (B16F10), Mesothelioma (AK7) and 
fibrosarcoma (MCA102) (Borg 2004)103 when DC are present in the assay. None of these 
tumours are associated with abnormal tyrosine kinase activity.   
 
Interestingly, Imatinib has been shown (in combination with IL-2) to increase a population of 
cells (in mice) with the molecular profile of both NK and DC. This sub-population described 
by Chan (2006)104 is high producers of IFN-  and kill typical NK targets (Mignot 2008)105. 
Defined as CD11cint B220+ NK1.1+, (the latter a marker of murine NK cells), these cells can 
also stimulate T-cells, and as such have been named IFN-  producing killer DC (IKDC). 
Expansion of the IKDC with IM is dependent on IL-15 and CCL2 (MCP-1). Interestingly, the 
activity of IKDCs is reduced with progressive loss of DAP-10 and DAP-12. These adapter 
proteins are important in the downstream signalling of aKIR molecules. Therefore, this 
suggests a potential link between KIR and Imatinib induced anti-tumour function. There is 
however, no data currently on a similar IKDC cell type in humans.  
 
49 
 
To date, no data is available on the role of KIR in IM treated malignancies. However, as IM 
seems to have diverse effects on the NK cell as described above, it is possible that the drug 
may affect specific KIR interactions and in turn inherited KIR repertoire may influence 
treatment response. The fact that IKDC response is lost with reduction in KIR associated 
proteins suggests that their function maybe KIR related. Therefore, this suggests a rationale 
to investigate a potential link between KIR and Imatinib anti-tumour function. 
 
Recently, Kreutzman (2010)106 has reported the presence of clonal, Ph negative NK and T-
lymphocyte populations in patients with CML, which further expand with IM, and Dasatinib 
(Bristol-Myers-Squibb; New York, USA; a second line TKI with more potent function than 
IM). In this study, 10/12 Imatinib treated patients had TCR-γδ clones at diagnosis which 
persisted and expanded during therapy, although only patients treated with Dasatinib had 
an absolute lymphocytosis documented. Dasatinib induced lymphocytosis has also been 
shown by Mustjoki and colleagues (2009) and was seen to predict for improved response to 
TKI therapy due to improved NK cytotoxicity. Whilst TCR-γδ rearrangements are most 
characterised for T-cells they can also be seen to occur in NK cells. T-cells with TCR-γδ 
rearrangement have been demonstrated to selectively kill Ph positive cells (Siegers 2008)108. 
Interestingly, expansions of LGL (NK cells) with TCR-γδ rearrangements have been 
associated with increased survival following allo-SCT (for a variety of different 
haematological malignancies) (Mohty 2002)109. Whilst data is limited, it is conceivable that 
as TKI induce such clonal NK expansions, of certain KIR expressing clones which may 
influence disease response in CML (or GIST). 
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Whilst there are data suggesting IM has potent pro-NK effects, evidence also exists 
suggesting a possible impairment of the NK response to CML. BCR-ABL over-expression in Ph 
positive cells increases their susceptibility to NK mediated lysis (Baron 2002)110 however this 
mechanism has been shown to be affected by IM with the disruption of a number of 
interactions; IM can cause modulation of both MICA/B and UL-16BP (ULBP), which as 
mentioned are NKG2D ligands, and furthermore it may interfere with the NK immunological 
synapse (IS). The IS, is the dynamic interface formed between an NK cell and its target cell, a 
focus point where receptors and their ligands cluster and mediate their signals, followed by 
a cytoskeleton reorganisation and the formation of a cleft through which NK cytolytic 
enzymes are secreted toward its target111. Cebo and colleagues have demonstrated that IM 
induces surface GM1 ganglioside expression which prevents redistribution of MICA/B in lipid 
rafts upon interaction with the NK cell112. KIR molecules have also been shown to be 
important in the formation of an inhibitory synapse (InS), which prevents the activating 
synapse formation113. This (InS) promotes NK detachment from potential targets and blocks 
the recruitment of activating receptors (reviewed in Orange 2008)114. It can be seen that the 
synapse is an important site of interactions between activating and inhibitory NK receptors. 
As IM affects the activating synapse, and the strength of the inhibitory signal at this site is 
important for synapse function, it can be postulated that differing effects on differing KIR 
molecules by IM, may affect the effector cell ability to mount an anti-CML response at the 
synapse interface.  
 
Therefore as CML is sensitive to immune control and in particular by NK cells, and that the 
most effective treatment for this disease is associated with expansion of this cellular subset, 
modulates its activity, it is possible that certain NK subsets expressing certain surface 
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receptors may play an important roles in dictating treatment response. This hypothesis is 
strengthened by existing data suggesting that KIR genotype may play a susceptibility role in 
the development of CML. Ph+ cells have indeed been demonstrated to be present in normal 
individuals without the development of disease suggesting robust tumour 
immunosurveillance.  
 
1.8 Haematopoietic Stem Cell Transplantation 
 
Haematopoietic stem cell transplantation (HSCT) remains an important treatment strategy 
for patients suffering from a wide range of haematological (and non-haematological) 
malignancies. For many diseases HSCT is the only treatment modality, which offers potential 
cure. There are two main subtypes of HSCT (1) autologous (ASCT) whereby an individual’s 
(CD34+) stem cells are harvested prior to administration of high dose (myeloablative) 
chemotherapy and then returned as a ‘rescue strategy’ resulting self haematopoietic 
reconstitution (2) allogeneic (allo-SCT) whereby the stem cell source following 
chemo/radiotherapy conditioning is not ‘self’ but rather sourced from a stem cell donor 
who may be related to the patient (such as a sibling; sib-allo), an unrelated volunteer (VUD) 
or from stem cells derived from donated umbilical cords (cord-SCT). In allo-SCT, the 
emerging haematopoietic and immune systems are donor derived. 
 
ASCT is widely used as standard consolidation therapy in patients with multiple myeloma 
(MM) (see below) after initial remission induction therapy, and relapsed lymphoma. ASCT 
may also be used as a strategy to allow high dose chemotherapy administration for other 
solid tumour types such as germ cell tumours and neuroblastoma. Additionally, there is 
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increasing interest in ASCT as a means of eradicating non-malignant T-cell auto-reactive 
clones in patients with severe phenotype autoimmune conditions such as multiple sclerosis 
(MS) and Scleroderma.  
 
Briefly, in MM and lymphoma treatment, the patient’s stem cells are mobilised into the 
peripheral blood using chemotherapy plus granulocyte colony stimulating factor (G-CSF) at a 
time of best remission. The mobilised CD34+ stem cells are then harvested by apheresis 
technique, enumerated and cryo-preserved. Following high dose chemotherapy the CD34+ 
stem cells are thawed and returned to the patient allowing bone marrow repopulation. The 
minimum CD34+ cell dose for a safe effective haematopoietic reconstitution is between 
1.5–2.0 x 106 / kg body weight115.  NK cells post transplant are those of patient origin. 
 
In the case of allo-SCT, the recipient receives a ‘foreign’ stem cell source and thus NK cells 
are non-self. In order to prevent severe and lethal graft versus host disease (GvHD) (see 
later) or graft rejection, the stem cells must be ‘matched’ to the recipient. Tissue 
compatibility between the transplant recipient and donor is determined by the genes of the 
major histo-compatibility complex (MHC) also known as the Human leucocyte antigen (HLA) 
system.  This is a multi-genic system encoding homologous glycoproteins with a high degree 
of polymorphism within humans, and the HLA genes are the most polymorphic of the 
human genome (Marsh 2002, 2010)116, 405 Immune responses against HLA are a major 
barrier in HSCT. As such, the degree of HLA matching has important consequences on 
transplant outcome.  
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The HLA gene products can be divided into either Class I or II molecules. Class I HLA 
molecules are HLA-A, HLA-B, and HLA-C and are present on most nucleated cells, Class II 
molecules are HLA-DR, -DQ and -DP and found on antigen presenting cells (APC). Typically, 
class I and II molecules present peptides to CD8+ and CD4+ T-cells respectively. In addition 
to recognizing peptide, the T-cell receptor (TCR) also recognizes allogeneic MHC at high 
frequency (1–10% of T-cells respond to allo-MHC) (Afalzi 2007)117. The combination of 
inherited HLA alleles on the same segment of chromosome (chromosome 6) is known as an 
HLA haplotype.  
 
The best donor for an allo-SCT recipient is an HLA-genotypically matched sibling, who has 
inherited the same haplotype from each parent as the recipient, and as such has the 
identical HLA-A, B, C, DR, DQ, and DP genes (12/12 match). Although there is weak linkage 
disequilibrium between DQ and DP and mismatch at DP is seen in 11.2% of sibling 
transplants (10/10 match)115.  
 
Where no sibling is available then an unrelated matched donor can result in comparable 
outcome (Petersdorf 2007)118. Mismatches at A, B, C, and DR loci result in inferior outcome 
due to the generation of GvH reactions (GvHD). The role of DQ and DP is less defined (Little 
1998) and as such the National Marrow Donor program (NMDP) (United States) 
recommends typing potential donors for A, B, C and DR, i.e. an 8/8 match (Hurley 2006).  
Umbilical cord stem cell transplants (UBCT) (not discussed here) require less stringent 
matching (HLA/B low resolution, DR high resolution), as cord blood appears to be less HLA 
restricted. Donor selection also involves an evaluation of donor gender, age and CMV sero-
status.  
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1.9 NK cells and autologous stem cell transplantation 
 
Autologous transplant 
As mentioned ASCT remains the standard treatment for younger patients with multiple 
myeloma (MM) and those with relapsed or refractory chemo-sensitive lymphoma (r-Lym) 
(Non-Hodgkin’s lymphoma, and Hodgkin’s disease). ASCT represents the majority of all stem 
cell transplantation procedures performed in Europe and North America (EBMT and CIBMTR 
data).  
 
1.9.1 Natural Killer cells and ASCT 
 
Following high dose therapy and stem cell rescue, NK cells are the first immune cells to 
recover (Neiderweiser 1987)120. The CD56+, CD16+ lymphocyte subset (NK cells) have been 
demonstrated to have a faster recovery than T or B-lymphocytes after ASCT, when using 
either bone marrow or peripheral blood (PBSC) as the stem cell source (Parrado 1997)121. A 
number of studies suggest NK cells to be the abundant cell population in the immediate 
post transplant setting. The presence of relatively increased NK numbers in the PB during 
haematopoietic reconstitution suggests that they have important roles to play. Such NK 
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activity may also be increased in this immediate post-SCT period where there is 
dysregulation of the immune system and an abundance of cytokines known to affect NK 
growth. Therefore NK cells are in a position to be the prime effectors of eradicating residual 
disease and in preventing infectious complications until full haematopoietic reconstitution.   
 
 
1.9.2 Absolute lymphocyte counts and ASCT outcome   
 
A large number of studies have shown that an elevated absolute lymphocyte count (ALC) 
early post ASCT, (between days 15 and day 30), are predictive for both overall (OS) and 
progression free survival (PFS). 63-65. Such a survival advantage for an elevated ALC has 
been shown in patients after ASCT for a number of tumour types, including NHL, HD, other 
lymphomas (T-NHL and mantle cell lymphoma subtypes), MM, breast cancer, primary 
systemic amyloidosis, ovarian carcinoma and acute myeloid leukaemia (AML) (Porrata 2001, 
2002, 2004, 2004, 2005, 2006, 2008 122-127 Boulassel 2006128, Joao 2006129, Hiwase 2008130, 
Ferrandina 2003131 Kim 2003)132. The NK cell is the predominant cell within the ALC. In a 
prospective study of 50 patients transplanted for NHL, improved OS and PFS was directly 
correlated to NK cell number (>80 cells/ l blood at day 15) on a multivariate analysis and NK 
cells were the only lymphocyte subset predictive for outcome. Further indirect evidence 
that the NK subset is important in the early phase post-ASCT, is that increased interleukin 
(IL-15) levels have been associated with improved outcome in NHL patients, and that this IL-
15 level is directly correlated to NK-15 (Porrata 2010)133.  
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As these data suggest a role for NK cells in controlling malignant cell growth during the early 
phase of haematopoietic reconstitution, it is conceivable that some of these effects maybe 
due to the presence of surface KIR molecules expressed on the NK cell surface, and that KIR-
ligand interactions may be of importance as seen in the setting of allogeneic SCT (see 
below). This is especially interesting in light of the data by Yu et al (2009), which suggests 
the existence of a temporary loss of self-tolerance in the immediate post allo-SCT period. 
They showed that in the HLA-matched setting where there is KIR and KIR-ligand matching, 
emerging NK cells with iKIR for ‘non-self MHC’ (which theoretically should non-licensed for a 
cytotoxic response) are indeed responsive when they sense lack of ligand (ligand which is 
also missing in the their normal host). Such cells are robust CK producers and are initially 
activated rather than hypo-responsive against ligand deficient cells. This temporary lack of 
tolerance was seen to occur in the first 100 days post HSC infusion. The authors suggest this 
might explain the improved outcomes even in HLA-matched siblings. Therefore, this 
temporary loss of tolerance could also conceivably occur in the post autologous setting, 
where again KIR and HLA of patient and emerging NK cells are matched. Such temporary 
loss of tolerance could result in eradication of residual malignant cells post auto-PBSCT. 
 
1.9.3 KIR-ligand mismatch and ASCT 
 
Whilst much work has focused on the role of KIR-HLA immunogenetics in the setting of allo-
SCT, there is a paucity of information of their role in the autologous setting.  
 
To date, only two small studies have been reported in the literature; Leung and colleagues 
reported a prospective study of 16 paediatric patients undergoing ASCT for lymphoma and a 
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number of other solid tumour types (including neuroblastoma and Ewing’s sarcoma) to 
determine if the KIR-ligand mismatch model was also applicable in the setting of ASCT as in 
allo-SCT (see below)134. They divided patients into 2 risk groups based on the number of KIR-
ligand mismatches present according to HLA and KIR genotype data (KIR genes present for 
which no self HLA ligand was encoded in the genome). This study identified significantly 
improved DFS post-ASCT in the low risk group (≥ one KIR–ligand mismatch) as compared to 
the high-risk (no mismatch) patients. This study also confirmed that sub-populations of NK 
cells expressed each of the KIR genes identified in the patients KIR repertoire. The emerging 
NK cells were stem cell derived following both myeloablative chemotherapy and CD133 
(stem cell marker) graft selection. Conversely, Stern and colleagues (Cancer 2008)135 
reported that in a larger series of 67 ASCTs for lymphoma and solid tumours, KIR-ligand 
mismatch did not impact on either disease DFS or on relapse rates.   
 
In the United Kingdom, plasma cell disorders such as multiple myeloma (MM) account for 
the largest single indication for ASCT. There is no data on the role of KIR-HLA 
immunogenetics in this patient group, MM is a disease acutely sensitive to immune cell 
modulation (see below). 
 
 
1.10 NK cells and allogeneic stem cell transplantation 
 
The rate of allo-SCT procedures performed in Europe continues to increase with over 11,700 
such procedures reported to the European Group for Blood and Marrow transplant (EBMT) 
per annum136.   
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NK cells are also the predominant subset at day +100 following allo-SCT (Vitale 2004137, 
Cooley and Miller)138 and NK levels are seen to be within the normal range at 1 month, 
regardless of transplant conditioning (myeloablative or reduced intensity) in both adults and 
children (Aversa 2006, Small 1999, Kook 1996)139, 140, 141. The NK subset is also the first to 
normalize when umbilical cord blood is used as the stem cell (UCT) source (Thompson 
2000)142. 
 
As NK cells predominate early in haematopoietic reconstitution following an allo-SCT 
procedure, it is highly likely that they have an important immunological role to play. 
Additionally, any regulatory influences on their actions by other cell types are likely to be 
diminished or even absent. The ALC-30 effect on outcome, well described in the setting of 
ASCT, has also been demonstrated following allo-SCT (Savani 2007)143 where an increased 
ALC and in particular increased NK cell numbers associated with improved outcome. 
Therefore the study of KIR – HLA immunogenetics in patients undergoing allo-SCT is of great 
interest.  
 
 
1.10.2 Haplo-identical allogeneic stem cell transplantation 
In some patients no appropriate HLA-matched donor can be found. This is often the case for 
example in non-Caucasian patients due to a relative lack of non-Caucasian donors. If no 
donor is available then a parent or a sibling sharing only one haplotype may be considered 
as the donor source. Haploidentical stem cell transplantation (haplo-SCT) is a treatment 
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option for the approximately 70% of patients who do not have an HLA-identical sibling 
donor (Spitzer 2005)144 
 
The early complication of severe GvHD initially limited the use of non-identical or haplo-
identical donors (Powles 1983, Beatty 1985, Anasetti 1989)145, 146, 147. However, profound T-
cell depletion of the graft below a threshold of 1–5 x 104 CD3+T-cells/kg significantly 
reduces GvHD (Mehta 2004)148. Aversa and colleagues (1998)150 demonstrated that using 
significant T-cell depletion strategies combined with high dose CD34+ stem cell grafts from 
haplo-SCT resulted in minimal GvHD allowing such transplants to be performed with 
favourable long term outcome (Aversa 2005)149. This is thought in part to be due to an anti-
leukaemia effect of the non-depleted NK population. In haplo-SCT therefore, the donor graft 
is typically highly depleted of donor (CD3+) T-cells and CD34+ cell enriched by dual negative 
CD3+ cell and positive CD34+ cell graft manipulation. 
 
The role of NK cells in the setting of haplo-identical transplant is a field of great interest and 
it is in this setting that the role of KIR has been most extensively studied and is discussed at 
length below.  
 
The seminal work on the role of KIR in allo-SCT was published in 2002 by the Perugia based 
transplant group of Andreas Velardi and colleagues (Science 2002)151. This group clearly 
demonstrated the existence of an in-vivo ‘missing ligand’ effect in humans following Haplo-
SCT. Recipients receiving donor stem cell grafts containing NK cells expressing KIR molecules 
recognizing HLA molecules expressed on donor cells but which were absent on recipient 
haematopoietic cells (KIR-Ligand mismatch in the graft versus host direction), lead to the 
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presence of allo-reactive NK clones. This donor versus recipient NK cell allo-reactivity 
correlated with the ability to eliminate leukaemic relapse and graft rejection, and protected 
against graft versus host disease (GvHD) (see below).  
 
This study of 112 patients with acute myeloid leukaemia (AML), demonstrated that patients 
with allo-reactive NK clones had a 60% event free survival (EFS) as compared to 5% in 
recipients lacking any such a clone. KIR-ligand mismatch was the only predictor of survival 
and conversely lack of mismatch was the only independent predictor for poor outcome. In a 
follow-up publication, the authors further defined that KIR-ligand mismatch was the most 
beneficial factor for long-term relapse-free survival in patients transplanted in complete 
remission (EFS: 3% v 47%). Notably this effect was only seen in AML and not in ALL. In 
patients with allo-reactive NK clones, those receiving stem cells from haplotype B donors 
with ≥ 3 activating KIRs had significantly improved EFS.   
 
In a different study of haplo-SCT in 62 patients with a variety of haematological 
malignancies, (ALL, AML, and CML) reduction in the depth of T-cell depletion (compared to 
the previous study) was associated with loss of KIR mismatch effect on disease relapse 
(Bishara 2004)152. Potential NK allo-reactivity as determined by KIR mismatch was associated 
with increased risk of severe GvHD (see below) and inferior OS. Furthermore, increasing 
numbers of aKIR correlated with GvHD grade. The only main difference in this and the 
Perugia study was the total number of CD3+ T-cells in the stem cell graft. In the current 
study the median number of CD3 cells 10.8 x 104 vs 3 x 104. This is above the cut-off CD3 
dose found by Mehta et al (above)148 to be associated with GvHD. Severe GvHD is likely to 
mask any survival benefit secondary to KIR–ligand mismatch which may explain the different 
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findings between these studies, further, study may not have been powered to detect KIR 
mismatch effect compared to the first study with double the number of patients. Similarly, 
minimal T-cell depletion in a paediatric patient cohort undergoing haplo-SCT also showed no 
advantage for KIR-ligand mismatching but again an increased risk of GVHD (acute and 
chronic) and death (Lowe 2003)153. These data suggest KIR-ligand to be a very important 
mediator in the success of haplo-identical SCT but that any reduction in the extent of T-cell 
depletion in the conditioning abrogates this effect of NK allo-reactivity possibly by an effect 
of T cells either on NK cells, or by a masking of NK effect by GvHD affecting OS 
 
 
1.10.3 KIR and Unrelated Haematopoietic Stem cell Transplantation 
 
The role of KIR-ligand mismatching in the context of an unrelated (HLA-matched) transplant 
(above) is more complex and results are conflicting. Similar to T-replete haplo-SCT, two 
studies in T-replete or minimally depleted allo-SCT (Davies 2002, Farag 2006)154, 155 failed to 
show any advantage for KIR-ligand mismatching. This has been postulated to be due to poor 
reconstitution of allo-reactive NK bearing clones relative to the highly T-deplete haplo-
identical setting where there is both a decreased T cell component to the graft and an 
enriched NK source (CD34 progenitors) (Velardi EBMT)115. As described, T-cell depleted have 
on average a 4-log more T-cells than a haplo-identical graft, which is thought to affect NK 
development. 
 
In contrast to these findings, two independent large studies in T-replete myeloablative allo-
SCT cohorts have shown a protection against relapse for myeloid malignancy (Hsu 2006, 
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Miller 2007)156,157. The reason for such difference findings is unclear. One possible 
explanation for the observed improved outcome with KIR-ligand mismatch in what is a 
relatively small cohort (n=178) by Hsu in patients with myeloid disease, is that unlike the 
former studies this investigation performed formal KIR genotyping to identify mismatch 
rather than using HLA typing to determine the potential for NK allo-reactivity (where NK 
allo-reactivity is defined as a donor HLA genotype containing KIR ligands (MHC) not part of 
the HLA genotype of the donor). This basis of determining mismatch may not always be 
correct, as KIR and HLA segregate independently and the KIR repertoire is regulated by the 
KIR and not the HLA genotype.  
 
Therefore, KIR typing by PCR is more accurate. A similar number of patients (to the Hsu 
cohort), who did not have KIR genotyping group, did not show any survival advantage 
(Davies 2002)154. Indeed Leung has determined that KIR genotype is superior for the 
determination of NK allo-reactivity to HLA methods. Miller (2007)157 whilst not using KIR 
genotyping, was able to show an advantage for KIR-ligand mismatch, however this study 
investigated some 481 more patients compared to Farag. Such increased numbers could 
conceivably have overcome the less accurate effect non-KIR genotyping to show a 
difference. Additionally, the protective effect of mismatch described by Miller was more 
predictive for early myeloid malignancy as compared to more advanced stage. In the study 
by Farag155, almost 50% of patients were in advanced phase disease and they did not 
separately analyse patients by stage at transplant. The stage at transplant may be very 
important to know as such NK alloreactivity akin to T-cell allo-reactivity is more likely to be 
successful in patients with minimal disease.  
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More recently, it has been demonstrated that in the first 3 months following HSCT, NK cells 
from unmanipulated (no/minimal T-cell depletion) donor grafts have reduced KIR expression 
as compared to T-cell depleted grafts (Cooley and Miller 2009)168. This reduced KIR 
expression was also associated with inferior survival. This may in part explain the 
discrepancies of the effect of KIR mismatch seen in stem cell transplants with differing 
degrees of T-cell depletion. This hypothesis is supported by data from Giebel (2003)169  who 
reported a survival advantage in KIR-ligand mismatched allo-SCT in myeloid malignancies 
following T-cell depletion using in-vivo ATG. Similarly, use of ATG in the conditioning of 
patients with has shown similar results in mismatched allo-SCTs for MM (Kroger 2005)170.  
 
1.10.4 KIR Haplotype and Allogeneic Stem Cell Transplantation 
 
Independent of KIR mismatching, patients transplanted with stem cell grafts from donors of 
KIR Haplotype Bx (see above) have been demonstrated to have superior transplant 
outcome. Cooley et al171 reported a 30% improvement in relapse free survival in patients 
receiving a B haplotype derived (T-replete) stem cell source. This haplotype was associated 
with a slight increase in chronic (but not acute) GvHD. A combination of KIR2DS1, KIR3DS1, 
and KIR2DL5A, haplotype B conferring KIR genes, has also been associated with reduced 
relapse of myeloid disease in the T-deplete setting (Stringaris 2009)172.  
 
The role of the KIR haplotype in allo-SCT has been further refined; within Group A and B KIR 
haplotypes, the position of each KIR gene is fixed resulting in distinctive centromeric and 
telomeric gene-content motifs (Figure 1.3). The B haplotype can therefore be seen as 
containing the KIRs; 2DS2, 2DL2, 2DL5B, 2DS3, 2DP1, and 2DL4 in the centromeric portion, 
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whereas the telomeric portion contains 3DS1, 2DL5a, 2DS5, and 2DS1. The centromeric 
portions of haplotypes A and B are known as CEN A and CEN B respectively, and their 
telomeric portions TEN A and TEN B (Gourrad 2010)173.  Linkage disequilibrium splits around 
KIR2DL4, which lies between TEN and CEN motifs. Genes within the CEN regions show LD 
with each other, as do the genes within the TEN region. So for example KIR2DS2 and 
KIR2DL2 are in strong LD. In addition, the CEN genes KIR2DL5B and KIR2DS3 show moderate 
LD with the TEN genes and KIR2DL4 shows moderate LD with the CEN genes.  
 
These defined motifs may have clinical relevance. Cooley et al174 demonstrated in over 1000 
unrelated donor allo-SCT for AML (though not in ALL) in which the stem cell donor 
possessed either the centromeric and/or telomeric motifs of haplotype B, a protection 
against relapse and improved OS as compared to donors with only haplotype A motifs.  
Furthermore, they showed that CEN B / CEN B homozygous donors conferred the greatest 
protection against relapse. This could in part explain the findings of Stringaris et al172 where 
the 3 genes conferring protection against CML were those of the TEL B motif.  
 
 
Figure 1.3 Schematic view of the KIR haplotypes A and B. Framework genes are depicted 
in white with activating and inhibitory KIR depicted in grey and black respectively. 
Centromeric and telomeric motifs of both haplotypes are shown.   
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1.10.5 KIR and Reduced Intensity allo-SCT 
 
Reduced-intensity conditioning (RIC) refers to the use of reduced dose (less intense) chemo-
radio therapeutic regimens than are used in conventional full-dose myeloablative allo-SCTs. 
The goal of RIC is to reduce disease burden, but also to minimise treatment-related 
morbidity and non-relapse mortality (NRM) in the period during which the beneficial GvL 
effect of allogeneic transplantation develops. RIC has allowed HSCT to be used in older 
patients. Patients undergoing RIC allo-SCT initially exhibit mixed T-cell and whole blood 
chimerism (a situation in which both donor and recipient haematopoiesis is evident). Most 
patients will subsequently convert to full-donor chimerism.  
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In respect to RIC allo-SCT, the potential benefits of KIR-ligand mismatch remains debatable. 
As described, following RIC, there is the potential for an initial state of mixed chimerism, and 
in this setting, KIR-ligand mismatch in the host versus graft direction has been shown to 
correlate to increased graft rejection together reduced rates of achievement of complete 
donor chimerism (associated with less relapse) (Sobecks 2008)175. This suggests that residual 
recipient NK cells may also affect donor haematopoietic tissue and may therefore 
conceivably reduce any GvL effect. This could counteract any effect of KIR-ligand mismatch 
in the GvH direction. This theory is strengthened by the findings of Baron and Storb 
(2009)176, who demonstrated increased early donor NK chimerism was associated with low 
relapse rates (without high rates of GVHD). These data support the notion that high NK cell 
numbers early post-SCT are important effectors of disease control and important regulators 
of GvHD (discussed below). However, in this study, no impact was seen after adjustment for 
KIR mismatching. This could in part be due to the fact that the study had relatively small 
numbers, and that and recipient T-cells as well as autologous (donor) T cells present during 
the mixed chimeric state, might potentially affected KIR expression. To date there are no 
studies which have addressed KIR development in a mixed chimerism setting.   
 
1.10.6 Breaking of tolerance following allo-SCT  
 
Several studies have shown an anti-leukaemic effect in the situation of fully HLA-matched 
allo-SCT (Clausen 2007177, Hsu 2006166 and Hsu 2005178). In this situation, there can be no 
mismatch effect.  Such findings have led to the suggestion that it is possible there is break of 
NK self-tolerance in the post-transplant setting.  As briefly mentioned above, Yu and 
colleagues demonstrated in T-cell depleted HLA/KIR matched allo-SCT39, that there is a 
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defined period where emerging NK cells with iKIR to ‘non-self’ have not fully acquired self-
tolerance and instead of being in a hypo-responsive state, are activated according to the 
conventional missing ligand theory. Similarly in the immediate post transplant setting, iKIR 
(licensed) for ‘self HLA’ become hyper-responsive. Thus there is a transitional state in the 
first 3 – 6 months post transplant, when most NK cells expressing KIR recognise missing 
ligands and are ‘responsive’ before they undergo progressive anergy and tolerisation. 
During this period NK are capable of allo-reactivity. This may explain the lower relapse rates 
observed after HLA-identical transplants if the patient lacks class I ligands for donor KIR. The 
defined period of reduced tolerance and hyper-responsive licensed cells may explain the 
finding that at 1 year allo-reactive clones were not demonstrated after haplo-identical allo-
SCT (Ruggeri 1999)179-180 as NK clones become tolerised to their new immunological milieu 
(Yu 2007)39  
 
1.11 The role of NK cells in Graft Versus Host Disease  
 
Graft versus host disease (GvHD) is a serious complication following allo-SCT, which limits 
the use of this potentially curative procedure (Ferrara 1992)181. Acute GvHD (aGVHD) is the 
most frequent morbid complication after allo-SCT (Weisdorf 2007)182 which may occur in 
30% to 50% of HLA-identical sibling donor transplantations and more frequently after 
unrelated donor transplantations (Cahn 2005, Weisdorf 2007)182, 183.  
 
GvHD is mediated by the activation and proliferation of allo-reactive T-cells resulting in 
subsequent tissue damage. The pathogenesis of GvHD is multi-factorial: (1) the conditioning 
regimen toxicity exposes neo-antigens, enhances pro-inflammatory cytokine production, 
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and increases APC presentation of allo-antigen to donor T-cells (2) Infused donor T-cells 
recognise allogeneic peptides presented by the APC, are activated, expand and migrate to 
lymphoid organs resulting in a further expansion before target tissue infiltration (Przepiorka 
1995)184.  
 
Acute GvHD is defined as occurring within the first 100 days following stem cell infusion, 
whereas GvHD occurring after this time period is referred to as chronic (cGvHD). This 
definition is not ideal, and ‘late-onset acute GvHD’ may occur after 100 days and an overlap 
syndrome with features of both acute and chronic is described (National Institutes of Health 
1991)185.  
 
The organs most commonly affected by aGvHD include the skin (81%), the gastro-intestinal 
(GI) tract (54%) and the liver (50%) (Martin, Blood 1990)186. Skin GvHD may present as a 
simple erythematous rash progressing in its more serious form to bullae or toxic epidermal 
necrolysis (Rowlings 1997187, Martin 1998188, Weisdorf 1990189). GI symptoms typically 
present as nausea and vomiting (Glucksberg 1974, referenced in 189) but most 
characteristic is a secretory diarrhoea which can be often high volume, GI ulceration may 
occur, leading to haemorrhage associated with poor prognosis (Nevo 1999) 190. Liver GvHD 
can range from a mild derangement of liver function to frank hepatic failure. GvHD is itself 
immunosuppressive, resulting in an increased propensity to infections. For severe GvHD 
(grades III-IV), survival rates beyond 1-years are approximately 10–15%. (Leisenring 
2006)191.  
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NK cells can suppress GvHD whilst maintaining a GvL effect. Donor NK cells have been 
demonstrated to lyse host APC, thus preventing donor T-cell activation and GvHD induction 
(Ruggeri 2002151, 2006)192.  In murine models, the infusion of activated NK cells promotes 
survival due to a reduction in the rate of GvHD. This beneficial effect is abrogated by anti-
TGF-  monoclonal antibodies, suggesting that the effect of NK is may be through TGF-  
(Asai 1998)193. Post allo-SCT, NK cells are found in the lymphoid organs where T-cell 
activation and proliferation occurs, and can also be found in target organs (Olson 2009)194. 
Thus, NK cells are situated in close proximity to allo-reactive T-cells, supporting a NK – T cell 
crosstalk.  
 
 
 
NK cells proliferate in lymphoid organs where T-cell activation and proliferation occur (Olson 
2009)194. Similarly, such cells are also found in the target organs where activated alloreactive 
T-cells can be demonstrated. Activated T-cells up-regulate the ligands (MICA and MICB) for 
the activating NK NCR, NKG2D. Autologous NK cells have also been shown to lyse such 
MICA/B expressing T-cells. This represents a mechanism by which NK cells may control 
rapidly proliferating GvHD inducing T-cells. Olson (2010)195 and colleagues have more 
recently demonstrated that allo-reactive T-cells are also the target of direct killing by 
autologous NK cells. In a murine model of SCT, donor NK cells when infused into mice with 
donor allo-reactive T-cells resulted in increased numbers of T-regs cells without loss of GvL 
effect.  
 
70 
 
It is possible that allo-reactive NK cells may have enhanced ability to kill APC in the KIR-
ligand mismatched setting. The concept of NK cell clones affecting DC function has been 
shown in NKG2A/CD94+ NK cells, where during ongoing inflammation, these NK cells 
acquire cytotoxic function against (autologous) immature (monocyte derived) DCs, and are 
associated with a down-regulation of HLA-E (cognate ligand for NKG2A/CD94) (Della Chiesa 
2003)197. However, in this study did not show any effect mediated by KIR+ (KIR3DL1+ or 
KIR2DL+ cells) following the down regulation of DC expressed HLA-C. However, more 
recently, Sivori et al (2011)198 have demonstrated killing of allogeneic DC, (and T-cell blasts), 
by KIR2DS1+ NK cells. The mechanism for this remains unclear. This suggests that certain KIR 
expressing NK clones may indeed be more effective at inducing GvHD whereas others may 
be important in limiting GvHD. The KIR repertoire, and the rate of acquisition KIR following 
HSCT may therefore influence GvHD rates. In the study by Miller suggesting mismatch may 
be associated with GvHD, the authors were unable due to lack of KIR genotyping, to 
implicate specific KIR-ligand mismatches. 
 
If KIR3DL1 reduces DC killing by NK cells, then one would expect it to be associated with 
increased GvHD. Whilst there is no supportive evidence for this, interestingly, KIR3DS1 the 
antagonistic receptor to KIR3DL1 however been associated with a reduced risk of GVHD in a 
KIR genotype analysis (Venstrom 2010199). 
 
There is some evidence to suggest that KIR-mismatch and KIR B haplotype are associated 
with GvHD (Miller 2007167, Kroger 2006170, Geibel 2009)169. The mechanism for this, is to- 
date unclear, however T-cells also express KIR, and KIR recognition of foreign antigen could 
theoretically activate T-cells. In a murine model, Sun et al (1999 abstract only available)200, 
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reported that infusion of activated NK cells 4 hours pre-BMT (where the graft contained T-
cells), prevented GvHD. Conversely, such NK infusions 72 hours following stem cell infusion 
significantly exacerbated GvHD. The reason for this is unclear, however NK cells can be seen 
to have an effect on DCs, and this effect may be greatest when there are no/few T-cells 
present, as T-cells have been described to modulate NK Cells in the post-transplant setting 
(see above). Further evidence that NK cells may be implicated in GvHD induction is 
evidenced by Rhoades et al (1993)201 who describe significant increases in CD16+, CD56+ 
cells in skin biopsies with grade II-IV without any significant increases in CD3+ cells (CD4+ or 
CD8+). However a number of other studies have shown that the biopsies of GvHD organs 
are not infiltrated by NK cells but dominated by CD8+ T-cells (Heldal 2004202, Dickinson 
1998203, Sviland 2001 204). These conflicting data highlight that the role of NK cells in GvHD is 
far from fully elucidated.  
 
1.12 Multiple Myeloma 
 
Multiple myeloma (MM) is a haematological neoplasm characterised by the infiltration of 
the bone marrow, by a malignant plasma cell clone. The malignant clone also most 
commonly produces a monoclonal immunoglobulin (paraprotein) which itself also gives rise 
to symptoms. The complications and symptoms in MM vary according to both tumour 
burden and the disease biology (cytokine and immunoglobulin secretion). Approximately 
10-40% of patients with MM are asymptomatic at diagnosis. Symptoms may include bone 
pain and spontaneous fractures, weakness and weight loss, and increased propensity to 
infection. High paraprotein levels may lead to renal failure (50% of patients develop renal 
impairment at some stage), neurological symptoms, or symptoms of hyperviscocity.  
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With current available therapies, MM remains incurable. Furthermore, the outcome of 
patients treated with conventional approaches (mainly alkylating agents and 
glucocorticoids), is unsatisfactory. High-dose therapy with ASCT has led to improved 
survival, with a median survival of 2 to 3 years for older, and 5 to 6 years in younger 
patients. However, most patients will relapse following ASCT suggesting failure of ASCT to 
eradicate the malignant clone and the presence of sanctuary sites allowing re-population by 
the residual disease post auto-PBSCT.  
 
Allo-SCT remains the only potentially curative treatment, at least in part because of a graft-
versus-myeloma (GvM) effect. However, high TRM remains a barrier to more widespread 
acceptance and use of allografting. The GvM effect supports a role for the immune system 
in the outcome of MM. Thus, identification of biological factors that can help predict the 
outcome of current standard therapies (ASCT) and hence direct the use of more intensive or 
additional novel treatments would be valuable. There is clinical urgency to develop novel 
strategies to improve the outcome of patients undergoing auto-PBSCT. 
 
An increased ALC (see above) early post-transplant is associated with improved outcome of 
ASCT for MM. Two large independent studies of patients with MM have shown that 
elevated ALC-23 or ALC-30 both predict for both improved OS and PFS127, 130. These data 
suggest that the host immune system influences progression of the plasma cell clone  
 
As MM, the largest indication for ASCT is sensitive to immune control, and NK cells appear 
to be important in control of malignant plasma cells, together with emerging data 
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suggesting a possible role for KIR-ligand interactions after ASCT. It is highly possible that the 
KIR repertoire may be important in influencing outcome after ASCT in MM.    
 
1.13 Killer Immunoglobulin Receptors and Infection  
 
1.13.1 Viral Infections  
 
The role of NK cells in the control of infections is best characterised for viral infection. The 
two viruses where the roles of KIR and KIR-HLA immunogenetics have been extensively 
studied and a clear role demonstrated are the human immunodeficiency virus (HIV) and the 
hepatitis C virus.  
 
1.13.2 Human Immunodeficiency Virus 
HIV-1 infection is a major public health problem Worldwide, with exponential increases in 
the number of UK sero-positive individuals. Between 5 and 15% of HIV-1 infected individuals 
are long-term non-progressors. Non-progressors maintain normal CD4+ T-cell counts and do 
not progress to Acquired Immune Deficiency Syndrome (AIDS) in the absence of anti-
retroviral treatment (Deeks 2007). Identification of factors, which prevent AIDS, or which 
reduce the risk of sero-conversion after virus exposure is the major goal of physicians 
treating HIV+ patients.  
 
NK cells are the major effectors of the immune response to HIV-1 infection, and are seen to 
expand early after infection. (Alter 2007)206. NK activity has been shown to be inferior in HIV 
sero-converted subjects as compared to individuals exposed to the virus but remaining sero-
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negative. In particular it is the KIR3DS1 and KIR3DL1 expressing NK sub-sets that are 
preferentially increased in HIV, and it is thought such cells may be important in the 
aggressive response to early infection. KIR3DS1 in association with an HLA-B molecule with 
an isoleucine residue at position 80 (HLA-B4 80I) has been associated with a protective 
effect against the progression to AIDS in HIV+ treatment naïve individuals (Martin 2002)207. 
This was the first demonstration of an epistatic association between KIR and HLA in human 
disease. Further studies revealed that this interaction correlated with both decreased viral 
load (VL) and protection from opportunistic infection (Qi 2006208) and that KIR3DS1 
homozygotes were over-represented in HIV exposed individuals who remained HIV sero-
negative (Boulet 2008)209.  
 
This genotype effect has been borne out in functional NK activity studies, with KIR3DS1+ NK 
cells inhibiting viral replication in HLA-Bw4 80I +ve HIV infected cells with no inhibition seen 
by KIR3DS1 -ve cells (Alter 2007)210. Following 14 day incubation with autologous infected 
CD4+ T lymphocytes, KIR3DS1+ NK cells were seen to decrease HIV viral replication (as 
assessed by an enzyme-linked immunosorbent assay; ELISA for p24 protein, an HIV virus 
capsid protein and marker of infection). In order to exclude that this was not simply due to a 
reduction in p24 secretion with prolonged infection as opposed to reduced infection, the 
investigators also looked at p24 expression by intracellular cytokine (ICC) staining. This 
technique, which directly determines the number of infected cells, demonstrated that co-
incubation with KIR3DS1+ NK cells contained viral spread, and that viral replication whilst 
inhibited in all CD4+ cells, inhibition was most prevalent in the HLA-Bw4 80I +ve fraction.   
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KIR3DS1/DL1 transcript number is also noted to be increased in apparently protected 
individuals (Ravet 2007)211. Whilst it is easy to understand the effect of the activating 
receptor KIR3DS1 in reducing viral replication, the association with the inhibitory KIR3DL1 is 
less clear. 
 
KIR3DL1 surface expression on NK cells may be of high intensity (3DL1*h), low intensity 
(3DL1*l) or absent (3DL1*004).  KIR3DL1*h/*y individuals  (where only high expression 
alleles are present) in-conjunction with HLA-B57 (an HLA-Bw4 80I allele) have been 
associated with the most profound reduced risk of progression to AIDS (Martin 2007)212 and 
decreased risk of infection (Boulet 2008)213 One hypothesis is that KIR3DL1 cells are more 
finely tuned to kill infected cells after the preferential down-regulation of HLA-B (inhibitory 
ligand) by the action of the HIV Nef protein.  
 
However, it should also be noted that 3DL1 and 3DS1 share 97% amino acid homology, are 
thought to share the same ligands, and exhibit strong LD. It is conceivable therefore, that NK 
cells expressing either (or both) receptors have improved anti-HIV activity as compared to 
‘bulk’ NK cells.   
 
Recent work by Boulet and colleagues214 has suggested that similar to the KIR3DS1+ cells in 
the study by Martin, KIR3DL1+ NK cells are also endowed with preferential activity against 
HIV infected CD4+ cells. They demonstrated in KIR3DL1+, Bw4+ individuals, that 3DL1+ NK 
cells had an increased fraction of tri-functional cells with increased IFN- , TNF-  and CD107a 
expression compared to 3DL1-ve cells. In HLA-Bw4 negative, (Bw6+) individuals, only TNF-  
expression was increased in this sub-population.  
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Conversely, certain KIR genes have been associated with a worse outcome in HIV sero-
positive individuals. In genotype studies, the activating KIR2DS4*001 allele and KIR2DS2 has 
been associated with both increased VL and accelerated HIV-I transmission (Merino 2008, 
Gaudieri 2005)215, 216. The reason for this association is unclear but both KIR2DS4 (Merino 
2008)215 and KIR2DS2 (Estefania 2006)217 are associated with genital infections, which 
increase the HIV transmission risk.  
 
The work on the role of KIR expressing NK cells in the setting of HIV infection highlights the 
possibility of different KIR expression conferring different effector properties.  
 
 
1.13.3 Hepatitis C 
Hepatitis C virus (HCV), as with HIV, is a virus of major public health importance, with as 
many as 170 million people affected Worldwide (Wong 2006)218. The principal route of 
transmission is intravenous needle use. In the natural history of hepatitis C, approximately 
80% of infected individuals develop chronic infection, 10-20% of those developing cirrhosis 
with 2% subsequently developing hepatocellular carcinoma (HCC). Similarly to HIV, NK cells 
play an important role in the control of this virus (Golden-Mason 2006)219. NK and NK-T cells 
have been shown to directly induce the apoptosis of virus infected hepatocytes after co-
culture (Kakimi 2000)220, and have also have been demonstrated to suppress HCV RNA 
expression in HCV-replicon containing cell. Increased numbers of CD56bright cells are seen 
in the peripheral blood of non-viraemic carriers suggesting that such cells can modulate the 
natural history of the disease. Furthermore, defective NK responses have been associated 
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with the persistence of HCV viraemia following infection (Coardo 1997221, Kawarabayashi 
2000222, and Deignan 2002223). IFN-  used in the treatment of HCV infected patients with 
persistent viraemia, results in a significant improvement of NK activity, which correlates 
with treatment response (Gabrielli 1995224, Bonavita 1993225).   
 
With regard to KIR genetics, Khakoo and colleagues (2004)226 demonstrated a protective 
role for KIR2DL3 in-conjunction with HLA-C group 1 (C1), which was associated with 
spontaneous virus clearance. The KIR2DL3/C1 interaction has also been shown to be 
associated with spontaneous viral clearance after treatment with pegylated IFN-  and 
Ribavirin, and this was gene dose dependant (both KIR and HLA) (Vidal Castineira 2009)227. 
One proposed explanation such observations in which an inhibitory KIR show improved viral 
control, is that KIR2DL3 has a lower avidity for HLA-C1 than KIR2DL2. Viral peptide (influenza 
virus) expression on MHC molecules can interfere with the binding of KIR (Fadda 2010)228. 
Therefore it is has been suggested by Khakoo and Jamil (2011)229 that hepatitis C peptides 
may more easily interrupt the already relatively weak inhibitory KIR2DL3-C1 interaction 
resulting in anti-viral responses. In KIR2DL3-C1 patients, the addition of KIR2DS4 in the KIR 
repertoire confers even greater protection against hepatitis C (Zuniga 2009) 230.  KIR2DS2 on 
the other hand has also been associated with an increase in treatment non-responder status 
(Vidal Castineira 2009227, Askar 2009)231.  
 
1.13.4 Cytomegalovirus 
 
After GvHD, post transplant infection is the most common cause of mortality after allo-SCT. 
Bacterial, fungal and viral infections are seen and are a significant cause of mortality or 
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morbidity in the transplant patient. In this period of immune compromise, in addition to 
opportunistic infection, reactivation of latent viruses such as cytomegalovirus (CMV) is 
commonly seen. 
 
Two independent studies have demonstrated that increased numbers of activatory KIRs are 
associated with a reduction in CMV reactivation after myeloablative sibling allografts. This 
effect seen in the study by Cook et al was subsequently lost if in-vivo Alemtuzumab (anti-
CD52 Mab) was used for T-cell depletion.  The presence of KIR2DS2 and KIR2DS4 has also 
been shown to confer the protection against CMV reactivation in a genotype association 
(Zaia 2009)232. Stern and colleagues more recently (2011)233 have shown that following renal 
transplantation TEN B positive individuals have greatest protection from CMV reactivation. 
TEN B contains, KIR2DS1, which along with KIR2DS2 is increased in its expression on CMV 
specific CD8+ T-cells during peak viraemia. KIR2DS2/DL2 and KIR2DL1/DS1 are seen in 
increased frequency on T-cells in CMV infected healthy patients. Thus it can be seen that 
CMV reactivation a major problem post-SCT is likely dictated by KIR.  
 
1.13.5 Other Viruses 
KIR3DS1 and KIR2DS1 have also been associated with protection from severe respiratory 
papillomatosis (benign upper airway tumours) caused by human papilloma virus  (HPV-6/11) 
(Bonagura 2009)234. Whilst these activating KIR appear to be protective against viral 
infection, data suggest that the presence of other KIR genes maybe associated with poor 
responses to after viral infection; KIR2DS2/DL2 is associated with recurrent herpes virus-1 
following primary infection, interestingly this gene is also the same KIR correlates with non-
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response to HCV treatment (above). KIR2DS1 and KIR2DS3 are both increased in frequency 
in patients with a fatally poor response against Zaire Ebolavirus (Wauquier 2010)235.  
 
1.13.6 Non-Viral infections 
 
Whilst the majority of data suggesting a role for KIR molecules in control of infection is in 
the context of viral disease, limited emerging data suggests that KIR interactions may be 
important in parasitic and bacterial infections.  
 
Continuing the theme that an individual’s KIR repertoire may be important in significant 
pathogens in man, KIR genotype has been associated with susceptibility to malarial 
infection. Worldwide approximately 300 million people suffer from malarial infections, 
accounting for 1 million deaths per annum (WHO 2003). The NK cell appears important in 
the initial response to plasmodium infection (hepatic and blood phases of the disease). In-
vitro data show significant up-regulation of NK IFN-  production after co-culture with 
infected erythrocytes, suggesting that NK cell receptors recognise parasite-derived 
molecules as cognate ligands (Artavanis-Tsakonas 2003)237.  
 
KIR3DL2*002 allele was implicated in this response as an increased frequency of NK cells 
expressing this receptor was seen within the high IFN-  expressing NK cell population. 
(Artavanis-Tsakonas 2003)237. Further evidence of a role for KIR in malaria was 
demonstrated by Taniguchi and Kawabata (2009)238 who showed an increased frequency of 
KIR3DS1/3DL1 heterozygotes in conjunction with KIR2DS4 (non-deleted alleles, see later) 
compared to an increase of KIR2DS4 negative 3DS1 homozygotes in plasmodium positive 
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versus plasmodium negative subjects.  The authors suggest that this is due to a masking 
inhibitory effect of KIR3DL1 on the two activating receptors. 
 
1.14 NK Cells and Bacteria 
 
NK cells play an important role in the response against intracellular and pyogenic bacteria, 
fungal and protozoal infection (Tay review)239. The ability of NK cells to exert their effector 
function without first requiring a clonal expansion allows them to be the first line of defence 
against such invading pathogens.   
 
The percentage NK of cells in PB, has been demonstrated to be elevated during gram-
negative sepsis, correlates with survival (Giamarellos-Bourboulis 2006)240. This percentage 
increase seen in severe bacterial infection may indeed be species dependant, as  greater NK 
cell increases during sepsis have been seen with some gram positive as compared to gram 
negative organisms (Holub 2003)241.   
 
During bacterial infection, a complex interaction exists between the various cells of the 
innate immune system. NK are central to this process. NK cells produce chemokines, which 
attract and activate neutrophils (Robertson 2002)242, and also may prolong neutrophil 
survival (Costantini 2010243). NK cells have also been demonstrated to interact with infected 
monocytes; infection of monocytes, by Mycobacterial species has been shown to result in 
the production of significant amounts of NK derived IFN- , which subsequently results in the 
stimulation of monocytes to increase cytokine production, including IL-15 and IL-18. These 
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interleukins are important for the expansion of clonal Mycobacterial responsive CD8+ T-cells 
(Vakayalapati 2004)244.  
 
Microbial infection can result in the generation of highly reactive oxygen species (ROS) by 
activated neutrophils. These ROS can inhibit NK effector function and also affect NCR 
expression; ROS have been demonstrated to reduce the NKp46 expression on CD56dim NK 
cells and to increase their susceptibility to apoptotic death. CD56dim cell depletion has been 
shown to be associated with chronic Mycobacterium infection, supporting the above data 
that such cells have important anti-microbial function.   
 
During microbial infection, NK cells are activated by cytokines produced by APCs. This leads 
to the secretion of the pro-inflammatory cytokines IFN-  and TNF- , which (as described) 
subsequently modulate the function of monocytes, and also dendritic cells increasing the 
overall anti-bacterial response.  NK cells respond to cytokines from pathogen-associated 
molecular patterns (PAMPS) activated innate cells (Haller 2002).  
 
 
1.16.2 Killer Immunoglobulin and Bacterial Infection 
 
With regard to KIR molecules, there is a paucity of data on their role in bacterial infection. 
Mendez et al (2006)247 suggested that increased KIR2DL3 frequency was associated with 
susceptibility to Mycobacteria tuberculosis infections and that the combination of KIR2DS2 
and HLA C1 was less prevalent in a tuberculosis cohort as compared to controls, suggesting 
that this compound genotype conferred some protection. With respect to bacterial infection 
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post allo-SCT, killer immunoglobulin haplotype Bx donors have also been associated with a 
reduced risk of bacterial infection in recipients of unrelated allo-SCT (Tomblyn 2010)248. 
 
The most compelling data that KIR and bacterial responses are linked, comes from an 
elegant study by Sivori and colleagues249. They demonstrated that KIR3DL2 was able to bind 
to CpG ODN (Type C) at the cell surface (with a subsequent decreased KIR density observed). 
The KIR3DL2 and bound CpG were seen to then be co-internalized and translocated to the 
endosomes. Endosomes are rich in TLR-9, here KIR3DL2 was seen to dissociate from CpG 
allowing the binding of the bacterial product to its receptor. In this way KIR3DL2 is thought 
to act as a chaperone molecule associating with CpG. Following stimulation with CPG ODN, 
only KIR3DL2 positive cells were stimulated to produce IFN-  and hence have demonstrate 
anti-microbial activity. Notably neither flagellin (TLR-5 ligand), Poly I:C (TLR3 ligand) nor 
RNA40, Poly U or R848 (TLR-7 and 8 ligands) modulated KIR3DL2 expression or caused 
cytokine production, suggesting that binding was specific to CPG ODN.  
 
In addition, KIR molecules have also been shown to directly bind to other molecules such as 
the heat shock proteins (Hsps) (discussed in depth later). Briefly hsp are major antigens of 
many pathogenic organisms and recognition of these proteins results in strong humoral and 
cellular responses to infections (Zugel 1999)250. Immune responses against bacterial derived 
hsp (most frequently hsp-60, hsp-70, and hsp-90) from many infectious agents including 
Klebsiella pneumoniae, Escherichia Coli, Pseudomonas aeruginosa, Mycobacteria species, 
Aspergillus fumigatus, and Candida albicans have been demonstrated in humans. 
Interestingly all these organisms are also important pathogens in the context of allo-SCT 
(and indeed ASCT).   NK cells have been shown to be activated by hsp, and Hsp-70 has been 
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shown to increase the expression of MICA, resulting in inflammatory cytokine production 
following NKG2D ligation (Qiao 2008)251. Furthermore hsp-70 expressed on the surface of 
(pancreatic) tumour cells has been shown attract NK cells, (in a dose dependant mechanism) 
which on migration to the tumour environment subsequently cause NK mediated tumour 
cell lysis (Gastpar 2004)252. This and other similar studies have resulted in a number of 
clinical trials of hsp vaccination in patients with cancer.   
 
 
 
 
 
 
KIR2DS2+ CD4+ CD28- T-cells have been shown to bind directly to hsp 60, resulting in a 
significant up-regulation of the inflammatory cytokine IFN- . This pro-inflammatory effect of 
KIR2DS2+, CD4+,CD28- cells against vascular endothelial cells is implicated in the 
development of atherosclerotic lesions and coronary vascular disease253.  
 
Whilst a large body of evidence strongly supports an important role for NK cells in the fight 
against infection, there is data, which suggests that in some cases they may be detrimental. 
In murine models, during severe sepsis, NK depletion has resulted in a reduced mortality 
(Emoto 2002)254. This decreased mortality correlated with reduced levels of pro-
inflammatory cytokines (IFN-  and TNF- ). It is believed that NK cells contribute to the 
excessive systemic pro-inflammatory response seen early in severe sepsis and that this CK 
release contributes to resultant organ infiltration and pathology (reviewed in Chiche 
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2011)255. NK cells, after an initial period of severe sepsis and activation may then, with 
continued infection, acquire anti-inflammatory properties (possibly in a homoestatic 
mechanism to counteract their excessive response to severe sepsis). During severe sepsis a 
condition known as compensatory anti-inflammatory response syndrome (CARS) develops. 
This state of immune dysfunction is associated with an increased mortality in part due to an 
increase in a nosocomial infection. NK cells have been seen (following Toxoplasma gondii, 
Listeria monocytogenes, and Yersinia pestis infection) to secrete IL-10. One postulation is 
that IL-10 after severe sepsis contributes to CARS and is a second reason why NK may be 
detrimental in severe sepsis.  
 
 
 
Furthermore, NK cell numbers are seen to fall in ICU patients with ongoing infection (Von 
Muller 2007)256. Late in sepsis, there is an increased risk of CMV reactivation, which is 
associated with NK dysfunction/reduced numbers (Chiche 2009)255. Further studies and in 
particular clinical studies in humans are required to fully understand the role of the NK cell 
in the situation of severe sepsis.  
 
As certain KIR molecules, bind PAMPS, they may have differential responses to severe 
infection or to infection during HSCT where there is limited regulation of their activity. The 
understanding of particular KIR clones may therefore be important especially in the context 
of the potential NK infusion trials.  
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HYPOTHESIS 
 
1. The role of the killer immunoglobulin-like receptor in response to treatment in a 
haematological malignancy. 
Since NK cells appear to play an important role in disease control in CML and they are 
affected by tyrosine kinase inhibitors we hypothesise that KIR-HLA genotype will predict 
response to TKI treatment.   
 
2. The role of the killer immunoglobulin-like receptor in autologous haematopoietic stem 
cell transplantation for haematological malignancies. 
 
We hypothesise that following ASCT for myeloma treatment, the NK cell is the major 
determinant of relapse. At the time of NK regeneration there maybe loss of the normal 
regulatory mechanisms, and as such, an individual’s KIR-HLA genotype impacts on EFS and 
OS. 
 
3. The role of the killer immunoglobulin-like receptor in allogeneic haematopoietic stem 
cell transplantation for haematological malignancy 
 
In CML patients undergoing allo-SCT we propose that the KIR repertoire impacts both on 
DFS and OS, and that certain KIR expressing cells may influence the development of graft 
versus host disease. 
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Chapter 2. Materials and Methods  
 
 
Sample Collection 
Informed consent for the retrospective use of archived patient material including DNA has 
been obtained from all patients at initial presentation to Imperial NHS Healthcare Trust, at 
Hammersmith Hospital campus. This allowed access to archived patient samples. Killer 
immunoglobulin (KIR) genotyping and HLA-typing of patient samples was approved by the 
both the National Research Ethics Committee (NREC) and the local ethics review board.   
 
Myeloma Patients 
For the KIR genotyping analysis, all recipients of a peripheral blood autologous stem cell 
transplant (auto-PBSCT) for consolidation treatment of multiple myeloma (MM) were 
identified from the Imperial College NHS Healthcare trust, Hammersmith Hospital campus 
database, which is used for reporting to the European group for blood and marrow 
transplant (EBMT). Patients who had received an auto-PBSCT either as part of a tandem 
auto-PBSCT /auto-PBSCT or tandem auto-PBSCT /RIC-allo SCT, or who had less than12 
months follow-up data were excluded from the study. Archived genomic DNA was collected 
on patients suitable for inclusion in the study where available. Of the 335 auto-PBSCTs 
performed at this institution complete data and adequate DNA samples were available on 
190.    
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Chronic Myeloid Leukaemia Patients  
 
Discovery Sample 
For the KIR genotyping analysis and HLA-typing, all consecutive patients treated with 
Imatinib Mesylate (Gleevec; Novartis: Basel Switzerland) at Imperial College within 6 months 
of diagnosis and who had received no prior treatment for their leukaemia other than 
hydroxycarbamide (previously known as hydroxyurea) were identified. All patients had 
given prior consent for the use of DNA. Access to patient samples was obtained by the kind 
permission of Professor Jane Apperley (Clinical department chair) and from Professor Letizia 
Foroni (head of molecular diagnostics).  
 
Validation sample 
Following the results of the initial study using those patients described above, a validation 
cohort was indentified in order to attempt to replicate results and strengthen our findings 
(see Chapter 4). DNA was obtained from patients enrolled in the SPIRIT 1 study (the 
treatment details of this trial are outlined in chapter 4). Briefly, SPIRIT 1 was a phase III 
multi-centre open labelled treatment study, which opened to patients with CML in first 
chronic phase in October 2005, and which closed to recruitment in February 2009.  
Agreement to use these patient samples was obtained from the trial chief investigator 
Professor Stephen O’Brien (Newcastle UK) and the study management committee consisting 
of Professors J Apperley and T Holyaoke, Dr R.E Clarke and Ms C Hedgley and the NCRN CML 
working group, Newcastle, United Kingdom. Archived trial material was obtained from 
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storage in the laboratory of Professor Letizia Foroni (minimal residual disease, molecular 
diagnostics department of Imperial College NHS Healthcare Trust). Patient data remained 
anonymised and assigned trial numbers were used at all time points.  The codes for the trial 
remained unbroken for this study. 
 
GvHD Patients 
For the study of KIR on the occurrence of GvHD (chapter 5), patients undergoing a stem cell 
transplant for CML in first chronic phase were identified from the specific CML transplant 
database of in-house resident statistician Dr Richard Szydlo. Attempts were then made to 
identify DNA from the stem cell donors (related and unrelated) of these recipients. Due to 
the historical use of serological HLA typing of donors, DNA was only found to be available in 
142 of cases. Of those cases where DNA was found, recorded laboratory sample numbers 
were further crosschecked with the recipient data stored within the HLA laboratory archive. 
Re-reviewing the transplant database made a final check of donor ID to recipient ID. 
 
DNA Concentration Determination  
 
In order to perform KIR genotyping, accurate measurement of 500ng of double stranded 
(ds) genomic DNA was required. This was calculated by use of an automated 
spectrophotometer (Nanodrop 200, Thermo-Fischer Scientific DE, USA) according to 
procedures specified by the manufacturer. Briefly, DNA (1 l) was pipetted directly onto the 
machine pedestal and the arm closed allowing the formation of a liquid sample column. The 
pedestal was the allowed to automatically re-adjust to obtain an optimal path length 
(readings were taken at path lengths of 0.2 and 1mm which allowed a large dynamic range 
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for nucleic acid detection). The DNA containing solution was then exposed to UV light at 
260nm, measures the amount of light passing through (that is the light minus that which is 
absorbed by dsDNA) detected by a photometer). An optical density (OD) of 1 is equivalent 
to 50 g/ml of ds DNA. This was then directly analysed using the corresponding software 
(Nanodrop) and a concentration of DNA estimated. De-ionized H2O was used as a ‘blank’ 
measurement prior to the determination of each batch of DNA measurements; this value 
was then subtracted from all subsequent readings.  
 
Killer Immunoglobulin Receptor Genotyping  
 
Genomic DNA was typed for the presence or absence of the following genes: the inhibitory 
KIR genes; KIR2DL1, KIR2DL2, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL3, the activating KIR 
genes; KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, and KIR3DS1, the framework genes; 
KIR2DL3, KIR2DL4, KIR3DL2, and KIR3DP1, plus the pseudogene KIR2DP1.  
 
Briefly, genotyping was performed using PCR amplification with two locus sequence specific 
primers (PCR-SSP) (InvitrogenTM WI, USA). The primer sets amplified alleles described by 
the International Nomenclature Committee of the WHO (www.ebi.ac.uk/ipd/kir). Internal 
control primers that amplify an 800 bp-fragment and a 200 bp-fragment of the alleles of 
KIR3DP1 (framework gene expressed in nearly all haplotypes) were used to confirm robust 
PCR amplifications. Amplification was performed in 10µl of PCR mix containing 500ng of 
genomic DNA and 5U/µl Taq polymerase (Bioline UK). Cycling was performed as follows: 30 
cycles of; 94° for 20 s, 63° for 20 s, and 72° for 90 s. PCR products were then loaded onto 
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and electrophoresed in a 2% agarose gels containing thidium Bromide and predicted size 
products were visualized under ultraviolet light (An example is shown in Figure 2.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Positive PCR product in KIR3DS1 well: 
KIR3DS1 positive individual  
No PCR product in KIR3DS1 well: 
KIR3DS1 negative individual  
Figure 2.1 A. Example of a photograph of gel electrophoresis of PCR for KIRs from 2 
patients: (left arrow denotes a positive for reaction product with primers of 3DS1 in one 
patient, right arrow denotes a different patient who is negative for the same gene.  B) 
Worksheet from KIR typing kit (Invitrogen®), the red/green arrows denote haplotype Bx 
conferring KIR.  
A 
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KIR Genotype determination 
 
KIR genotype was assigned as follows: Individuals with only inhibitory KIR genes or including 
only KIR2DS4 (allele group A or B) as the only activating receptor gene present, were 
assigned as being haplotype A/A. Individuals with any one or any combination of the 
following genes: KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 or KIR3DS1 with or without the 
presence of the gene encoding the KIR2DS4 alleles were designated as having a genotype B 
or Bx (this includes both heterozygotes (A/B) and homozygotes (B/B) for genotype B). 
 
 
 
 
 
B 
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HLA Typing 
 
HLA tissue typing results for KIR genotype–ligand analyses were obtained from the 
computerized records of the HLA and immunogenetics laboratory at Imperial NHS 
Healthcare Trust, Hammersmith Hospital Campus. For a significant number of myeloma 
patient samples (N=105), only serological typing was available.  In these cases complete HLA 
typing was performed as outlined below. In the CML cohorts, no HLA typing was available 
and this was done on genomic DNA isolated for the KIR genotyping.  
 
To achieve this aim, archived DNA material was indentified and samples were cross- 
referenced with the comprehensive patient database, to confirm that sample number 
corresponded to correct subject.  
 
Low/medium resolution was performed in association with the HLA laboratory staff using in-
house polymerase chain reaction sequence specific primers (PCR-SSP) to amplify regions of 
DNA, which encode defined HLA antigens. DNA was then mixed with specific forward and 
reverse primers at a concentration of 30µg/ml. High resolution HLA class I typing was 
achieved by reference strand conformational analysis (RSCA) using locus in-house specific 
primers to amplify the HLA-A, B and C loci using PCR technique. Briefly: PCR product is 
hybridised to fluorescently labelled reference strands (FLR's) to form heteroduplexes which 
are run on a non-denaturing polyacrylamide gel with a laser based fluorescence detection 
system. Mobility values differ depending on the similarity of the PCR product with the 
labelled reference strand. Types are assigned by comparing the obtained mobility values 
with known values for different alleles.  
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As described in chapter 1, different KIR2 receptors interact with either group 1 or group 2, 
therefore for detailed analyses, HLA-C alleles were classified as group 1 and group 2 based 
on the amino acid at position 8.0. Group 1- Cw*01 (02, 03), Cw*03 (02, 03, 041), Cw*07 (01, 
02, 03, 04, 05, 06), Cw*08 (01, 02, 03), Cw*12 (021, 022, 03, 06), Cw*14 (002, 03), Cw*16 
(01, 03, 041) and group 2- Cw*02 (021, 022, 023, 024) Cw*04 (01), Cw*05 (01), Cw*06 (02), 
Cw*07 (07), Cw*12 (041, 042, 05), Cw*15 (02, 03, 04, 051, 052), Cw*16 (02), Cw*17 (01, 
02), Cw*18 (01, 02) alleles are characterized by the presence of an Asn residue or a Lys 
respectively. Group 1 HLA-Cw motifs are the ligands for KIR2DL2 and KIR2DL3, whereas 
group 2 motifs are ligands for KIR2DL1. 
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Processing, freezing and thawing of PBMNC 
 
Isolation and enumeration of PBMNC 
Peripheral blood mononuclear cells (PBMNC) were isolated from whole blood by density 
gradient separation. Volunteers and patients had approximately 25mls of blood withdrawn 
into EDTA (Ethylenediaminetetraacetic Acid); whole blood (WB) was then mixed in a 1:1 
ratio with RPMI 1640 media (GIBCO / Invitrogen), and 15mls of lymphoprep (Axis Shield, UK) 
was gently layered under 30ml aliquots in a 50ml Falcon tube. After centrifugation at 1800 
rpm for 30minutes (without centrifugation braking) an interface containing PBMNC was 
visible between the plasma above and lymphoprep/red cell pellet below. This ‘buffy coat’ 
(mono-nuclear layer) was collected by gentle suction pipetting and re-suspended in 30-40 
mls of RPMI. Two washing steps were then performed at 1200 rpm for 10 minutes. The cell 
pellet was then re-suspended in 1 ml of buffer and the cells were counted and viability 
determined using 0.4% Trypan Blue (Sigma Aldrich). Cells were counted using a glass 
haemacytometer (Neubauer 2 cells standard, Hawksley UK) briefly; 10 l of cell suspension 
was added and the cells in one large grid (1mm2) were counted using the 10x microscope 
lens, the cell number was then multiplied by 104 to estimate the number of cells/ ml.  
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Cell Freezing 
 
PBMC were re-suspended in freezing media (RPMI-CM with 20% foetal bovine serum (FCS 
GIBCO-Invitrogen)) and 20% DimethylSufoxide (DMSO) (Sigma-Aldrich, UK) by gentle mixing 
on ice, and aliquoted into cryovials. PBMNCs were then stored in -80ºC freezer for 24 hours 
before transfer to liquid nitrogen storage. Foetal bovine serum (FBS) was heat inactivated by 
thawing at 37ºC and then heating to 57ºC for one hour.  
 
Cell Thawing 
 
Cryovials of PBMC were removed from the liquid Nitrogen and transferred to a container 
with ice. The crovials were then placed in a water bath at 37ºC. Once the pellet was mobile, 
the cell solution was transferred to 10mls of RPMI containing 20% FBS. The Cell suspension 
was then centrifuged at 1200rpm for 10 minutes and the cell pellet re-suspended in 1ml of 
media. Cell count and viability assessment were then performed as described above.    
 
Natural Killer cell surface phenotyping 
 
Peripheral blood samples collected from healthy volunteer controls were used for cell 
surface and intracellular co-staining experiments. Cells were cryopreserved and stored in a 
liquid nitrogen freezer. PBMC were then thawed and direct immunoflourescence was used 
to stain for cell surface molecules. The volume of monoclonal antibody (Mab) was 
determined in dose titration experiments (not shown). The volume which resulted in 
maximal mean fluorescence intensity (MFI) and maximal percentage of positively staining 
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cells was selected for each specific monoclonal antibody. The monoclonal antibodies used 
are shown in Table 2.1. Staining was performed according to protocol; briefly, thawed cells 
were washed in 1 ml of PBS (GIBCO-Invitrogen) (pH 7.2). Approximately 1 x105 cells were 
used per sample. Samples were incubated at 4ºC for 30 minutes in the dark with different 
volumes of monoclonal antibody to the surface receptors together plus CD56 (conjugated 
with FITC) and CD3 (conjugated with PerCp) for NK determination. Cells were then washed 
in 2ml PBS buffer and re-suspended in 100μl prior to analysis. Cell surface expression was 
determined using FACSCaliber® and data analysis using Flojo ® software (Ashland, OR, USA). 
The panel and clones of Mabs used for phenotyping experiments is shown in Table 2.1.  
 
Intracellular Cytokine staining   
 
Fresh PBMC were harvested from volunteer donors using the Ficoll separation technique 
described above. Cell counts and cell viability estimations were performed.  1x106 fresh 
PBMC were suspended in 10% FCS containing CM were added to the wells of a 96 well flat-
bottomed plate. The cells were rested overnight at 37 C and 5% CO2. For each cytokine 
investigated a concomitant positive and negative control well was also set up. The following 
morning, 10 l of BFA (1:10 dilution) together with 5 l of Monensin (1:10 dilution) was 
added to each well. To the positive control and test wells 10 l of PMA (1:100) and 8 l of 
Ionomycin (1:50) was added. Wells were mixed and allowed to incubate for a further 6 
hours at 37 C and 5% CO2. Following incubation, cells from each well were harvested with 
gentle pipetting and transferred to a FACS tube. The wells were washed with 200 l of PBS to 
maximize the cell retrieval.  
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Cells were washed with PBS. All washes were performed using 2 mls of PBS and spun at 
2000 rpm for 5 minutes. After discarding the supernatant by gentle pipetting, the cells were 
stained with anti-KIR2DL2/DS2/DL3 conjugated to APC, in the cold (4 C) for 15-20 minutes. 
Cells were then washed to remove excess antibody. Cells were then stained with anti-CD56 
FITC and anti-CD3 PerCP for 15 – 20 minutes at room temperature in the dark. For 
KIR2DL2/DS2/DL3 (and for the intra-cellular cytokine) monoclonal antibodies, control 
staining was performed by using identical samples stained with the identical antibodies 
except the one of interest; fluorescence minus one (FMO). Following surface staining cells 
were then rewashed and re-suspended in 1 ml PBS. To this 1 ml solution, 55 l of 37% 
formaldehyde was added and the suspension gently vortexed, this suspension was then 
incubated for 20 minutes in the dark. Following a further washing step, the cells were then 
suspended in 2mls of a permeabilisation buffer containing (0.5% Saponin) and incubated for 
a further 15 minutes in the dark at room temperature. The manufacture of 0.5% Saponin 
and the permeabilisation buffer solutions are described below. Cells were re-washed and 
stained for the appropriate intracellular marker as follows: MIP-I : 1.25 l of a 0.2mg/ml 
suspension equivalent to 0.25 g; MIP-1 : 1.5 l of 1:10 antibody:PBS suspension (equivalent 
to 0.03 g of antibody); 5 l of anti-IL-2. Cells were incubated with the relevant antibody for 
30 minutes in the dark at room temperature, and a final wash was performed. To the final 
suspension, 100 l of 10% formaldehyde solution was added. Cells were then placed at 4 C 
in the dark until data acquisition suing FACS Caliber. Data analysis was performed using 
FlowJO.  
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The 0.5% Saponin solution was prepared as follows; 10% Saponin solution was made by 
dissolving 5g Saponin (Sigma #S-7900) in 50 ml PBS (Invitrogen) pH 7.4 at room temperature 
in a fume cupboard. This mixture was then placed at 37 C in a water bath until the Saponin 
has dissolved completely. This solution was the filtered through a 0.22 m filter and stored 
at 4 C. The Permeabilisation buffer was prepared as follows; 5 ml of the made 10% Saponin 
solution (above) was added to 95 ml of a PBS/BSA/Azide buffer. This PBS/BSA/Sodium Azide 
buffer was made by the addition of 650 l of 10% Sodium Azide to 1 litre of PBS pH7.4. To 
this solution 5g of BSA (bovine serum albumin) was layered on top and allowed to dissolve 
at room temperature, without stirring. This mixture was the filtered and stored at 4 C until 
subsequent use.  
 
Heat Shock Protein stimulation of PBMC 
 
Recombinant human heat shock Protein 60 was obtained from PROSPEC Tany TechnoGene 
Ltd (Ness Ziona, Israel). This Recombinant HSP-60 is produced in E.Coli as a single polypetide 
chain (containing 593 amino acids) with a purity of 95.0% as determined by RP-HPLC and 
SDS-PAGE. The formulation contained 20mM Tris-HCL buffer (pH 8.0), 5mM Dithiothreitol 
and 10% Glycerol, and was stored at -20 C. Each HSP-60 vial contained 20ug/ul.  
 
Fresh PBMNC were isolated as described above, 2.5 x106 cells were re-suspended in RPMI 
supplemented with 20% FCS. Three different doses of HSP-60 were added to wells 
containing PBMNC; 5, 10, and 20 g/ml, gentle mixing allowed dispersal of HSP-60. Cells 
were incubated overnight (12 hours) at 37 C and at 5% CO2. At 12 hours, BFA and Monensin 
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were added as described above and the cells were incubated at the same conditions for a 
further 6 hours. Similarly positive and negative control wells were set up. To the positive 
well, PMA and Ionomycin were added (as described above) in place of the HSP-60. PMA and 
Ionomycin were added at the same time as the BFA and Monensin. The greatest expression 
of IFN-  was seen using 20ug/ml of HSP-60; therefore this dose was used in subsequent 
experiments. (Figure 2.2) 
 
 
 
Figure 2.2: Simulation of peripheral blood NK cells with incremental doses of heat shock 
protein 60 (HSP-60) and IFN-  expression. A: No stimulation. B: Increasing expression of 
IFN-  is seen with incremental doses of HSP-60 used.  
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Table 2.1: Monoclonal antibodies (Mab) used in both surface and intracellular cytokine 
analysis. The molecule against which the Mab is directed, the conjugated fluorochrome 
and the manufacturer are shown. 
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Natural Killer Cell expansion and selection 
 
Following the discovery that certain KIR maybe more adept at killing CML stem cells and 
preliminary data (briefly discussed in chapter 5) that certain KIR may be important 
mediators of an anti-bacterial effect after ASCT, it is conceivable that in certain situations 
that specific NK cell infusions may have clinical use. With this in mind we have started to 
expand NK cells from PBMC and to select CD56+ CD3- NK cells from the expanding product. 
The preliminary results of the expansion experiments are briefly discussed later.  
 
 
Natural Killer Cell expansion 
Unselected fresh PBMNCs were cultured in T25 flasks (TPP, Trasadingen, Switzerland) at a 
concentration of 0.5 x 106 cells/ml in CellGro SCGM serum-free medium (CellGenix, 
Freiburg, Germany) with the addition of 5% human serum (Bioline UK) and gentamicin 
(125mcg/100ml) (GIBCO UK).  To this cell suspension, 500U/mL of recombinant interleukin-2 
(rhIL-2) was added (Proleukin; Chiron, Emeryville, CA). For the first 5 days of the culture, the 
medium was supplemented with anti-CD3 monoclonal antibody (Orthoclone OKT-3; Ortho 
Biotech, Raritan, NJ) to a final concentration of 10 ng/mL. On day 5 of culture, the OKT-3–
containing medium was washed out, and fresh medium containing IL-2 (500 U/ml) and 5% 
human serum was used. Culture conditions of 370C and 5% CO2 in air-atmosphere were 
maintained throughout. The cultures were then replenished with fresh medium on alternate 
days throughout the culture period.  
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On days 0, 5 to 6, 9 to 10, 14 to 15, and 20, the total cell number in the culture was assessed 
and cell viability assessed by Trypan blue technique. Absolute lymphocyte sub-set cell 
counts (including NK and T-cell counts) were calculated by multiplying the total number of 
cells by the percentage of each specific subset as determined by flow cytometry. Only 
techniques and materials that conformed to good manufacturing practice (GMP) were used.  
 
Purification of NK cells from PBMNC  
NK cells were purified for NK cytotoxicity assays, using MACS-PE beads according to the 
manufacturer’s protocol (Miltenyi Biotec, Bisley, UK). Briefly, cells were washed in 1ml 
MACS buffer (PBS pH 7.2, containing 0.5% BSA and 2nM EDTA). Cells were stained by 
incubating with 10μl of NK cell depletion biotin-conjugated antibody cocktail (Mabs are 
directed at determinants on non-NK cells i.e., T-cells B-cells, stem cells, dendritic cells, 
monocytes, granulocytes and erythroid cells) and 40μl MACS buffer per 1 x 107 cells on ice 
for 20 minutes. Cells were then incubated on ice with 20μl PE microbead cocktail and 30μl 
MACS buffer per 1 x 107cells for 15 minutes. Cells were then washed in 2mls MACS buffer 
per 1x107cells and centrifuged for 10 minutes at 300xg. Magnetic selection was performed 
using an MS column placed in the magnetic field of a miniMACS separator. This MS column 
was prepared for use by applying 500μl MACS buffer and allowing it to run through. The cell 
suspension was then applied to the column and allowed to run through. The column was 
subsequently washed three times with 500μl MACS buffer to optimise cell collection of the 
non-labelled non-NK cell depleted fraction. This fraction was then centrifuged at 300xg 
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before final suspension in 1ml MACS buffer and cell count determination. The purity of the 
selected population was assessed by FACS staining. 
 
NK separation has now been performed on PBMC from volunteer donors and expanded NK 
cell cultures (above). Purification using the above technique has yielded >90% purity. An 
example is shown in Figure 2.3 
 
 
 
Fig 2.3: Example of NK purity of cells for cytotoxicity assay following Selection using Miltenyi NK 
negative selection cocktail and magnetic beads. Cells show >92% purity of NK cells (upper left quadrant), 
<1% T-cell / NK cell contamination can be seen (upper and lower right quadrants). 
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Statistical Methods  
 
In both the myeloma and CML studies, the probabilities of overall survival (OS) and 
progression-free survival (PFS) were calculated using the Kaplan-Meier method and groups 
compared using the log-rank test. In the CML patients PFS was defined as survival without 
evidence of progression to accelerated or blast phase disease. The probability of cytogenetic 
response was calculated using the cumulative incidence (CI) procedure, where cytogenetic 
response was the event of interest and death and disease progression were the 
competitors. For cytogenetic response analysis, patients were censored at discontinuation 
of Imatinib, for PFS and OS patients were analyzed in an intention to treat basis. In the 
myeloma patients, PFS was defined according to the international uniform response criteria, 
Survival and progression-free survival curves were calculated using the Kaplan-Meier 
method. KIR genotypes that were significant at the P <0.20 level in the univariate analyses 
were entered into a multivariate analysis using a backward stepping procedure that also 
included previously identified prognostic factors including disease state at ASCT (good risk 
vs poor risk), number lines of previous chemotherapy regimens (1 vs >1), β2M (<3.5 vs >3.49 
mg/l), and albumin (< 3.5 vs > 3.49 g/dl). Variables were tested for proportional hazards 
using a time-dependent covariate method. In both studies, P-values <0.05 were considered 
significant. For comparisons of cytokine production between the KIR2DS2/DL2 positive and 
negative T and NK subsets, the Wilcoxon signed-rank test was used, again P values <0.05 
were considered significant. 
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Chapter 3. Chronic Myeloid Leukaemia 
 
 
 
Investigation into the effect of KIR-HLA immunogenetics on prediction 
of complete cytogenetic response and survival in newly diagnosed 
chronic myeloid leukaemia patients treated with Imatinib 
 
 
 
Chronic Myeloid Leukaemia 
Chronic myeloid leukaemia (CML), as discussed in Chapter 1, is a clonal myeloproliferative disorder 
resulting from the malignant transformation of a single haematopoietic stem cell, and is characterized 
by the presence of the Philadelphia (Ph) chromosome.  
 
This unique chromosomal abnormality results from a reciprocal translocation, between chromosomes 
9 and 22; t(9;22) (q34.1;q11.2)[3] and leads to the translocation of the ABL1 gene within the BCR 
(breakpoint cluster region) gene257, 258. The resultant fusion gene, BCR-ABL1, results in the normal ABL 
gene product (an enzyme responsible for phosphorylating intracellular proteins containing tyrosine 
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residues, which are involved in relaying downstream intracellular signalling pathways) constitutively 
active. Constitutive activity of ABL can be seen to result in the constitutive activation of a number of 
mediators of the cell cycle regulation system (as described in chapter 1)259. The resultant effect is a 
clonal myeloproliferation, which displaces normal haematopoiesis. 
 
The clonal cellular expansion in the bone marrow results in symptoms of anaemia (such as dyspnoea 
and tiredness), and thrombocytopenia (easy bruising and bleeding). It also results in the constitutional 
symptoms of a malignant process (such loss of weight, loss of appetite, and night sweats). In males 
the increased peripheral leucocyte count can result in priapism, which is a urological emergency. The 
annual incidence of CML is approximately 1.5 per 100,000 of the population. The male: female ratio is 
1.3:1 and median age at presentation is 50 years89, 260. 
 
CML can be described as having three distinct clinical disease phases; chronic (CP), accelerated (AP), 
and blastic phase (BP). The diagnostic features of the three phases are shown in Table 3.1 (below).  
Patients in CP are often asymptomatic at presentation and are often diagnosed after an incidental 
abnormal finding on routine blood investigation. Patients may remain in CP for 6-12 years before 
progression. Median survival in untreated patients in CP is approximately 5 years. BP is analogous to 
an acute leukaemia, and its prognosis is universally very poor261, 262. 
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Table 3.1  The criteria for defining advanced phase CML 
 
Chronic Phase  Accelerated Phase Blastic phase 
Demonstration of Ph chromosome 
By  FISH or BCR-ABL by RT-PCR 
15-29% blasts in peripheral  
blood or marrow 
Blasts + Promyelocytes >30% 
Basophils >20% 
Persistent platelet count <100 
not related to treatment   
>30% blasts in peripheral blood  
or bone marrow 
 
RT-PCR: Quantitative real time polymerase chain reaction 
FISH: Fluorescent In-situ hybridization  
Accelerated and blast phases are known as advanced disease CML   
 
Adapted from Baccarani et al. Bloo 2006 264;108(6):1809-20.  
 
 
Current Management of CML 
Historically, the standard treatment for patients with CML was allogeneic haematopoietic stem 
transplantation, for those able to tolerate the procedure. Allo-SCT, is however associated with a 
significant mortality rate, and a risk of developing GvHD which is also associated with a considerable 
mortality and long-term morbidity. Patients not suitable for allo-SCT were previously managed with 
alkylating agents (typically cytarabine) and/or interferon alpha (IFN- ) with limited success89.  
 
However, In the last 10 -15 years the introduction into clinical practice, of the ‘targeted’ tyrosine 
kinase inhibitors (TKI) Imatinib Mesylate (IM) (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland) 
109 
 
has revolutionized treatment of CML and is now standard treatment. The introduction of Imatinib 
(described in greater detail in chapter 1) has led to a substantial reduction in the number of patients 
requiring allo-SCT for CML. 
 
The therapeutic goals of TKI therapy are the subsequent achievements of complete haematological 
response (CHR), complete cytogenetic response (CCyR) and major molecular remission (MMR), 
defined as normalisation of the peripheral blood count, with elimination of immature myeloid cells, a 
complete absence of detectable Ph+ cells in the bone marrow, and a minimum 3-log reduction below 
a standardised baseline of BCR-ABL to BCR transcripts respectively. The CML consensus group of the 
European.Net, has established guidelines on the time-points at which these milestones should be met 
and what is defined as sub-optimal response or failure (Table 3.2)264 
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Table 3.2 The European Leukameia.Net definitions of optimal, sub-optimal and treatment failure 
following instigation of Imatinib mesylate therapy (400mg once daily) in patients with chronic 
myeloid leukaemia in chronic phase. 
 
Time from  
Treatment start  
Optimal  
Response 
Sub-optimal  
Response 
Failure of  
Response 
Warning signs 
3  Months  CHR, at least  
Minor CyR 
No CyR <CHR  
6  Months  At least PCyR < PCyR No CyR  
12 Months  CCyR PCyR <PCyR <MMR 
18 Months  MMR MMR >CCyR  
Anytime Stable or  
Improving  
MMR 
Loss of MMR  
Mutations 
Loss of CHR 
Loss of CCyR 
Mutations  
Increase in BCR-Abl 
Transcript levels 
 
 
Modified from 2010 recommendations from the European LeukaemiaNet for the management of 
chronic myeloid leukaemia 
CHR: Complete haematological remission; CyR: cytogenetic response; PCyR: Partial cytogenetic 
response; CCyR: complete cytogenetic response; MMR: Major molecular response 
 
The efficacy of Imatinib in treating CML was clearly demonstrated by results of the first large 
prospective study of its use, the International Randomized Study of Interferon and STI571 (IRIS) study.  
This study compared IM to standard IFN-  plus cytarabine. The cumulative incidence (CI) of CHR and 
CCyR for the two therapies at 18 months were 95.3% vs. 55.5% and 73.8% vs. 8.5% respectively. PFS at 
12 months was 96.6% vs. 79.9%265.  
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However, whilst this drug shows considerable success in CML, the use of Imatinib does not result in 
long-term disease control in all patients. Despite its proven efficacy to induce hematologic and 
cytogenetic responses, the majority of patients have persisting disease as assessed by quantitative 
real-time polymerase chain reaction (RT-PCR) for BCR-ABL1 transcripts. Data from Imperial College 
NHS Healthcare Trust, demonstrated that the 5-year cumulative incidence (CI) of CCyR and MMR was 
just 82.7% and 50.1%, respectively with estimated OS and EFS at 83.2% and 81.3% respectively266. 
These data suggest that despite its efficacy, approximately a third of IM treated patients will have a 
sub-optimal response.  
 
The CML Initiating or Leukaemia Stem cell  
Whilst this reduced response seen in some patients is likely in part to be due to the development of 
secondary mutations within the BCR-ABL fusion protein which confer resistance to IM, in many cases 
the cause remains poorly understood. In addition, a majority of patients in MMR still have 
demonstrable persisting disease as assessed by quantitative real-time PCR (RT-PCR) for BCR-ABL1 
transcripts. A common belief amongst the CML scientific community is these results are likely to be 
due to survival of quiescent ‘leukemic stem cells’ also known as ‘leukaemia initiating cells’ (LIC), which 
have been shown to be resistant to TKIs267,268.  This theory is supported by the results of the non-
randomised STOP Imatinib (STIM) trial in which patients in complete MMR for 2 years stopped TKI 
therapy. Sixty-one percent of patients in this trail subsequently relapsed after Imatinib 
discontinuation (although all were able to re-achieve MMR with drug re-introduction)269. This suggests 
the presence of a long-term surviving leukaemic progenitor(s).  
 
The reason for CML Leukaemia initiating cell (LIC) (‘stem cell’) resistance to Imatinib is unclear. 
Potential mechanisms include the fact that Ph+ CD34+ cells have been demonstrated to have higher 
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levels of BCR-ABL1 expression, are typically in the quiescent state, and that they have over-expression 
of membrane drug transporters all of which favour IM resistance.  Furthermore, a number of 
mechanisms not directly related to the BCR-ABL1 protein have also been shown to confer protection 
on the LIC. Such mechanisms include the constitutive activation of Forkhead box O protein 3a 
(FOXO3a, discussed later)270, 271, and an increase in promyelocytic leukaemia protein (PML) protein 
which both favour a quiescent stem cell.272 Selective over-expression of the B-cell specific Moloney 
Leukaemia Virus (MLV) insertion site -1 protein (BM-1) in Ph+ CD34+ CML cells has been associated 
with enhanced cell self-renewal capacity273. IL-1 RAP a co-receptor for IL-1 is also relatively over-
expressed in the Ph+ LIC274.  
 
Natural killer cells have been shown to be important anti-CML effectors against the CD34+ Ph+ cell (as 
discussed in greater detail in chapter 1). NK cells are also seen to be clonally expanded on TKI therapy. 
Therefore, it is possible that certain KIR expressing NK clones may have differing capabilities in 
inhibiting the LIC, and that IM may have different effects on certain KIR expressing clones. As the 
effectors’ profile of certain NK subsets (see section on HIV and KIR) may differ, certain clones may 
produce cytokines, which affect the expression or function of pivotal LIC proteins such as FOXO3a. As 
certain proteins (such as IL-1 RAP) are preferentially expressed on the surface of the LIC, they may act 
as antigenic determinants for specific NK cells.  
 
With these factors in mind we investigated the impact of KIR genotype on the response and outcome 
of patients with CML treated with Imatinib as first line therapy. Our results suggest novel 
immunological interactions between NK and CML cells of clinical relevance 
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Patient characteristics and treatment 
 
Discovery Sample: Imperial Cohort 
One hundred and sixty-six consecutive adult patients with BCR-ABL1-positive CML in chronic 
phase (CP) who received Imatinib as first line therapy at Imperial College NHS Healthcare 
Trust were included as the ‘discovery set’ in the study.  
 
Patient characteristics are detailed in Table 3.3. The median follow-up was 36 months, and 
75% of the patients were followed for a minimum of 24 months. No patients were lost to 
follow-up. Patients were commenced on Imatinib within 6 months of diagnosis with no prior 
treatment for leukaemia other than hydroxycarbamide (also known as hydroxyurea) for 
initial cytoreduction. All patients gave written informed consent for the use of their data for 
this analysis. CP was defined by conventional criteria (as described above).  
 
Patients received Imatinib 400 mg daily orally, and the dose was adjusted according to 
tolerance and response 1. The dose of Imatinib was reduced in the presence of grades III-IV 
toxicity, with the aim of maintaining the dose at or above 300 mg/day. The criteria for 
changing to a second generation tyrosine kinase inhibitor (2G-TKI) such as Dasatinib, were 
those recommended by the European LeukemiaNet2(see table 3.2). Thirty-eight patients 
discontinued Imatinib therapy and received either a 2G-TKI (n=22) (Dasatinib; Bristol Myers 
Squibb, or Nilotinib; Novartis) or allo–SCT (n=16). 
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Bone marrow morphology and cytogenetics were assessed at diagnosis, and then at 3-
monthly intervals until patients achieved complete cytogenetic response (CCyR). Thereafter, 
patients were monitored by RT-PCR for BCR-ABL1 transcripts and annual bone marrow 
examination. CCyR was defined by the failure to detect any Ph chromosome-positive 
metaphases in a bone marrow examination with a minimum of 20 metaphases examined. 
 
Table 3.3: Characteristics of patients with chronic myeloid leukaemia who received 400mg 
Imatinib mesylate as first line treatment (discovery sample). 
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Validation sample 
 
The prognostic influence of the KIR genes found to be significant in the discovery sample 
was then subsequently validated using a second independent sample of 174 patients with 
CML in CP treated with first-line Imatinib within the UK multi-centre trial (SPIRIT-1). Briefly, 
the SPIRIT 1 trial is a phase III study in which newly diagnosed CML patients in CP, were 
randomly allocated to receive either Imatinib 400 mg daily or Imatinib 800 mg daily (see 
Figure 3.1). The monitoring schedule employed was similar to the one described above in 
the discovery cohort. The median follow-up for the whole group was 34 months and 131 of 
the patients have been followed for at least 24 months.  
 
Figure 3.1. Randomisation of patients entered into the multi-centre STI571 Prospective 
International Randomised Trial (SPIRIT-1). Patients within three months of diagnosis of 
CML in chronic phase were randomized to receive Imatinib mesylate at a dose of 400 mg 
or 800mg daily, or 400mg plus Interferon alpha.  
 
 
 
 
www.spirit.org 
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Statistical Methods  
Probabilities of overall survival (OS) and progression-free survival (PFS) were calculated 
using the Kaplan-Meier method. PFS was defined as survival without evidence of 
progression to accelerated or blast phase disease (see table 3.1). The probability of 
cytogenetic response was calculated using the cumulative incidence (CI) procedure, where 
cytogenetic response was the event of interest and death and disease progression were the 
competitors. For cytogenetic response analysis, patients were censored at discontinuation 
of Imatinib, for PFS and OS patients were analyzed in an intention to treat basis.  
 
Univariate analyses to identify prognostic factors for survival, PFS and cytogenetic response 
were carried out using the log-rank test. In the validation study the prognostic influence of 
the KIR genes was analyzed using a log-rank test stratified by allocated therapy.  
 
Variables found to be significant at the p<0.10 level were entered into a proportional 
hazards regression analysis; a forward stepping procedure was employed to find the best 
model. We did not analyze the prognostic influence of an individual KIR gene (see below) if 
the gene prevalence was less than 10% of the population (15 patients). P-values were 2-
sided.  
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DISCOVERY STUDY  
The discovery study included 166 patients with CML-CP who received Imatinib as first line 
treatment within 6 months of diagnosis. During follow-up 119 (71.7%) patients achieved 
CCyR, 10 (6.0%) progressed to advanced phase disease and 7 (4.2%) died. The 2-year 
cumulative incidence of CCyR was 72.2% and the 2-year probabilities of PFS and OS were 
95.7% and 97.3% respectively.  
 
KIR genotype and CCyR, PFS and OS 
The KIR gene frequencies are summarized in Table 3.4  The 2-year probabilities of achieving 
CCyR, PFS and OS according to the KIR genotype are shown in Table 2. The presence of the 
activating KIR genes KIR2DS1, KIR2DS3 and the inhibitory KIRs KIR2DL5A and KIR2DL5B 
alleles, and absence of the activating KIR gene KIR2DS4 were significantly associated with a 
lower probability of achieving CCyR (Table 3.4).  
 
The presence of KIR2DL5A, KIR2DS1 KIR2DS5, KIR3DS1 were associated with significantly 
shorter 2-year probabilities of PFS and OS (Table 3.4). There was no significant influence of 
KIR haplotype or the number of activating KIRs or inhibitory KIRs on the probability of 
achieving CCyR, PFS and OS. 
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Table 3.4. Association between individual KIRs and achievement of CCyR, progression free 
survival and overall survival at 2 years on univariate analysis.  
 
 
Abbreviations: CCyR, complete cytogenetic response; KIR, killer immunoglobulin-like 
receptor; OS, overall survival; PFS, progression free survival. *P for significance on univariate 
analysis  
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As reported previously, we found a strong linkage disequilibrium between several genes (23, 
24 and 25). The following genes were in strong positive linkage disequilibrium: KIR2DS1, 
KIR2DL5A, KIR2DS3, KIR2DS5 and KIR3DS1 (p<0.0001 in all cases).  On the other hand, 
KIR2DS1 and KIR2DS4 were in perfect negative linkage disequilibrium (p<0.001).  
 
We also examined the prognostic influence of the variables shown in Table 1 on the 2-year 
probabilities of achieving CCyR, PFS and OS. Sokal risk score at diagnosis was the only 
predictive variable for achievement of CCyR; the 2 year probability of CCyR for the low, 
intermediate and high Sokal risk groups were 82.6%, 69.8% and 62.1% respectively, p=0.04. 
None of the variables (including Sokal) were found to predict for PFS and OS.  
 
We carried out a multivariate analysis for each outcome (CCyR, PFS and OS) including the 
KIR genes identified in the univariate analysis and for the CCyR analysis we also included the 
Sokal risk score. The presence of KIR2DS1 (RR=1.51, p=0.03) and Sokal risk score (low risk 
RR=1, intermediate risk RR= 1.53, p=0.04 and high risk RR=1.69, p=0.034) were the only 
independent predictors for failure to achieve CCyR.  Furthermore, the presence of KIR2DS1 
alleles within a patient’s KIR repertoire was the only independent predictor for shorter PFS 
(RR=3.1, p=0.03 and OS (RR=2.6, p=0.04). Figure 3.2 and Table 3.5 show the probabilities of 
achieving CCyR and OS according to KIR2DS1 status.  
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Figure 3.2. The 2-year probabilities of CCyR and OS according to KIR2DS1 genotype on 
multivariate analysis. The 100 patients who were KIR2DS1 positive (broken line) had a 
significantly lower probability of achieving CCyR (a) and lower overall survival (b) than the 
66 patients (solid line) who were KIR2DS1 negative, namely 65.6% vs 82.3% (p=0.03) and 
92.3% vs 100% (p=0.04) respectively.  
a. 
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b 
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Table 3.5: The relative risks of non-achievement of CCyR or disease progression on 
multivariate analysis  
 
 
 
 
 
 
 
 
 
 
VALIDATION STUDY  
In order to validate our results we explored the influence of the KIR genotype on the 
achievement of CCyR and on the probabilities of PFS and OS in an independent patient 
cohort.  
 
KIR genotype was determined in 174 patients with CML-CP treated with first line Imatinib in 
the SPIRIT 1 trial (see methods section). The 65 patients who were KIR2DL5A allele positive 
had significantly lower 2 year probabilities of achieving CCyR, PFS and OS compared to the 
109 patients who were negative for this gene, namely 80.4% vs 86.8% (therapy stratified 
log-rank test =0.03), 85.7% vs 98.1% (therapy stratified log-rank test =0.007) and 94.3% vs 
100% (therapy stratified log-rank test =0.017) respectively.  
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Furthermore, the 66 KIR2DS1 positive patients had lower probabilities of achieving CCyR 
and lower PFS and OS than the 106 KIR2DS1 negative patients, namely 76.9% vs 87.9% 
(therapy stratified log-rank test =0.003), 85.3% vs 98.1% (therapy stratified log-rank test 
=0.007) and 94.4% vs 100% (therapy stratified log-rank test =0.015) respectively (in 8 
patients KIR2DS1 status could not be accurately determined) (Figure 3.3). In accord with our 
finding in the initial patient cohort, on multivariate analysis of the SPIRIT 1 patients, KIR2DS1 
positivity remained the only independent predictor for all three outcomes.  
 
Figure 3.3: The 2-year probabilities of CCyR and OS according to the KIR2DS1 genotype in 
the validation sample. The 66 KIR2DS1 positive patients (broken line) had a lower 
probability of achieving CCyR (a) and lower OS (b) than the 106 KIR2DS1 negative patients 
(solid line), namely 76.9% vs 87.9% (p=0.003) and 94.4% vs 100% (p=0.015) respectively.  
a. 
 
 
124 
 
 
 
b 
 
 
 
 
Influence of KIR2DS1 and HLA-C on CCyR 
Because KIR2DL1 interaction with HLA-C2 (group 2) molecules on target cells would 
theoretically inhibit an activating signal mediated by KIR2DS1, we hypothesized that any 
effect of KIR2DS1 would be greatest among individuals who are missing group 2 HLA-C 
ligand for KIR2DL1. Therefore, we determined the various combinatorial frequencies of 
KIR2DS1 with group 2 HLA-C alleles in the discovery plus the validation patients (n = 340). 
We subdivided patients into 3 groups on the basis of KIR2DS1/2DL1 genotype and group 2 
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HLA-C alleles (C2) genotype to include; group I: KIR2DS1-ve, KIR2DL1+ve, and C2+ve (n = 80); 
group II: KIR2DS1+ve, KIR2DL1+ve, and C2+ve (n = 85); and group III: KIR2DS1+ve, 
KIR2DL1+ve, and C2-ve (n = 46). The probability of achieving CCyR at 2 years for patients 
ingroup I was 98.6% compared with 74.8% for group II and 64.1% in group III (P = .00006; 
Figure 3.4). These data suggest that the association between the activating gene KIR2DS1 
and CCyR is even more significant when the HLA ligand for the closely related inhibitory 
receptor KIR2DL1, is absent. 
 
Figure 3.4 Association between KIR2DS1/KIR2DL1 and HLA-C genotype. Patients who were 
KIR2DS1+/KIR2DL1+/C2– (open boxes) have significantly lower 2-year probability of CCyR 
compared to KIR2DS1+/KIR2DL1+/C2+ (black circles) and KIR2DS1-/KIR2DL1+/C2+ patients  
(solid line) (P = 0.00006). 
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Discussion 
 
CML cells are susceptible to immune effector responses and NK cells have well documented 
anti-leukaemia activity as discussed in chapter 1. Indeed, the association between KIR 
genotype and outcome following allo-SCT for myeloid leukaemia has been shown by a 
number of groups.  
 
Using a large homogeneous cohort of newly diagnosed patients with CML-CP treated with 
upfront Imatinib, we show here that patients carrying the activating KIR gene KIR2DS1 have 
a significantly lower probability of achieving CCyR, and lower 2-year probabilities of PFS and 
OS compared to those who are KIR2DS1 negative. On the other hand, absence of KIR2DS1 
was associated with better response to Imatinib. This effect was independent of Sokal risk 
score (the most important predictor of progression) and was subsequently validated in a 
second independent large cohort of patients.  
 
On univariate analysis, five KIR genes were found to have prognostic implications in CML 
patients on TKI therapy. The presence of KIR2DS1, KIR2DS3, KIR2DL5A and KIR2DL5B and the 
absence of KIR2DS4 were associated with significantly lower probabilities of achieving CCyR 
at 2 years. Two of these genes (KIR2DS1 and KIR2DL5A) were also associated with the 
reduced probabilities of PFS and OS. As previously reported and discussed in chapter 1, the 
TEL genes KIR2DS1 and KIR2DL5A, are in strong LD with each other, as are the CEN genes 
KIR2DS3, and KIR2DL5B. Furthermore, both KIR2DL5B and KIR2DS3 are also in moderate LD 
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with the TEL genes (2DS1 and 2DL5A). We confirmed strong linkage disequilibirium between 
these genes (P=0.0001).  
 
In multivariate analysis, KIR2DS1, a gene with a prevalence of up to 50% in the population, 
together with the Sokal risk group, were found to be the independent predictors for disease 
response (failure to achieve CCyR, RR=1.51, p=0.03). Furthermore, this gene was the only 
predictor for both shorter PFS and OS (RR=3.1, p=0.03 and RR=2.6, p=0.04, respectively).  
 
This association of KIR2DS1 with a reduced probability of achieving CCyR at 24 months and 
inferior PFS and OS in the discovery population, was also observed in the validation cohort, 
which included newly diagnosed patients with CML treated on the multi-centre SPIRIT 1 
trial, namely 76.9% vs 87.9% (p=0.003), 85.3% vs 98.1% (p=0.007) and 94.4% vs 100% 
(p=0.015) respectively. This is especially relevant, since the patients in the validation set 
were randomly assigned to treatment with different doses of Imatinib (with some patients 
receiving 800mg compared to 400mg of those in the discovery set), underscoring the strong 
predictive role of KIR2DS1 on outcome of CML, irrespective of the dose of Imatinib that the 
patient may have received.  
 
The impact of the KIR2DS1 genotype on the probability to achieve CCyR was even greater 
when the expression of this gene was considered together with the presence or absence of 
the ligand for the corresponding inhibitory KIR receptor (KIR2DL1). This suggests that in the 
presence of the HLA ligand (C2), the action of the corresponding inhibitory KIR may 
neutralize the effect of the activating KIR. This same phenomenon has also reported in 
psoriasis where subjects with activating KIR2DS1 genes were found to be significantly more 
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susceptible to developing psoriatic arthritis when the HLA ligand (HLA-C group 2) for the 
homologous inhibitory receptors, KIR2DL1 was missing475.  
 
Activating KIR molecules are known to bind with reduced affinity to HLA molecules 
compared to that observed for inhibitory KIRs, perhaps explaining the observed dominance 
of inhibition over activation of NK cells. Indeed, KIR2DS1 has significantly lower affinity for 
C2 group molecules than KIR2DL1276, 277. The increased susceptibility effect of KIR2DS1 in the 
absence of group 2 HLA-C alleles suggests that ligands for KIR2DS1 may not be the same HLA 
molecules recognized by homologous KIR2DL1 receptors.  
 
Data from mice indicate that viral proteins structurally similar to class I molecules serve as 
ligands for activating receptors on NK cells278-281, raising the possibility that activating 
receptors in humans may also recognize foreign molecules on target cells as opposed to 
recognition of self class I molecules. Indeed KIR2DS2 has been shown to bind to heat shock 
protein 60 KDa in addition to its known HLA-C ligand. It is therefore possible that KIR2DS1 
can recognize non-MHC molecules, such as aberrantly expressed normal cell surface 
proteins (e.g. leukaemia-associated antigens), or complexes of CML-derived peptides bound 
to MHC class I molecules. Certain molecules expressed by the LIC (such as BM-11 or other 
such molecules) may be recognized by KIR2DS1 but not by other KIR proteins. However, this 
does not explain the reduced survival in KIR2DS1 positive individuals unless the interaction 
results in a pro-survival rather than cytotoxic effect.  
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The mechanism by which KIR2DS1 affects outcome in patients with CML-CP on Imatinib is 
unclear90, 91. As previously described (in 1.7.1), NK cells exert cytotoxicity against CML 
progenitors and kill quiescent CML stem cells. However, the interaction between TKI and NK 
cells is not fully elucidated. Imatinib has been shown to act on the c-kit signalling pathway of 
host myeloid dendritic cell subsets to promote NK cell IFN-γ secretion and anti-tumour 
cytotoxicity282. On the other hand Imatinib has been shown to impair NK anti-leukemic 
activity, possibly by down regulating expression of ligands for NKG2D, an NK receptor 
important in mediating an anti-tumour response283.  
 
As TKI have been shown to induce clonal expansion of NK cells (as discussed in chapter 1)107, 
it is possible that Imatinib may result in the expansion of certain KIR expressing subsets. It is 
also possible that Imatinib interacts differentially with individual NK subsets or their specific 
ligands to abrogate or enhance any NK anti-tumour function. Recently NK cells expressing 
KIR2DS1 were shown to secrete significant amounts of transforming growth factor-beta 
(TGF- ) after ligation with soluble HLA-C (Cw4), conversely KIR2DL1 down regulated TGF-  
after ligation. The TGF-  produced by this KIR2DS1-HLA-C interaction was demonstrated to 
reduce target cell cytotoxicity284. This was in part due to a down regulation of both IFN-γ 
and TNF-α production. Furthermore, this TGF-  decreased cell lysis induced by ligation of 
NKG2D (shown be important for CML killing in both Sconocchia and Yong’s studies discussed 
in chapter 190-91. TGF-  can also modulate antigen presenting cell (APC) function and 
lymphocyte differentiation, leading to expansion of regulatory T-cells and the suppression of 
auto-reactive T-cells285. With this in mind it is possible that KIR2DS1 derived TGF-  dampens 
down any inherent anti-CML activity of both NK and T-cells. 
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Furthermore, evidence that TGF-  affects CML responses is the recent demonstration that it 
is a critical molecule in the PI3K/Akt signalling pathway. This pathway is stimulated by the 
BCR-ABL protein and the subsequent Akt signalling leads to the inactivation of FOXO3a in 
the CML cell. This inactivation of FOXO3a results in increased cellular proliferation and 
contributes to the myeloproliferative capacity of the leukaemic cell. However, in the LIC, 
FOXO3a appears to protect the cell from oxidative stress limiting the production of reactive 
oxygen species. Furthermore, Naka and colleagues286 recently demonstrated that FOXO3a 
depletion from the LIC lead to an increase in cell cycling and eventual cellular exhaustion. 
This reduced the ability of the LIC to cause disease when such cells were subsequently 
transplanted into mice compared with FOXO3a positive LIC They further showed that it was 
TGF-  which inhibited AKT signalling leading to FOXO3a retention in the LIC and thus 
promoted the persistence of this subset which is responsible for persistent disease. 
Interestingly, they also showed that TGF-  inhibition in conjunction with IM had a significant 
impact on transplanted LIC to initiate disease.  
 
Therefore as TGF-  may be an important cytokine contributing to both the resistance of the 
LIC to Imatinib and T-cell mediated responses, this may in part explain the reduced response 
rates seen in KIR2DS1 individuals. If Imatinib increases preferentially this subset then it can 
explain why KIR2DS1+ individuals have worse outcome. It is however possible that rather 
than being directly involved in the disease process, KIR2DS1 may be simply a surrogate 
marker for another neighbouring gene that is directly involved in CML response to TKI. 
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In conclusion, our data demonstrate that KIR2DS1 may predict response to Imatinib and 
identify patients at greater risk of treatment failure. KIR immunogenetics further supports a 
role for NK mediated immunological responses in the control of disease response in CML. 
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Chapter 4. KIR and Autologous Hematopoietic Stem cell Transplantation  
 
 
 KIR-HLA Genotype study in multiple myeloma patients undergoing 
autologous stem cell transplantation consolidation therapy 
 
Introduction 
Multiple myeloma (MM) is a haematological neoplasm characterised by the infiltration of 
the bone marrow, and in some patients, other organs (extramedullary disease) by a 
malignant plasma cell clone. The most recent Cancer Research UK (CRUK) data, show that 
the crude and age standardised incidence rates (SIR) per 100,000 of the (European) 
population are 4.8 and 6.6 respectively. This accounts for approximately 4,000 new cases in 
the United Kingdom per annum.  There is a male predominance, and the lifetime risks for 
males and females are 1 in 148, and 186 respectively287. MM is more commonly found in 
individuals of Afro-Caribbean decent. The median age at diagnosis is 71 years, and the 
incidence is seen to increase with advancing age288.  
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Approximately 10 - 40% of patients with MM will be asymptomatic at the time of diagnosis, 
which is often made during routine investigations. The complications and symptoms of MM 
vary according to both the tumour burden, and the disease biology (cytokine and 
immunoglobulin secretion). Symptoms experienced may include; bone pain and 
spontaneous fractures, weakness and weight loss, increased propensity to infection 
(particularly bacterial), hypercalcaemia (as a result of cytokine (IL-6) induced osteoclast 
activation), and haemorrhage subsequent to thrombocytopenia +/- interruption of the 
normal coagulation pathways by the secreted immunoglobulin (Ig) (paraprotein). Renal 
impairment occurs in 50% of patients at some point during their disease. Neurological 
symptoms, hepato-splenomegaly, symptoms of hyperviscocity (due to high plasma levels of 
secreted paraprotein), local complications of tumour (plasmacytoma) and amyloid 
deposition may also occur288. In addition, increased incidences of acute and chronic myeloid 
leukaemias in patients with MM have been reported.   
 
Currently, MM remains incurable and the outcome of patients treated with conventional 
approaches, which mainly employ alkylating agents in conjunction with glucocorticoids, is 
unsatisfactory. High-dose therapy and autologous peripheral blood stem cell transplantation 
(ASCT) has led to improved survival, with a median survival of between 2 to 3 years for 
older, and 5 to 6 years in younger patients. (Attal 1996, Child 2003, and Palumbo 2004)289-
291. However, despite these improvements, relapse rates are high and patients are highly 
unlikely to be disease free beyond ten years292. These data suggest, that current transplant 
conditioning regimens alone fail to eradicate the malignant plasma cell clone, allowing re-
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population of normal haematopoeitic tissue by residual disease following ASCT, and leading 
to frank relapse. 
 
In the last few years, two classes of drugs; the immunomodulatory agents (in particular 
thalidomide and lenalidomide) and the proteasome inhibitors (bortezomib), have been 
shown to increase response rates in patients with MM (Cavo 2005, Lokhorst 2008, Rajkumar 
2008, Roccaro 2008, and Stewart 2009)293-7. These responses can be further enhanced by 
subsequent ASCT. However, with relatively short follow-up, it is unclear whether these 
responses will be seen to be durable, or lead to better overall survival (OS). As such, ASCT 
remains the current standard of care (Attal 2009, Lokhorst 2008)298, 299. 
 
Allogeneic stem cell transplantation (allo-SCT) (discussed in more detail in chapter 1) 
remains the only potentially curative treatment for MM. This is thought to be at least in part 
due, to the generation of a graft-versus-myeloma effect (GvM) (Lokhorst 2004 Perez-Simon 
2004)299-300. However, high transplantation-related mortality (TRM) remains a barrier to 
more widespread acceptance and use of allografting in such patients (Crawley 2007 and 
Gahrton 2001)301-302. The reasons for such high TRM rates are not fully understood, although 
the advanced median age of patients with MM is likely to be a contributory factor. Attempts 
to reduce the TRM by using reduced intensity conditioning regimens (see chapter 1) have 
led to a reduction in procedure related mortality rates, to approximately 15% in some series 
(Kroger 2002 and Maloney 2003)303, 304 however, this is at the expense of higher rates of 
disease relapse.   
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Strategies to reduce this relapse post allograft have included attempting to reduce the pre-
transplant tumour burden. Recently, investigators have published improved OS rates using 
ASCT followed by HLA matched sibling donor RIC allo-SCT (TRM 10%) over tandem ASCT. 
This strategy, suggests a possible role for ASCT in disease control, prior to a procedure 
allowing generation of a GvM effect305. However, the place of allo-SCT in the management 
of MM in younger patients remains controversial.  
 
Therefore, it can be seen that ASCT remains standard therapy for MM, and optimising this 
treatment approach is crucial. The identification of biological factors that can help to predict 
the outcome of current ASCT strategies, and hence direct the use of more intensive upfront 
or novel maintenance treatments would be highly valuable.  
 
As discussed in the introduction (chapter 1), NK cells are an important component of the 
innate immune system, providing first-line defence against altered tissues including 
transformed cells. The role of NK cells in the graft-versus-leukaemia (GvL) response has 
been demonstrated in the haplo-identical setting and also studies in the matched related 
donor and unrelated donor settings in acute leukaemia. Myeloma can also be seen to be 
sensitive to a graft versus tumour effect. This information, together with in-vitro evidence 
that NK cells are capable of killing both allogeneic and autologous myeloma cells, suggests 
that NK cells may also play an important role in the outcome of patients with MM.  
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It is possible that the role of the NK cell in the immediate post ASCT phase may be crucial to 
the overall outcome of the procedure. The absolute lymphocyte count (ALC) early post 
transplant (described in chapter 1 in the context of other haematological malignancies) also 
appears to be important in affecting the outcome of ASCT for MM. Two independent studies 
of large cohorts of patients undergoing ASCT, have demonstrated that an elevated ALC-30 
or ALC-23, predict for both improved overall survival (OS) and progression free survival 
(PFS). Furthermore, the strength of ALC-23 as a predictive factor was shown by Kim et al 
(2006)132, remaining the only predictor of outcome on multivariate analysis. In this study, 
ALC-23 was a stronger predictor for relapse than the percentage of tumour (malignant 
plasma) cells present in the stem cell graft. The differences in outcome with increased ALC, 
amount to real improvements in patient quality of life (QoL) in MM where post-ASCT 
relapse can be early; Hiwase et al (2008)130, showed that patients with an ALC-30  >10x109/l 
had a 48 and 14 month outcome advantage for OS and PFS respectively. As the ALC 
correlates strongly to NK numbers it is further evidence to suggest that this cell type may 
influence progression of the plasma cell clone.  
 
The data above, together with emerging data suggesting a possible role for KIR-ligand 
interactions in the context of ASCT, indicate a possible role for KIR receptors in outcome of 
ASCT for MM. As MM is the largest indication for ASCT in the UK this may be of significant 
clinical importance. The aim of this study was to investigate the role of the KIR repertoire on 
the outcome of patients with MM after ASCT.  
 
 
137 
 
 
 
 
Results 
 
Patient characteristics 
 
Genomic DNA for KIR genotyping was available on 182 patients, 111 (61%) of whom were 
male. The median age at ASCT was 58.5 years (range, 26.7 - 72.4 years). Patient and disease 
characteristics are summarised in Table 4.1. All patients were sero-negative for HIV-1 and 
HIV-2 and hepatitis B and hepatitis C viruses. Response to induction therapy before ASCT 
was defined according to the European Group for Blood and Marrow Transplantation 
criteria (Blade 1998). Induction chemotherapy regimens are shown in Table 4.1. None of the 
patients received bortezomib or lenalidomide before ASCT in accordance with national 
(United Kingdom) guidelines on the use of such agents as first-line therapy.  
 
At ASCT, 149 patients were defined as having chemosensitive disease (complete or partial 
remission) and 33 had progressive disease (PD) or chemo-refractory disease, thus defining 
GR and poor-risk groups, respectively. One hundred forty-one patients (77%) underwent 
ASCT after first line of chemotherapy and 41 (32%) had received more than 1 line of 
therapy.  
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Cytogenetics  
 
Plasma cell cytogenetics results were available in 76 patients; Giemsa-banding alone, FISH 
alone, and Giemsa-banding plus FISH were performed in 25, 24, and 27 patients, 
respectively. Poor risk cytogenetics were found in 33 of 76 patients (43%). Three patients 
had del13q as the sole abnormality; in all 3 cases this was identified by Giemsa-banding.  
 
 
Serum Markers 
 
Beta-2 Microglobulin ( -2m) and serum albumin results were available in 171 of 182 (94%) 
and 167 of 182 (92%) of patients before ASCT, respectively. Median -2m and serum 
albumin levels at ASCT were 2.0 mg/L (range, 0.9 - 13.0 mg/L) and 3.7 g/dL (range, 2.4 - 4.8 
g/dL), respectively.  
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Transplant Characteristics 
 
Transplantation conditioning used melphalan 200 mg/m2 in 126 patients and in 56 patients. 
Patients were conditioned with the 140 mg/m2 due to age older than 65 years, or due to 
pre-existing renal dysfunction. In all patients the stem cell source was peripheral blood stem 
cells (PBSC) collected after Cyclophosphamide (4g/m2) or Etoposide (1.6 g/m2) and 
granulocyte–colony stimulating factor mobilisation. The median CD34 stem cell dose infused 
was 3.4 x 106/kg (range, 1.7 - 19.2 x 106/kg). Of note, none of the patients received 
maintenance therapy after ASCT.  
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Table 4.1. Patient characteristics 
 Value 
Male-to-female ratio 111:71 
Median age at ASCT, yr (range) 58.5 (26.7-
72.4) 
Disease status at ASCT 
Chemosensitive disease 149 
Chemo-refractory disease/progressive disease,  33 
Induction chemotherapy 
VAD (Vincristine, adriamycin, dexamethasone) 94 
CTD (cyclophosphamide, thalidomide, dexamethasone) 47 
Z-Dex (Idarubicin, dexamethasone) 34 
ABCM, (Adriamycin, carmustine, cyclophosphamide, melphalan) 1 
Melphalan,  1 
Cyclophosphamide/Prednisolone,  2 
Disease subtype 
Immunoglobulin G,  102 
Immunoglobulin  A,  35 
Immunoglobulin D,  13 
Light chain myeloma,  21 
Nonsecretory,  11 
Median βeta-2 microglobulin level at ASCT, mg/L (range) 2.0 (0.9-13 
Median serum albumin level at ASCT, g/L (range) 3.7 (2.4-4.8 
Median plasma cell percentage at ASCT, % (range) 10 (0-90) 
Median CD34 cell dose, x 10
6
/kg (range) 3.4 (1.7-19.2) 
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KIR genotypes and PFS 
 
The frequencies of KIR haplotypes and individual KIR genes in our patient cohort were 
comparable to published data in healthy controls. 
 
The median overall (OS) and progression free survival (PFS) for the whole group were 62 
months (95% CI, 50 - 75 months) and 18.8 months (95% CI, 16 - 21 months), respectively. 
Factors found to be significantly associated with shorter PFS on univariate analysis included 
PD or chemo-refractory disease at time of transplantation (poor-risk disease; (P <0.0001), 
adverse cytogenetics (P=0.026), low serum albumin level at transplantation (3.5 g/dL; 
P=0.002), low serum  2M level (<3.5 mg/l; P = 0.07), KIR haplotype Bx (P=0.036), the 
presence of the activating KIRs KIR2DS1 (P=0.041) and KIR3DS1 (P=0.01), and the presence 
of 3 or more activating KIRs (P=0.046). Absence of the inhibitory KIR, KIR2DL5 alleles 001 or 
005 was associated with a longer PFS (P=0.019). (Table 4.2) No significant influence of the 
number of previous chemotherapy regimens or the melphalan dose on PFS was found. 
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Table 4.2. Association between individual KIRs and progression-free survival on univariate 
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distribution of KIR in the study population is presented. **P for significance on PFS on 
univariate analysis. †Values statistically significant 
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Association between KIR3DS1 genotype and PFS according to disease status at ASCT 
 
As expected, disease status at ASCT was the most significant predictive factor for outcome 
in all patients. Inclusion of KIR2DS1, KIR3DS1, and KIR2DL5 genotypes and disease status in a 
multivariate analysis resulted in KIR3DS1 being identified as the most significant factor for 
PFS in patients with GR (complete or partial remission at ASCT) but not in those with poor-
risk disease. GR patients who are KIR3DS1 negative have a median PFS of 24 months (95% 
CI, 20 - 28 months) compared with 15.3 months (95% CI, 11-19 months) for those who are 
KIR3DS1 positive (P=0.003; Figure 4.1).  
 
The PFS was reduced for patients with poor-risk disease irrespective of KIR3DS1 status, with 
median PFS of 9.7 months (95% CI, 0 - 21 months) and 11 months (95% CI, 8 - 13 months) 
for patients who were KIR3DS1 negative and KIR3DS1 positive, respectively (P=0.31) 
Importantly, the median PFS for patients with GR disease who were KIR3DS1 positive was 
not significantly different from those with PD (15.4 months; 95% CI, 11-20 months) or 
chemo- refractory disease (11.1 months; 95% CI, 8.4-13.8 months, P=0.061; Figure 4.1), 
underscoring the predictive value of KIR3DS1 in determining outcome. The presence of 
KIR2DS1, KIR2DL3, and KIR2DL5A were not significantly associated with PFS in multivariate 
analysis. 
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Figure 4.1. The presence of KIR3DS1 shortens time to progression following ASCT for 
myeloma:  DNA samples from patients with both good and bad risk myeloma were 
genotyped to identify KIR loci. The Kaplan-Meier curves demonstrate that PFS for good 
risk patients who were KIR3DS1-ve was significantly better than those KIR3DS1+ve [24 
months (20-28) compared to 15.3 months (11-19): P=0.003]. The median PFS for bad risk 
patients was not significantly different from good risk, KIR3DS1+ve patients [11.1 months 
(8.4-13.8) compared to 15.3 months (11-19): P=0.061. 
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Patients were stratified into 3 groups on the basis of on disease status at ASCT and KIR3DS1 
genotype; group 1: GR, KIR3DS1 negative; group 2: GR, KIRDS1 positive; and group 3: poor 
risk, KIR3DS1 positive or KIR3DS1 negative. The RR of disease progression or death was 1.0, 
1.9 (95% CI, 1.3-3.1; P=0.002), and 3.0 (95% CI, 1.9-4.8; P=0.0001), respectively (Table 4.3). 
Adjusting for factors shown on univariate analysis to be associated with PFS after ASCT, 
including albumin and -2m levels, the RR of progression for patients with GR KIR3DS1 
negative, GR KIR3DS1 positive; and poor risk were 1.0, 1.8 (95% CI, 1.2-2.8; P=0.008), and 
2.7 (95% CI, 1.6-4.3; P=0.001), respectively (Table 3). Cytogenetic results were available for 
76 patients only, and, when cytogenetics was incorporated into the model, the RRs for the 
same 3 groups were 1.0, 2.7 (95% CI, 1.2-6.2; P=0.021), and 5.3 (95% CI, 2.4-11.7; P<0.0001), 
respectively (Table 4.3). 
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Table 4.3. Multivariate analysis of factors associated with PFS after ASCT for myeloma. 
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Patients were stratified into 3 groups based on (1) disease status at ASCT; (2) KIR3DS1 
genotype; and (3) good risk KIR3DS1 negative  good risk KIR3DS1 positive, poor-risk patients. 
The RR after further adjustment for albumin level, -2M level, and bone marrow 
cytogenetics are also shown. RR indicates relative risk; 95% CI, 95% confidence interval; GR, 
good risk; and -2M, -2 microglobulin. 
 
Figure 4.2. The importance of HLA-Bw4 status in good risk KIR3DS1+ patients undergoing 
ASCT for myeloma: KIR3DS1+/KIR3DL1+ patients who lack the HLA-Bw4 epitope have 
significantly reduced PFS compared to KIR3DS1+/KIR3DL1+ who are HLA-Bw4 +ve and to 
KIR3DS1-ve patients irrespective of HLA-Bw4: (12.2 months (11.9-12.6) compared to 16.7 
(12-21) and 24 months (19.7-28) respectively). 
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To ascertain that any association between KIR3DS1 genotype and PFS was not due to a 
differential response to remission induction chemotherapy, we compared the KIR genotype 
of GR and poor-risk patients at ASCT. No significant difference was observed in the 
proportion of patients with KIR3DS1 positive between the 2 groups; 31% of GR patients 
were KIR3DS positive compared with 42.4% of poor-risk patients (P=0.23). Similarly, no 
difference was found for KIR3DS1 genotype and the number of lines of chemo- therapy 
regimens before ASCT; 19% of KIR3DS1 positive and 25% of KIR3DS1 negative patients had 
received more than 1 line of chemotherapy regimens (P = 0.42). 
 
 
Presence of both KIR3DS1 and KIR3DL1 in the absence of the inhibitory ligand (HLA-Bw4) is 
associated with significantly worse PFS and OS 
 
The activating receptor KIR3DS1 is encoded as an allele of KIR3DL1 and shares greater than 
97% sequence homology in its extracellular domain with the KIR3DL1 receptor. KIR3DL1 
binds HLA-B allotypes that have the Bw4 epitope. The ligand for KIR3DS1 has not been 
determined, although the presence of this gene along with the presence of alleles encoding 
Bw4 have been shown to have an epistatic protective effect on progression of AIDS, (Martin 
2002) suggesting that like KIR3DL1, KIR3DS1 may recognize at least some of the Bw4 
allotypes in persons seropositive for HIV. 
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It is possible that KIR-mediated activation of NK cells, a phenomenon that increases both 
with the presence of certain activating KIR and with the absence of ligand for inhibitory KIR, 
may have an effect on PFS. Because KIR3DL1 interaction with the Bw4 ligand on target cells 
would theoretically inhibit the drive to cytotoxicity from an activating signal mediated by 
KIR3DS1, we hypothesized that an effect of KIR3DS1 would be greatest among persons who 
are missing the Bw4 ligand for KIR3DL1. In our cohort, 167 of 182 patients (92%) were 
positive for KIR3DL1.  
 
We subdivided these patients into 3 groups on the basis of on KIR3DS1 and KIR3DL1 
genotype and HLA-Bw4 status to include group I: KIR3DS1 positive, KIR3DL1 positive, and 
Bw4 negative (n = 26); group II: KIR3DS1 positive, KIR3DL1 negative, and Bw4 positive 
(n = 22); and group III: KIR3DS1 negative, KIR3DL1 positive (n = 119). The median PFS of 
patients in group I was 13.2 months (95% CI, 10-16 months) compared with 16.7 months 
(95% CI, 13-21 months) for group II and 20.4 months (95% CI, 18-23months) in group III 
(P=0.042; Table 4.2). This effect is more marked in patients with GR disease. Within the GR 
patients, the median PFSs were significantly different between patients in groups I, II, and III 
at 12.2 months (95% CI, 11.9-12.6 months), 16.7 months (95% CI, 12-21months), and 24 
months (95% CI, 20-28), respectively (P=0.002); Figure 4.2 Table 4.4. A trend toward 
improved OS was seen for patients in group III (KIR3DS1 negative, KIR3DL1 positive), 
although it did not reach statistical significance (P=0.10). These data suggest that the 
association between the activating gene KIR3DS1 and PFS is even more significant when 
Bw4, the HLA ligand for the closely related inhibitory receptor KIR3DL1, is absent. 
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Table 4.4. Association between KIR3DS1, KIR3DL1, and HLA-Bw4 on PFS following ASCT 
for multiple myeloma 
 
 
 
 
Patients were divided into three groups:  
(1) KIR3DS1 +ve / KIR3DL1+ve,  HLA-Bw4 -ve,  
(2) KIR3DS1 +ve / KIR3DL1 +ve, HLA-Bw4 +ve, and  
(3) KIR3DS1 –ve / KIR3DL1 +ve 
PFS indicates progression-free survival; and ASCT, autologous stem cell transplantation 
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We determined the various combinatorial frequencies of KIR2DS1/KIR2DL1 with group 2 
HLA-C alleles (Lys80) and KIR2DS2/3/KIR2DL2/3 and HLA-C group 1 (Asn80) alleles. The 
absence of ligand for inhibitory KIR occurs when persons are homozygous for either HLA-C 
group 1 (ligands for KIR2DL2/3) or group 2 (ligands for KIR2DL1). We found no significant 
association of these KIRs and their missing ligands on PFS P=0.31 and P=0.28, respectively). 
Similarly, we found no effect of KIR3DL2 and HLA-A3/11 status on PFS and OS (P=0.72). 
 
Discussion 
 
The association between KIR genotype and outcome after allo-SCT has been shown by a 
number of groups (Ruggeri 2002, Clausen 2007, Giebel 2003, and Miller 2007)180,177,169,167. 
However, the relationship between KIR genotype and outcome in the setting of autologous 
transplantation is unknown. With the use of a large homogeneous cohort of patients with 
MM, we have shown that patients carrying activating KIR genotypes, specifically the 
activating KIR receptor KIR3DS1, have a shorter PFS than persons who lack this receptor. 
This effect was more marked in patients who received an autologous transplant in complete 
or partial remission and who lacked HLA-Bw4, the inhibitory ligand for KIR3DL1. 
 
On univariate analysis, we found that the presence of haplotype Bx, more than 3 activating 
KIRs, and the activating NK receptors, KIR2DS1 and KIR3DS1, are associated with 
significantly worse PFS. These results contrast with a recent study by Cooley et al (2009)171 
who showed that with the use of a donor with a KIR Bx compared with an A/A haplotype 
resulted in a 30% improvement in the RR of relapse-free survival in patients receiving an 
unrelated allo-SC transplant for acute myeloid leukaemia (AML). Interestingly, another study 
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showed that the use of HLA-matched unrelated donors with haplotype A/A was associated 
with lower RR of relapse in patients with myeloid malignancies after a myeloablative allo-
SCT. In keeping with our findings, they reported that the use of a donor with more than 3 
activating KIRs or donors who are positive for KIR3DS1, KIR2DS1, or KIR2DS5 genes was 
associated with shorter PFS 
 
 
The discrepancy between our findings and that of Cooley et al could in part be explained by 
differences between the patient groups for the underlying diagnosis (lymphoid vs myeloid), 
transplantation conditioning (total body irradiation based vs chemotherapy based, and 
different stem cell source (predominantly bone marrow in the allogeneic setting compared 
with peripheral blood mononuclear cells only in the autologous setting). The clearest 
difference between the 2 studies is however the graft type. Our study was performed in the 
autologous rather than an allogeneic setting and therefore without any interference of an 
allo-reactive phenomenon or an immunosuppressive effect of graft-versus-host disease 
therapies. All of these factors may contribute significantly to the different KIR effects 
observed in these studies. 
 
In our patient cohort, KIR3DS1 genotype was associated with a significantly worse outcome, 
most evident in patients who received a transplant in complete or partial remission after 
induction chemotherapy, translating into a significant reduction in the median PFS (8.7 
months). As previously described (chapter 1), KIR3DS1 has been shown to be involved in 
other human diseases. KIR3DS1 appears to have a protective role in patients with HIV-1 and 
hepatitis C virus, and the presence of KIR3DS1 has been implicated in lower HIV infection 
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rates and in slowing disease progression (Martin 2003 and Alter 2009)207, 210. KIR3DS1 has 
also been shown to confer protection against the development of hepatocellular carcinoma 
in patients chronically infected with the hepatitis C virus (Lopez-Vazquez 2005)306. 
However, and in keeping with our results, a meta-analysis of 3 large independent studies on 
cervical carcinoma showed that in women with high-grade cervical intraepithelial neoplasia, 
KIR3DS1 is associated with increased risk of progression to invasive cervical cancer 
(Carrington 2005)63. Furthermore, contrary to the idea that activating NK receptors protect 
against malignancy, an analysis of more than 300 cases of nasopharyngeal carcinoma 
showed that increasing numbers of activating receptors are associated with an increased 
risk of nasopharyngeal carcinoma in persons seropositive for Epstein-Barr virus (Butsch- 
Kovacic 2005)67. 
 
These findings suggest that KIRs and the innate immune system may be involved in the 
pathogenesis and/or progression of some cancers (Carrington 2005)63. 
 
The greatest effect on PFS was observed in KIR3DS1 patients with GR disease in whom the 
ligand for the corresponding inhibitory KIR3DL1 receptor, HLA-Bw4, was missing. GR 
patients who had the genotype: KIR3DS1 positive KIR3DL1 positive HLA-Bw4 negative had a 
significantly shorter PFS (P=0.002) than patients with GR disease who were KIR3DS1 
negative, translating into a difference in median PFS of 12 months (12.2 vs 24 months). This 
suggests that, in the presence of the HLA ligand, the corresponding inhibitory KIR neutralizes 
the effect of the activating KIR (Figure 4.3). It is possible that KIRs and HLA class I alleles may 
have either beneficial or deleterious consequences, depending on the type of disease. 
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Figure 4.3: Proposed explanation for differing PFS in myeloma patients undergoing ASCT 
based on HLA-Bw4 genotype. The interaction between inhibitory KIR3DL1 and its ligand 
HLA-Bw4 (A) is stronger than the interaction between KIR3DS1 and its ligand (C). The 
signals induced by interaction A, are able to quench those of interaction C (Arrow B). 
Absence of the HLA-Bw4 – KIR3DL1 interaction leaves action of KIR3DS1 unchecked 
resulting in KIR3DS1 induced effector function (D). 
 
 
 
 
 
 
 
 
 
 
 
 
In contrast to previously published studies we failed to demonstrate an improved outcome 
with increased numbers of inhibitory KIR-ligand mismatches. Leung et al (2007)134 recently 
reported reduced relapse rates after ASCT for non-Hodgkin lymphoma (NHL) or solid 
tumours in paediatric patients with an inhibitory KIR–HLA mismatch. Similarly, in a larger 
study of 169 patients with Stage IV neuroblastoma treated with ASCT, a survival advantage 
was shown in patients lacking HLA class I ligands for autologous inhibitory KIRs (Venstrom 
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2009)297 Another study, however, failed to show any effect of missing KIR-ligand interactions 
in 67 recipients of ASCT who had solid tumours or lymphoma (Stern 2008)135 All these data 
support an association between KIR genotype and outcome in the setting of ASCT, although 
a better understanding of the biologic complexity responsible for these effects in different 
disease settings is needed. 
 
The mechanism by which KIR3DS1 affects outcome in patients after ASCT is unclear. The 
finding that a similar proportion of GR and poor-risk patients were KIR3DS1 positive at ASCT 
suggests that KIR3DS1 positivity did not affect response to induction chemotherapy but that 
any effect is more likely to be related to the peri-transplantation or post-transplantation 
period. It is possible that KIR3DS1 positive NK clones exert an immunomodulatory effect on 
antitumor responses. Any effect on antitumor responses is likely to have a greater effect 
after ASCT, at a time of lymphopenia-driven homeostasis and minimal tumour burden. Such 
potential immune modulation could be effected through the production of 
immunomodulatory cytokines, affecting T-cell function or through a direct NK effect on 
antigen presentation by dendritic cells (Ruggeri 2002)180 thereby indirectly affecting T-cell 
activation. Furthermore, it is also possible that T-cell populations expressing KIR are 
involved in this process. 
 
NK cells undergo rapid expansion after ASCT, consistent with their role in defence against 
viruses. Interestingly, recent studies have shown that proliferating NK cells expressing 
activating receptors secrete cytokines such interleukin-10 (IL-10) (Lee 2009)308 and 
transforming growth factor beta-1 (TGF -1) (Ghio 2009)284 that have inhibitory effects. This 
is believed to be a homeostatic protective mechanism to “dampen down” a pro-
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inflammatory response and to prevent autoimmunity. IL-10 has direct and indirect inhibitory 
effects on several T-cell responses, including CD8 T-cell cytotoxicity and CD4 T-cell 
proliferation, and results in selective expansion of regulatory T cells (Bettini 2009)309 IL-10 
also appears to be an important growth factor for malignant plasma cells (Klein 2003)310. 
 
Recently NK cells expressing the activating KIR receptors KIR2DS1 and KIR2DS2 were also 
shown to secrete TGF -1 with inhibitory effect on NK-mediated target lysis and pro-
inflammatory cytokine production.41 TGF -1 can modulate antigen-presenting cell function 
and lymphocyte differentiation, lead to regulator T-cell expansion and the suppression of 
auto-reactive T cells (Nakamura 2001)285 Furthermore, TGF -1 is elevated in the serum of 
patients with MM (Anagnostopoulos 2001)311 Therefore, it is possible that in patients with 
more than 3 activating KIRs, and more specifically in persons with KIR3DS1, the expansion of 
NK cells in the early period after ASCT might be associated with secretion of anti- 
inflammatory cytokines that either directly promote tumour growth or affect disease 
control indirectly by abrogating antitumor immune responses (Figure 3). Interestingly, 
Venstrom et al (2010)312 have recently shown that the risk and severity of graft-versus-host 
disease is significantly reduced in patients with myeloid malignancies receiving allogeneic 
stem cells from KIR3DS  donors. It is, however, possible that, rather than being directly 
involved in the disease process, KIR3DS1 may be simply a surrogate marker for another 
neighbouring gene that is directly involved in pathogenesis of myeloma. 
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Figure 4.4. The proposed effector functions of an unopposed KIR3DS1 signalling pathway. 
Absence of the HLA-Bw4 – KIR3DL1 interaction leaves action of KIR3DS1 unchecked 
resulting in effector mechanisms such as secretion of cytokines such as IL-10 and TGF 1. 
Such molecules, which have immunomodulatory effects on the cellular components of the 
immune system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion  
 
In conclusion, we report that KIR genotype may have a significant effect on the outcome of 
autologous transplantation for myeloma and that KIR3DS1, a gene with a frequency of 
greater than 30% in the general population, is also a negative prognostic marker in this 
disease. The mechanism by which the KIR gene products exert their effect is not yet clear; 
although an immune mediated effect seems most probable. In-vitro data support NK 
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cytotoxicity against both allogeneic and autologous myeloma (Alici 2008 and Shi 2008)313, 
314, and the use of NK cells in adoptive cell therapy in hematologic malignancies is an 
attractive therapeutic strategy. Within a person, a diverse NK-cell repertoire exists, and 
individual NK clones expressing a specific array of receptors have been shown to respond 
differently to diverse viral infections (Chan 2005, Bashirova 2005, and Miller 2007)42, 44, 167. It 
is therefore conceivable that in myeloma, depending on receptor expression and ligand 
engagement, different NK clones may exert divergent responses against the tumour. 
Selection of specific NK- clones may therefore improve the beneficial effect of NK-adoptive 
therapy. 
 
We propose that combining KIR-HLA genotyping with known factors associated with 
outcome in patients with MM, such as cytogenetics and serum albumin and -2M levels, 
may improve the prediction of outcome after ASCT and select patients who may benefit 
from more-intensive or novel treatment strategies. It is important to note, however, that 
the use of novel agents may affect the prognostic value of KIR3DS1; therefore, these data 
require validation in patients treated with such agents at induction. 
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CHAPTER 5 
 
The Role of the Killer Immunoglobulin Receptor in Graft Versus 
Host Disease 
 
 
 
 
 
 
Acute graft versus host disease  
 
Acute graft versus host disease (aGvHD) is the most frequent morbid complication occurring 
following allogeneic haematopoietic stem cell transplantation (allo-SCT) and occurs in up to 
40% of patients receiving HLA-identical stem cell grafts. As described briefly in the 
introduction (chapter 1), the allo-reactive response characterising GvHD occurs when donor 
derived T-cells recognise host tissue antigens (allo-antigens) as ‘foreign’ and mount a normal 
but exaggerated response against them. In his original description, Billingham (1966)315 
described the three requirements for GvHD to occur: the recipient must express antigens 
not present in the donor, the recipient is incapable of mounting an effective response to 
eliminate transplanted T-cells, and that the SC graft must contain immunologically 
competent cells. These requirement remains true, however investigators have further 
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defined the process of GvHD and three distinct phases (described later) leading to the 
clinical picture of GvHD are now well characterised. 
 
Acute GvHD is defined as occurring prior to day +100 following stem cell infusion, and a GvH 
effect >100 days is arbitrarily termed chronic GvHD (cGvHD). However, such definitions are 
not entirely satisfactory, as late-onset aGvHD may occur >100 days, and GvHD with a clinical 
picture more typical of cGvHD may occur earlier than this arbitrary cut-off. Filipovich and 
colleagues at the National Institutes for health (NIH) (2005)185 refined this classification to 
include the subgroup of aGvHD occurring after 100 days without any features of cGvHD, and 
also described an overlap syndrome in which features of both acute and chronic disease 
occur simultaneously.  
 
The main organs affected by aGvHD are the skin, gastro-intestinal (GI) system and the liver, 
although almost any organ may be involved. In one large series (Martin 1990)188, the 
frequencies of these organs affected by GvHD were reported to be 81%, 54%, and 50% 
respectively. Skin GvHD may range from a maculopapular rash to severe ulceration with 
bullae formation, and toxic dermal necrolysis.  GI symptoms may range from symptoms such 
as include nausea, vomiting, and diarrhoea to profuse (secretory) diarrhoea in more severe 
cases. GI mucosal ulceration can occur resulting in haemorrhage, which confers an inferior 
prognosis (Nevo 1999)190. Hepatic GvHD may range from a mild derangement of 
transaminase enzymes to frank hepatic failure. Whilst these organs are commonly affected, 
other organs such as the lung may be involved.  
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The severity of aGvHD is determined by the involvement of these principal organs and can 
be divided into I (mild), II (moderate), III (severe) and IV (very severe). The accepted system 
of staging and grading of GvHD is outlined in Table 5.1 (below). Severe aGvHD is associated 
with a significantly reduced long-term survival. In a large (French - Dana-Farber - IBMTR)183 
multicentre prospective study of >600 patients undergoing allo-SCT, the 4-year OS rates 
were 89%, 80%, 25%, and 5% for patients with GvHD of grades I, II, III, and IV respectively. 
Therefore, the development of severe aGvHD has a significant negative impact on the 
outcome of allo-SCT.  
 
Prophylaxis of GvHD 
 
With such inferior outcomes, the goal of the transplant physician is to achieve good anti-
tumour effect whilst limiting the occurrence of GvHD. A number of different agents are used 
in the prophylaxis of GvHD.  
 
One strategy is to reduce the donor graft T-cell component. Alemtuzumab (Campath-IH) is a 
recombinant humanised IgG1 monoclonal antibody directed against surface CD52. CD52 is 
found expressed on monocytes, macrophages, eosinophils, lymphocytes (B and T-cell), NK 
cells (Hale 2001)316, and more neutrophils (Ambrose 2009) 317. In-vitro or in-vivo T-cell 
depletion using Alemtuzumab is a commonly used strategy in allo-SCT. Alemtuzumab has a 
profound effect on the immune system and lymphocyte re-population, even in those 
patients not undergoing the myeloablative therapy of allo-SCT (Brett 1996)318. In allo-SCT, its 
use substantially reduces the incidence of severe aGvHD (Perez-Simon 2002)320, and its 
effect on GvHD is dose dependent. (Chakraverty 2010)319. However, whilst Alemtuzumab 
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maybe seen to reduce GvHD, its use is associated with an increase in the risk of leukaemic 
relapse subsequent to a concomitant reduction in any graft versus tumour effect (Apperley 
1987)321. Anti-T cell antibodies (anti-thymocyte globulin; ATG) are also an effective strategy 
in aGvHD prophylaxis.  
 
In addition to T-cell depletion, most transplant GvHD prophylaxis also use inhibitors of T-cell 
activation and proliferation. Methotrexate (MTX) reduces T-cell proliferation and is often 
used in combination with inhibitors of calcineurin (protein phosphatase-3, crucial for both T-
cell activation and proliferation). Selective T-cell inhibitors include Cyclosporine (CsA) and 
Tacrolimus, both of which have been shown to reduce the incidence of GvHD. 
Mycophenolate Mofitil (MMF) (an inhibitor of inosine monophosphate dehygrogenase, 
important in purine biosynthesis) is also used and increasingly used in place of MTX to 
reduce the incidence of mucositis and neutropenia.  
 
In patients who develop aGvHD post allo-SCT, initial treatment is most commonly the 
administration of corticosteroids, which have both anti-lymphocyte and anti-inflammatory 
activity. In mild skin aGvHD topical steroid therapy may be effective, but for more severe or 
systemic GvHD high dose intravenous steroids are commonly used. However, the results of 
corticosteroids in GvHD remain unsatisfactory. In a review of >440 patients with aGvHD 
treated with steroid as first line therapy, MacMillan and Weisdorf 322 demonstrated 
complete and partial response rates of just 35% and 20% respectively. On further analysis, 
even lower responses were seen in patients with GI aGvHD. For patients with steroid 
dependent or refractory GvHD, other modalities of treatment are increasingly available. 
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These include extra-corporeal photopheresis (ECP), monoclonal antibodies directed against 
cytokines implicated in the GvHD process, and mesenchymal stem cell infusion. 
 
Monoclonal antibody therapy will be discussed in more detail in relation to cytokine 
production analysis (see later). Briefly ECP involves exposing patient’s lymphocytes to DNA 
intercalating agents, which are then activated by subsequent exposure to ultraviolet light. 
This results in apoptosis of activated donor allo-reactive lymphocytes. In addition ECP may 
also modulate APC function via the induction of IL-10 production, reducing their capacity to 
induce T-cell proliferation and may stimulate T-reg generation. Mesenchymal stem cells 
(MSCs) also have a number immunomodulatory effects323. The results of these more novel 
therapies are conflicting and further study and clarification is required.  
 
Therefore, it can be seen current therapies for GvHD remain sub-optimal and reducing its 
occurrence in the first place is essential. Separation of the effector mechanisms that result 
in GvHD to those important in producing a graft versus leukaemia/lymphoma effect is the 
ultimate aim of investigators in the field of transplant immunology. 
 
With this in mind, we looked to investigate if certain KIR genes were associated with aGvHD, 
as this might suggest that T-cells and/or NK cells expressing certain KIR molecules may be 
specific effectors of the GvHD process thus providing a potential target for future GvHD 
reduction strategies.   
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Table 5.1 The consensus group staging and grading of acute GvHD following allogeneic 
stem cell transplantation. (Prezpiorka et al Bone Marrow Transplant 1994)184 
 
 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The role of KIR in acute graft versus host disease for chronic myeloid leukaemia in chronic 
phase 
 
Imperial College NHS Healthcare Trust is a regional tertiary referral centre for chronic 
myeloid leukaemia (CML). Prior to the introduction of the tyrosine kinase inhibitors (such as 
Imatinib; see chapter 3), CML in chronic phase (CP) was the largest indication for allogeneic 
allo-SCT. CML-CP patients represent a unique cohort of patients in whom to study the effect 
of KIR on the generation of GvHD.  
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CML-CP patients are a highly homogeneous group with respect to prior treatment. The 
majority of patient unlike other transplant cohorts will not have been exposed to high dose 
or variable chemotherapy induction. As such, these patients will have reduced risk of prior 
infective episodes or significant allogeneic blood component support, factors, which 
theoretically increase the activation state of APCs at the time of exposure to donor T-cells. 
The reduction in these variables allows more accurate assessment of factors such as donor 
KIR repertoire.   
 
Furthermore, restricting analysis to a single centre limits differences in transplant 
procedure, including T-cell depletion strategies, which may influence KIR function (chapter 
1). With these factors in mind, we sought to investigate the role of donor KIR genotype in 
patients undergoing allo-SCT for CML-in CP.    
 
Patient characteristics 
 
In total, we identified 142 consecutive myeloablative allo-SCTs performed for patients with 
CML-CP between February 1994 and July 2008, on which full clinical data and donor DNA 
was available. There were: 83/142 males (58%). The median age at transplant was 34.8 
years (range 13.5 - 60 years). The median time from diagnosis to transplant was 0.9 years 
(0.2 - 6.4 years).  
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In eighty-four (59%) patients, the stem cell source was an HLA-identical matched sibling 
donor, and 52 (36%) received a 10/10 HLA-matched volunteer unrelated donor. In six 
patients (4%), donor and recipient were mismatched at one or two HLA antigens. The SC 
donor was male in 87/142 (61%).   
 
Transplant conditioning was the same in all patients: cyclophosphamide (60mg/m2) plus 
MESNA (Uromitexan® Baxter UK; in order to prevent cyclophosphamide induced 
haemorrhagic cystitis) (60g/m2) was administered on days -6 and day -5. In recipients of an 
unrelated volunteer donor transplant (VUD), total body irradiation (TBI) was administered at 
a total dose of 14.4 Gy in twice daily fractions of 240 cGy, and in sibling allografts at a total 
dose of 13.2 Gy in twice daily fractions of 220 cGy respectively (on days -4 to -2 inclusive).  
 
GvHD prophylaxis employed CsA in all patients; a loading dose of 5mg/kg (intravenously) 
was administered on day -3 followed by a maintenance dose of 2.5mg/kg from day -2 and 
converted to oral preparation from day +7 until 3 – 6 months post transplant. MTX of 
(8mg/m2) was given on days +2, +4, and +8, with a fourth dose given on day + 12 in patients 
receiving a sibling allo-SCT. Recipients of unrelated stem cells received in-vivo T-cell 
depletion with Campath-1H (10mg) on days -10 to -6.  
 
All patients prior to transplant gave permission for use of their clinical data both at an 
institution level and internationally within the European group for Blood and Marrow 
transplantation (EBMT) outcome registry. Our local ethics committee approved this study.  
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Results  
After exclusion of those patients (n=6) with a one HLA-antigen recipient-donor mismatch, a 
total of 88/142 patients (64.7%) were documented as having developed acute GvHD (clinical 
GvHD +/- histological confirmation). Of the 88 patients with aGvHD, 31% (28/88), 45% 
(40/88), and 22% (20/88) developed grades I, II, and III-IV respectively. Forty-eight patients 
(35%) did not develop aGvHD.  
 
DNA for KIR genotyping was available for all 142 stem cell donors (sibling and unrelated) and 
complete KIR repertoire and haplotype was determined (as outlined in chapter 2). The 
frequency of the KIR genes is shown in Table 1. Thirty-three (23.2%) and 109 (76.7%) of 
patients were KIR genotype A/A and Bx, respectively. Patients with no GvHD (grade 0) or 
mild GvHD (grade I) were compared to those who developed clinical grades II-IV.  
 
On a univariate analysis, the presence of both the KIR2DL2 and KIR2DS2 genes within the 
donor KIR repertoire were both significantly associated with an increased risk of severe (II-
IV) aGvHD (P=0.013 and P=0.028 respectively). No other KIR gene was seen to predict for 
aGvHD incidence or severity. As predicted (see chapter 1), strong linkage disequilibrium (LD) 
was seen between KIR2DL2 and KIR2DS2 genes (P <0.0001).  
 
As described above, CD52 is highly expressed on both NK and T-lymphocyte cell surface. The 
use of in-vivo Campath-IH reduces both these cellular subsets from the incoming donor 
graft. Furthermore, Campath-IH has a long bio-available half-life in-vivo, and is likely to 
eliminate emerging immature lymphocytes. Therefore, we hypothesised that the greatest 
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effect of KIR (KIR2DS2/DL2) would be seen in those patients with who did not received anti-
CD52 T-cell depletion.  
 
We compared the effect of KIR genotype on the development of aGvHD between patients 
who received (VUD recipients) and patients who had not received (sibling recipient) GvHD 
prophylaxis using Campath-IH.  The KIR gene frequencies are shown in Table 5.2. 
 
The presence of either KIR2DL2 or KIR2DS2 in recipients of sibling SC grafts remained highly 
predictive for increased severity of aGvHD (P=0.002 and P=0.005, respectively) Table 5.3: 
58% of KIR2DL2 positive patients developed grade II-IV GvHD as opposed to 23% of patients 
who were KIR2DL2 negative. Similarly 57% of KIR2DS2 positive patients developed grade II-
IV GvHD as opposed to 26% of KIR2DS2 negative individuals.  
 
However, interestingly, the effect of KIR2DL2/S2 was completely abrogated when the 
recipients of VUD transplants were analysed (P=1.0 and P=1.0 respectively). This suggests, 
that the addition of Campath-IH is likely to have removed those cells (T-cells and/or NK 
cells) expressing KIR2DL2 and KIR2DS2, and it is these cell subtypes which are important in 
the generation of a GvHD process. 
 
Genotype Bx (containing the centromeric KIR2DL2/DS2+ genes; chapter 1) was also 
significantly associated with an increased risk of severe GvHD; 52% of patients with 
haplotype Bx developed GvHD grades II-IV as compared to 24% of patients with haplotype 
AA (P=0.056). Increasing numbers of activating KIR (aKIR) number was also associated with 
an increased risk of grade II-IV GvHD.  Of the patients with 4 aKIR present in their KIR 
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repertoire, 67% of patients developed severe GvHD as compared to 38% with 0-3 aKIR. 
(P=0.05).  
 
A thorough review of individual sibling transplant protocols identified 12/84 (14%) had 
received T-cell depletion (using Campath-1H). Therefore to prove our hypothesis that T-cell 
depletion influences the role of KIR on GvHD outcome, we divided the recipient of sibling 
allo-SCTs into two groups: T-cell depleted (TCD) (n=12) and non T-cell depleted (NTCD) 
(n=72). Within the NTCD group, the predictive value of the presence of KIR2DL2 and 
KIR2DS2 for developing grades II-IV GvHD was highly significant (P=0.001 and P=0.004 
respectively). Conversely this was lost in the TCD cohort (P=1.0 and P=1.0, respectively). 
 
KIR2DL2 and KIR2DS2 genotype was entered in a stepwise regression logistic multivariate 
analysis including those variables previously shown to confer increased risk of aGvHD: TBI 
dose, CMV sero-status, donor and patient gender. P-values ≤0.05 were considered 
significant. This revealed that the presence of the KIR2DL2 and KIR2DS2 genes remained an 
independent predictor of GvHD severity (P=0.005 and P=0.005 respectively). No KIR 
(including 2DL2/S2) genes in the donor repertoire were found to be associated with c GvHD 
(KIR2DL2: P=0.26 and P=0.84, KIR2DS2: P=0.32 and P=0.84 in sibling and VUD allo-SCT 
respectively).  
 
However, despite their association with aGvHD, no obvious graft versus CML effect was 
seen to be associated with neither KIR2DS2 nor KIR2DL2, as neither gene appeared to 
confer protection against rising BCR-ABL1 RT-PCR transcript number, or frank disease 
relapse following allo-SCT.  
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These data therefore suggested that cells expressing KIR2DL2 and DS2 maybe more adept at 
inducing GvHD in the host. At least in regard to CML it suggests that they are not the prime 
mediators of the GvL effect to which this haematological malignancy is acutely sensitive. 
Therefore, we decided to explore the expression of these receptors on the surface of 
peripheral blood NK and T-cells and to examine whether such cells were more capable of 
producing those cytokines, which promote GvHD reactions.  
 
Table 5.2. The frequencies of the killer immunoglobulin-like receptor genes in the KIR 
repertoires of donors of peripheral blood stem cells for patients transplanted for chronic 
myeloid leukaemia in chronic phase (n=142).  
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Table 5.3. KIR2DL2/DS2 status of patients with CML in CP who developed acute GvHD 
following sibling allogeneic stem cell transplantation. Patients who are KIR2DL2 or 
KIR2DS2 genotype positive have an increased risk of grade II-IV GvHD (P=0.002 and 
P=0.005, respectively). 
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Graft Versus Host Disease Pathophysiology 
 
In order to investigate potential mechanisms by which KIR2DS2/DL2 expressing cells might 
influence GvHD, it was first necessary to briefly review its pathogenesis.  
 
GvHD can be summarised into three distinct sequential phases (Ferrara review 2009)324 (see 
Figure 5.5).  
 
The first phase is the activation of antigen presenting cells by both the underlying disease 
and the transplant conditioning regimen. In this phase damaged recipient cells respond by 
the release of ‘danger-signal’ cytokines such as tumour necrosis factor alpha (TNF-α), and 
with increased expression of adhesion molecules and MHC antigens. Limiting this phase is 
thought to be the reason that reduced intensity of conditioning has been associated with 
reduced GvHD rates.  
 
The second phase in GvHD pathophysiology is the proliferation and differentiation of donor 
T-cells in response to the APC activation. These activated donor T-cells demonstrate 
increased transcription of those genes for certain cytokines including TNF-α, IL-2 and IFN-  
(these cytokines are discussed in greater detail below), which are involved in the 
propagation of aGvHD.  
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The third and final phase of GvHD is the effector phase where cytotoxic T-cells and NK cells 
lead to target (recipient) cell lysis. In addition to this, TNF-α has also been shown to cause 
direct tissue necrosis.  
 
With this accepted model of GvHD in mind, we sought to determine if a KIR2DS2/DL2 
positive genotype is associated with aGvHD because cells expressing these KIRs have an 
increased ability to produce cytokines implicated in the GvHD process. The cytokines 
investigated will be reviewed separately, below. 
 
Figure 5.5. A model of GvHD illustrating the three essential phases in its pathogenesis 
(Ferrara and Levine 2009). 
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KIR2DS2/DL2 expression on lymphocyte subsets 
 
 
The data suggesting that KIR2DS2/DL2 is associated with acute graft versus host disease led 
us to hypothesise that T-cells and/or NK cells expressing these receptors were 
phenotypically more pro-inflammatory with respect to their cytokine production when 
activated (either by the recognition of lack of self or cross- linkage with an allo-antigen). The 
fact that KIR2DS2/DL2 genotype did not also predict for improved disease free survival 
suggests that such cells may have GvHD potential without GvL effect (at least in the context 
of CML), and as such, if these cells were found to be more pro-inflammatory, then their 
selective depletion may be of use in strategies to reduce GvHD post allo-SCT. 
 
Using surface staining techniques as outlined in chapter 2, we were able to determine T-
cells, NK cells and NK-T cells based on the presence or absence of CD56 and CD3. Figure 5.1 
below demonstrates the identification of these subsets as CD56- CD3+; CD56+ CD3-; and 
CD56+ CD3+ respectively.  
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Figure 5.1: Identification of lymphocyte subsets by differential surface staining with CD56 
and CD3.  A: CD56-, CD3- representing monocytes/macrophage population; B: CD56+, CD3- 
represents the NK population; C:  CD56+, CD3+ represents the NK-T cell population; and D: 
CD56, CD3+ represents the T-cell population. 
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We determined the percentage of (lymphocyte gated) cell subsets in healthy controls 
(n=12). The mean T-cell, NK cell, and NK-T cell percentages were 62.375% (range 43.2% - 
79.1%) (Mean CD8+ and CD4+ T-cell subsets were 32.36% range 9.87% – 49.0% and 67.5% 
range 58.8% – 90.1%), 13.054% (range 1.95% - 27.5%) and 4.78% (range (0.90 – 9.67%) 
respectively. We then determined the relative frequencies of KIR2DS2/DL2 on the surface of 
the NK and T-cell populations. We then determined KIR2D expression on the various 
subsets. KIR2DS2 expression in T-cell, NK and NK-T cells was 1.28% (range: 0.42% – 3.28%), 
24.45% (range: 4.32% – 39.8%), and 15.22% (range 2.58% – 43.9%) respectively (Table 5.4). 
An example of subset KIR2D expression in an individual is shown in Figure 5.2. The KIR2D 
expression on CD8+ and CD4+ T-cell subsets was 2.55% (range: 0.93% – 4.04%) and 0.95% 
(range: 0.38% – 2.78%). Figure 5.3 illustrates KIR2D expression on T cells.  KIR2D expression 
was almost exclusively seen in the CD56 dim NK subset (Figure 5.4). 
 
Figure 5.2: Example of KIR2DS2 expression on lymphocyte subsets. (A) Healthy volunteer 
T-cell and NK cell subsets were identified by differential surface expression of CD56 and 
CD3. Surface staining of NK cells (B) and T-cells (C) revealed KIR2DS2 expression in 38.3% 
and 30.25% respectively.  
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Table 5.4 KIR2D expression in lymphocyte subsets in healthy volunteer controls (n=12).  
The percentage of the lymphocyte subset (T, NK and NK-T cells) of total lymphocytes is 
shown. The percentage of these cells which express surface KIR2D is also shown. Table B 
shows the percentages of CD8 and CD4 T-cell subsets with KIR2D expression.  
 
 
 
A 
B 
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Figure 5.3: KIR2D expression in CD8+ and CD4+ T-cell subsets. (A) T-cells are identified by 
CD3 expression and CD56 negativity. (B) Co-staining for surface expression of CD8 allows 
the identification of (C) CD8- CD4+ CD3+ T-cells and (D) CD8+ CD4- CD3+ T-cells.  
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Figure 5.4: (A) NK cells are divided into two distinct subsets based on expression of CD56 
(i) high (CD56 high) or (i) low (CD56 dim). (B) Example of differential expression of KIR2D 
within CD56 bright and CD56 dim NK subsets. KIR2D is not expressed in the CD56 bright 
subset (0.09%) and is almost exclusively expressed within the CD56 dim subset (99.1%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Tumour necrosis factor-alpha and acute GvHD 
 
The first cytokine whose production we evaluated in KIR2DS2/DL2 positive cells as 
compared to the corresponding KIR2DS2/DL2 negative population was tumour necrosis 
alpha (TNF-α).  
 
The rationale for investigating this cytokine is consequent on its pivotal role in the 
pathogenesis of aGvHD. The role of TNF-α in the initiation, amplification, and maintenance 
of GvHD is well characterised. TNF-α has both direct and indirect effects on aGvHD via the 
activation of effector cells, and via the induction of cell apoptosis within target tissue 
respectively325.  
 
In the first phase of GvHD (as outlined above), TNF-α is released by host tissues following 
damage induced by both cytotoxic drugs and radiotherapy used in the transplant 
conditioning. This released TNF-α results in activation of APCs with up-regulation of those 
proteins involved in the cross presentation of polypeptide proteins (such as minor histo-
compatibility antigens) to donor T-cells. This in turn, results in both the activation and 
proliferation of allo-reactive T-cells (the second phase of GvHD)325. One such mechanism by 
which TNF-α promotes this phase stimulation of APC Hyaluronan production, which is 
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essential in the binding of T-cells to APC at immune synapse (Bollyky 2010)326. In a positive 
feedback amplification loop, activated donor T-cells then themselves produce increased 
amounts of TNF-α together with other Th1 cytokines including IL-2, IL-1, and IFN-gamma 
(IFN-γ).  These cytokines synergise during phase three of GvHD, further amplifying the tissue 
injury and promoting inflammation (Ferrara and Deeg1991)327.   
 
The gastro-intestinal (GI) tract is especially susceptible to TNF-α mediated damage, and TNF-
α has been shown to induce mucosal cell apoptosis. This mucosal damage, leads to the 
translocation of lipopolysacchardide (LPS) into the peripheral blood stream, further 
activating APCs, instigating another amplification loop. Inhibition of TNF-α by specific 
monoclonal antibodies has been shown to ameliorate GI.  
 
Clinical evidence also supports a role for TNF-α in GvHD, with a number of studies 
demonstrating elevated TNF-α plasma levels in patients with aGvHD (Holler 1999 328-9, Choi 
2008300, and Kitko 2008331). TNF-R1, the receptor for TNF-α acts as its surrogate marker; 
following receptor-ligand interaction the TNF-R1 - TNF-α complex is shed into plasma. An 
increased TNF-R1: baseline TNF-R1 ratio, has been demonstrated at day +7 following allo-
SCT (both in the myeloablative and reduced intensity (RIC) settings) and furthermore, is 
elevated in grades II-IV GvHD as compared grades 0-I. This increase was also associated with 
an inferior TRM and OS (Holler328-9). Lower levels of serum TNF-R1 also correlate with less 
extensive tissue damage after RIC allo-SCT (Fowler 2004)332.  
 
 
This putative role for TNF-α in aGvHD generation is further strengthened by clinical data 
demonstrating improvement GvHD in patients following the administration of drugs, which 
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inhibit the cytokine. Currently, two such drugs are licensed for clinical use: Etanercept  
(Pfizer, NYC, USA), a soluble recombinant dimeric TNF-R which acts as a decoy receptor; and 
Infliximab  (Schering-Plough NJ, NYC), a monoclonal anti-TNF-α antibody. Clinical studies 
using Etanercept remain conflicting; Levine et al (2008)333 demonstrated complete 
resolution in 69% of patients with aGvHD as compared to 35% in an historical cohort treated 
with corticosteroids alone (MacMillan 2002)322. However, other studies have failed to 
demonstrate any benefit. Infliximab  has been shown to have promising results in a 
number of relatively small patient series (Busca 2007334, and Sleight 2007335). Meta-analysis 
of these studies (>100 patients) suggests a median response rate for Infliximab  of around 
63% in patients with severe steroid refractory GvHD. However, all such studies using 
Infliximab  demonstrated a considerable increased risk of invasive fungal infection (most 
likely due to the removal of TNF-α expressing monocytes and macrophages compromising 
any antifungal effect).   
 
 
This data all supports an important role for TNF-α in aGvHD. Following our demonstration 
that KIR2DS2/DL2 positive genotype associates with increased incidence of severe GvHD we 
investigated if this was a result of KIR2DS2/DL2 expressing T-cells (or NK cells) being more 
adept at TNF-α production following stimulation.  
 
Results 
 
Healthy donor PBMNC were isolated as described in chapter 2. The TNF-α production in 
both the T-cell and NK cells expressing KIR2DS2/DL2 was compared to their KIR2DS2/DL2 
negative counterparts. 
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In total PBMNC from 15 KIR2DS2/DL2 positive healthy controls were evaluated for TNF-α 
production capacity. Following stimulation with PMA and Ionomycin with subsequent 
intracellular staining with anti-TNF-α labelled Mab (as outlined in chapter 2) the percentage 
of TNF-α producing T-cells in each fraction was determined. Within each individual, the 
percentage of TNF-α producing cells in both KIR2DS2/DL2 positive and negative fractions 
were directly compared. The mean percentage of KIR2DS2/DL2 positive T-cells expressing 
TNF-α was 55.3% (range 20.1% – 78.3%; 95% CI: 41.35 – 61.53) as compared to 35.2% 
(range 16.9% – 65.6%; 95% CI: 27.50  - 46.33) of KIR2DS2/DL2 negative T-cells (P=0.0001) 
(Figure 5.7 and Table 5.5). The difference between the percentages of TNF-α producing cells 
within the KIR2DS2/DL2 positive and negative fractions of one individual are shown in 
Figures 5.6.  
 
Figure 5.6: Example of the intracellular expression of TNF-α in T-cells following stimulation 
with PMA and Ionomycin according to KIR2DS2/DL2 expression status. KIR2DS2/DL2 
positive and negative T-cells were determined by surface staining with anti- 
KIR2DS2/DL2/DL3 (A). KIR2DS2/DL2 negative cells (B) produced significantly less TNF-α 
than KIR2DS2/DL2 expressing cells (C).  
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Figure 5.7 and Table 5.5: The percentages of T-cells expressing intracellular TNF-α in 
healthy controls according to KIR2DS2/DL2 surface expression status. KIR2DS2/DL2 
surface positive and negative cells within each individual (n=15) are compared. 
KIR2DS2/DL2 positive cells express significantly more TNF-α than KIR2DS2/DL2 negative 
cells.  
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On finding an increased percentage of TNF-α producing cells in the T-cell fraction, we sought 
to determine if the expression of KIR2DS2/DL2 also was associated with an increased TNF-α 
production within the NK cell fraction.  
 
NK cells from 15 individuals were evaluated for TNF-α production following stimulation as 
described in Chapter 2 with PMA and Ionomycin Again a significant difference was seen in 
the percentage of NK cells, which stained positively for TNF-α following stimulation 
dependent on KIR2DS2/DL2 expression. The mean percentage of KIR2DS2/DL2 positive NK-
cells with intracellular expression of TNF-α was 49.70% (range 7.50% – 74.2%; 95% CI: 36.21 
– 57.94) as compared to 38.8% (range 12.2% – 69.4%; 95% CI: 27.48 - 46.72) (P=0.0158). 
(Figure 5.9 and Table 5.6). An example of the difference between the percentages of TNF-α 
producing cells within the KIR2DS2/DL2 positive and negative fractions of one individual are 
shown in Figure 5.8.  
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Figure 5.8: Example of the intracellular expression of TNF-α in NK-cells following 
stimulation with PMA and Ionomycin according to KIR2DS2/DL2 expression status. 
KIR2DS2/DL2 positive and negative NK-cells were determined by surface staining with 
anti- KIR2DS2/DL2/DL3 (A). KIR2DS2/DL2 negative cells (B) produced significantly less 
TNF-α than KIR2DS2/DL2 expressing cells (C).  
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Figure 5.9 and Table 5.6: The percentages of NK-cells expressing intracellular TNF-α in 
healthy controls according to KIR2DS2/DL2 surface expression status. KIR2DS2/DL2 
surface positive and negative cells within each individual (n=15) are compared. 
KIR2DS2/DL2 positive cells express significantly more TNF-α than KIR2DS2/DL2 negative 
cells.  
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These data suggest that as with the KIR2DS2/DL2 expressing T-cells, KIR2DS2/DL2 expressing 
NK cells, also produce significantly more cytokine than their KIR2DS2/DL2 negative 
counterparts. 
 
As we had demonstrated in the clinical data, that a donor genotype positive for 
KIR2DS2/DL2 was associated with an increased risk of severe aGvHD, the finding that 
KIR2DS2/DL2 expressing T-lymphocytes and NK cells had an increased capacity once 
stimulated to produce TNF-α data was very interesting. We described above that TNF-α 
plays a pivotal role in the pathogenesis of aGvHD. Therefore, effector cells, which have an 
increased synthesis and secretion of TNF-α, are likely to be important components of the 
GvHD reaction. It is possible by combining these two data to speculate that KIR2DS2/DL2 
expressing lymphocytes may represent a GvHD effector cell phenotype, and as such might 
be a potential target for clinical intervention in this life-threatening condition.  
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Interferon and GvHD Pathogenesis 
 
Following the demonstration that KIR2DS2/KIR2DL2 positive T and NK cells exhibit greater 
TNF-  production following stimulation, we sought to determine if this differential Th1 
cytokine capability also extended to the other cytokine with a well established role in 
aGvHD, Interferon-gamma (IFN- ). IFN-  is a type II IFN produced by a variety of cell types 
including T-cells (both CD4+ and CD8+), NK cells and APCs with both pro-inflammatory and 
anti-tumour activity336.  
 
IFN-  is believed to contribute to the aGvHD process through a variety of mechanisms336: 
IFN-  primes macrophages increasing their production of the inflammatory cytokines 
interleukin-1 (IL-1) and TNF-  in response to exposure to LPS (released following tissue 
damage); IFN-  also increases surface expression of Class II MHC and adhesion molecules on 
APCs, resulting in a net increase in antigen presentation and thus recruitment of effector (T-
) cells; IFN-  also increases APC surface expression of Fas. In addition to these effects, IFN-  
has also been shown to induce inducible nitric oxide (NO) synthetase (iNOS) synthesis 
resulting in the production of reactive NO species, which directly cause tissue damage337-342  
 
High serum levels of IFN-  (similar to TNF- ) correlate with more intensive tissue damage 
(Dickinson 1994)343, and T-cells from patients with active aGvHD, have been demonstrated 
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when stimulated (with PMA) to produce significantly more cytokine than T-cells from 
patients without aGvHD. Further evidence implicating IFN-  as an important cytokine in the 
aGvHD reaction, is the finding that anti-IFN-  antibodies prevent GI aGvHD in animal 
models. These data all point to an important deleterious role for IFN-  in aGvHD in humans.  
 
However, the role of IFN-  in aGvHD is not completely understood, and in contrast to the 
above data, accumulating evidence suggests that IFN-  may also have immunosuppressive 
properties. In animal models, exogenous IFN-  administered immediately post HSC infusion 
has been shown to protect against aGvHD (Brok 1993)344. However, interestingly if this 
administration is delayed by 3 days, this IFN-  confers no protection and indeed results in 
substantial aGvHD. Szebeni and colleagues345, also showed a protective effect of early 
exogenous IFN-  at HSC infusion.  However, a slight delay in administration (day +2) resulted 
in loss of this protection.   
 
It seems therefore that IFN-  exhibits pleiotropic effects in the aGvHD process, and that the 
timing of an increased IFN-  level in relation to stem cell infusion appears crucial to overall 
outcome. The mechanism for the proposed protection against allo-reactivity is currently 
unclear, although studies have shown that IFN-  leads to T-cell arrest and apoptosis, and 
reduces dendritic cell activation thereby limiting antigen presentation. It is possible that 
prior to the early phases of aGvHD, IFN-  limits allo-reactivity in part by its pro-apoptotic 
effect on T-cells (Murphy 1998)346. Further, donor T-cell derived IFN-  has been 
demonstrated to be essential for the inhibitory effect of IL-12 on the aGvHD process. 
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Interestingly, the effect of IFN-  may be different in different tissue microenvironments as it 
has shown to be protective in the lung but pathogenic for GvHD in the GI tract347  
 
 
 
 
Results 
 
In total, PBMNC from 18 healthy controls were evaluated for IFN-  production capacity. 
Following stimulation using PMA and Ionomycin and subsequent intracellular staining with 
anti-IFN-  labelled Mab (as outlined in chapter 2), the percentage of IFN-  producing T-cells 
was estimated. In each individual, the percentage of IFN-  producing KIR2DS2/DL2 
expressing T-cells was compared to T-cells negative for KIR2DS2/DL2 surface expression. The 
mean percentage of KIR2DS2/DL2 positive T-cells expressing IFN-  was 48.76% (range 8.07% 
– 88.1%; 95% CI: 35.464 – 62.070) as compared to 24.65% (range 7.03% – 64.9%; 95% CI: 
15.06 - 34.228) in KIR2DS2/DL2 negative cells (P<0.0001) (Figure 5.11 and Table 5.7). The 
difference in the percentage of IFN-  producing cells within the KIR2DS2/DL2 positive and 
negative fractions of one individual are shown in Figure 5.10  
 
These data suggests that as with TNF- , the KIR2DS2/DL2 positive T-cell fraction produces 
significantly more cytokine than their KIR2DS2/DL2 negative counterparts. This suggests 
that expression KIR2DS2/DL2 confers (or is a phenotypic marker for) a skewing towards a 
Th1 type effector cell. T-cells expressing KIR2DS2/DL2 are as such more likely to be involved 
in the aGvHD pathogenesis. 
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Figure 5.10: Example of the intracellular expression of IFN-  in T-cells following 
stimulation with PMA and Ionomycin according to KIR2DS2/DL2 expression status. 
KIR2DS2/DL2 positive and negative T-cells were determined by surface staining with anti- 
KIR2DS2/DL2/DL3 (A). KIR2DS2/DL2 positive cells (B) produced significantly more IFN-  
than KIR2DS2/DL2 expressing cells (C).  
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Figure 5.11 and Table 5.7: The percentages of T-cells expressing intracellular IFN-  in 
healthy controls according to KIR2DS2/DL2 surface expression status. KIR2DS2/DL2 Figure 
Figure 5.11 and Table 5.7: KIR2DS2/DL2 surface positive and negative T-cells within each 
individual (n=15) are compared. KIR2DS2/DL2 positive cells express significantly more IFN-
 than KIR2DS2/DL2 negative cells 
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We then sought to determine if the increased percentage of IFN-  producing cells seen in 
the T-cell fraction expressing KIR2DS2/KIR2DL2 was also seen in NK cells expressing this KIR 
molecule. NK cells from a total of 17 individuals were evaluated for IFN-  production 
following stimulation. As with the T-cells, a significant difference was seen in the percentage 
of NK cells staining positively for IFN-  following stimulation dependent on their 
KIR2DS2/DL2 expression. The mean percentage of KIR2DS2/DL2 positive NK-cells expressing 
IFN-  was 54.50% (range 2.37% – 94.5%; 95% CI: 40.636 – 68.368) as compared to 38.1% 
(range 2.86% – 90.3%; 95% CI: 25.324  - 51.048) (P=0.0002) (Figure 5.13 and Table 5.8). The 
difference between the percentage of IFN-  producing cells within the KIR2DS2/DL2 positive 
and negative fractions of one individual are shown in Figure 5.12. This data suggests that as 
with T-cells fraction, in the NK subset, KIR2DS2/DL2 expression identified a subset of cells 
with increased pro-inflammatory cytokine potential.  
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Figure 5.12: Example of the intracellular expression of IFN-  in NK-cells following 
stimulation with PMA and Ionomycin according to KIR2DS2/DL2 expression status. 
KIR2DS2/DL2 positive and negative NK-cells were determined by surface staining with 
anti- KIR2DS2/DL2/DL3 (A). KIR2DS2/DL2 positive cells (B) produced significantly more 
IFN-  than KIR2DS2/DL2 negative NK cells (C).  
 
Figure 5.13 and Table 5.8: The percentages of NK-cells expressing intracellular IFN-  in 
healthy controls according to KIR2DS2/DL2 surface expression status. KIR2DS2/DL2 
surface positive and negative cells within each individual (n=15) are compared. 
KIR2DS2/DL2 positive cells express significantly more IFN-  than KIR2DS2/DL2 negative 
cells.  
 
 
 
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following the discovery that KIR2DS2/DL2 expressing T and NK cells preferentially express 
TNF-  over their KIR2DS2/DL2 counterparts, the finding that this phenomenon was also 
found with respect to IFN-  was highly significant. IFN-  as we have described above, also 
has an established role in the pathogenesis of aGvHD. Therefore, the finding that the same 
cell type preferentially expressed these two significant cytokines suggested a skewing of 
such cells towards GvHD induction. Furthermore, this is supported by our clinical data. 
Whilst the role of IFN-  in the first few days after SC infusion may be beneficial with regard 
to GvHD, IFN-  produced after this period if highly deleterious. Donor T and NK cells 
engraftment is usually seen between days 10 and 14 post allo-SCT, as such donor 
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KIR2DS2/DL2 positive T-cell derived IFN-  during this period may be highly significant in the 
pathophysiology of GVHD. Thus, the combination of increased TNF-  and IFN-  capability 
suggests potentially highly toxic lymphocyte phenotype, which may have significant 
consequences on transplant outcome.   
 
 
 
 
Following the above demonstration that both TNF-  and IFN-  are preferentially expressed 
in KIR2DS2/DL2 positive cells, we attempted to demonstrate a similar preference for IL-2 
expression and thus more confidently describe KIR2DS2/DL2 positive cells as a Th1 type 
subset.  
 
 
Interleukin- 2 and Acute Graft versus Host Disease 
 
 
Interleukin-2 (IL-2) is a Th1 cytokine, which similar to TNF-  and IFN-  is implicated in the 
pathogenesis of aGvHD. As described, in the first phase of aGvHD, T-cell activation by APC 
results in transcription of a number of genes, including that encoding IL-2. This synthesised 
IL-2 then acts in an autocrine manner inducing its own up-regulation inducing further T-cell 
expansion (another positive feedback loop) together with activation of NK cells (Ferrara 
review)181. Therefore, it can be seen that IL-2, is another potential target for interventions to 
limit both the incidence and severity of aGvHD.  
 
As previously discussed, Cyclosporine (CsA) and Tacrolimus are both effective in prevention 
of aGvHD and are commonly used in preventive strategies (reviewed in Ram 2009)348. Both 
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drugs are potent inhibitors of calcineurin, an activator of IL-2 transcription. Interruption of 
the IL-2 pathway is thought to be how these agents prevent T-cell activation. The 
effectiveness of these two drugs in GvHD prophylaxis, underpins the importance of IL-2 in 
the generation of clinically significant aGvHD.  
 
 
 
Results 
 
In total, PBMNC from 15 healthy controls were isolated and stimulated with PMA and 
Ionomycin (as described in Chapter 2). Intracellular cytokine staining was performed to 
identify expression of IL-2.  
 
The first important finding was that in PBMC from all controls (n=15), IL-2 was found 
expressed only in CD3+ cells. No IL-2 was found to be produced by the CD56+, CD3- (NK cell) 
population (Figure 5.14). 
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Figure 5.14. Interleukin-2 expression of peripheral blood mononuclear cells following 
stimulation with PMA and Ionomycin. IL-2 is expressed by the CD3+ fraction and no IL-2 is 
seen expressed by the CD56+, CD3- NK cell population.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gating of CD3+ CD56- T-cells 
was performed to identify the KIR2DS2/DL2 positive and negative expressing cells. 
Intracellular IL-2 production (expressed as a percentage of IL-2 positive cells) between these 
populations was then compared. Figure 5.15 shows the percentage of cells with intracellular 
IL-2 expression between the two cell populations within each individual subject.  
 
The mean percentage of T-cells which were seen to express IL-2 in the KIR2DS2/DL2 
negative fraction and KIR2DS2/DL2 positive fractions were 28.63% (range: 3.87 – 50.6; 95% 
CI: 21.687 – 35.562) and 20.713% (range: 8.2 - 45.1; 95% CI: 13.580 – 27.845) respectively 
(P=0.003) (Figure 5.16 and Table 5.9). This suggested a highly significant difference in IL-2 
production between KIR2DS2/DL2 positive and negative T-cells. However, unlike the 
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differences seen for intracellular expression of TNF-  and IFN- , the increased proportion of 
IL-2 positive cells was in the KIR2DS2/DL2 negative T-cell fraction.  
 
Figure 5.15. Intracellular cytokine staining of interleukin-2 in CD3+, CD56- T-cells following 
stimulation with PMA and Ionomycin. IL-2 production by KIR2D negative cells (A) is 
significantly greater than that of KIR2D positive cells (B).  
 
Figure 5.16 and Table 5.9. The percentage of IL-2 production as determined by 
intracellular cytokine staining in CD3+, CD56- T-cells following stimulation with PMA and 
Ionomycin. The difference between KIR2D positive and negative T-cells within individuals 
is shown. 
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Discussion  
 
The expression of IL-2 within the T-cell fraction with a concomitant absence of expression in 
the NK cell population is in accordance with the absolute requirement of the NK cell for IL-2 
from other cell types (primarily T-cells) for growth and proliferation Nagashima (1998)349. 
Indeed NK cells express the high affinity IL-2 receptor in order to compete for picomolar 
amounts of IL-2 produced by activated T-cells (Caliguri 1990)350.  
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However, considering our previous data with TNF-  and IFN-  expression, the lack of 
expression of this Th1 cytokine from KIR2DS2/DL2 positive T-cells was unexpected. It is 
interesting, that this seemingly potent inducer of aGvHD is almost exclusively seen in the 
KIR2DS2/DL2 negative T-cell subset.  
 
However, there are emerging data, which may explain this discrepancy. Firstly, the data 
suggesting IL-2 to be important in phase 2 of the aGvHD process, naturally lead to the 
generation of anti-IL-2 Mabs for therapeutic use. However, in practice these therapies have 
only demonstrated to have limited success in the treatment of severe aGvHD. Some studies 
showed a modest improvement in GvHD severity using anti-IL-2 (Anasetti 1990351 and 
Przepiorka)184, whilst others have shown no benefit (Belanger 1993)352. Furthermore, in the 
largest randomised control trial of anti-IL-2 (Dacluzimab ) (n >100) for the treatment of 
aGvHD, an increased GvHD related mortality in the treatment arm was reported and lead to 
premature closure of the trial (Lee 2004)353. The increased risk of severe aGvHD seen in this 
study, suggested that IL-2 might indeed be a pleiotropic cytokine in the context of GvHD. It 
seems IL-2 may play a paradoxical preventative role against aGvHD development.  Such a 
role may be through the pivotal role of IL-2 in T-regulatory cell (T-regs) biology.  
 
Regulatory T-cells  
T-regs, are a subpopulation of CD4+, CD25+ T-cells accounting for between 5 -10% of 
circulating CD4+ T-cells (Picirillo 2004)354 whose primary role is the suppression of self-
reactive T-cells which escaped thymic negative selection. T-regs are characterised by 
expression of FOXP3 (Forkhead Box P3), which is highly restricted to this cell subtype and a 
marker for their detection and enumeration (Fontenot 2003355, Hori 20033356).  
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Interleukin-2 and T-regs  
Whilst T-reg biology is not fully understood, a pivotal role is suggested for IL-2, as they 
express the IL-2 receptor α-chain (CD25) (Read 2001)357, and are markedly reduced in mice 
deficient in IL-2, IL-2R, or IL-2 dependent signal transduction pathway proteins. IL-2 
deficiency has been associated with a >90% reduction in T-regs in peripheral lymphoid 
tissue, which can be restored by administration of exogenous IL-2 (Furtado 2002)358. IL-2 
acts via the activation of STAT3 and STAT5 pathways, which lead to increased expression of 
the FOXP3 gene (Zorn 2006)359. T-regs do not produce IL-2, therefore, rely on a paracrine 
cytokine source (Papiernik 1998, Thornton 1998)360-1 for their proliferation and 
differentiation. The predominant source of IL-2 for T-regs is activated T-lymphocytes.  
 
 
 
 
A marked peripheral expansion of T-regs has been reported in the lymphopenic 
environment (following chemotherapy for solid tumours) in patients receiving low dose IL-2, 
and these expanded T-regs were demonstrated to have similar potency for suppression to 
normal host T-regs (Zhang 2005)362. These data suggest that IL-2 and lymphopenia are 
primary modulators of T-reg cell homeostasis. It is possible that low levels of IL-2 during the 
period of immune recovery following HSCT, a lymphopenic state, may control the allo-
reactive processes through donor derived T-regs.  
 
Regulatory T-cells and Acute Graft versus Host Disease 
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Emerging data suggest that following allo-SCT, T-regs play an important role in determining 
both the development and severity of aGvHD. Increased donor T-regs in the PBSC graft have 
been shown to correlate with reduced aGvHD risk in recipients (HLA-matched siblings) 
(Rezvani 2006)363. Furthermore, patients with aGvHD, have been shown to have significantly 
reduced CD4+,CD25+,FOXP3+: CD4+,CD25+,FOXP3- cell ratios early in haematopoietic 
reconstitution suggesting that T-regs suppress effector T-cell activity (Rezvani 2006)363. 
CD4+, FOXP3+ cell frequency decreases linearly with increasing severity of aGvHD 
correlating to eventual maximal grade (Magenau BBMT 2010)364. Interestingly, the 
administration of corticosteroids (standard first line therapy for aGvHD) increases the 
relative proportion of T-regs in the peripheral blood (Ukena 2011)356. 
 
Pre-dating the identification of T-regs, IL-2 infusions early post-SCT was shown to protect 
against aGvHD mortality in animal models (Sykes 1990)366 and that this IL-2 induced 
protection was mediated via the inhibition of IFN-  and TNF- . T-reg impairment is also 
associated with chronic GvHD (Zorn 2005367, Matsuoka 2010)368 and in this situation, low 
dose IL-2 administration results in increased numbers with simultaneous improvement in 
disease severity (Koreth 2011)369. Therefore, although paradoxically IL-2 was originally 
thought to be deleterious in aGvHD due to its promotion of effector T-cell functions, its 
effects on the T-reg population may be dominant and hence beneficial (Blazar 2012)370.  
 
 
The clinical effectiveness of CsA is thought to be due to its relatively limited effect on T-reg 
function as compared to its action on activated T-cells. This protective effect would be 
removed with anti-IL-2 Mab and concomitant use is thought to upset this balance by 
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removing the T-regs and increasing GVHD (Martin 2004)371. Rapamycin (Sirolimus) (an 
inhibitior of mTor, mammalian target of rapamycin), also used successfully in GvHD 
prophylaxis, inhibits IL-2 T-cell activation but again preferentially spares T-regs. Indeed, the 
combination of Rapamycin with low dose IL-2 has been demonstrated to reduce aGvHD by 
selective expansion of (donor type) T-regs. Addition of IL-2 to Rapamycin can convert T-cons 
(conventional effector T-cells) to T-regs reducing IFN- and TNF-  secretion (Shin 2011)372.  
 
 
Conclusion  
 
Our study shows that KIR2DS2/DL2 positive T-cells are skewed to favour an environment, 
which promotes T-cell allo-reactivity on encountering foreign antigen. This includes reduced 
IL-2 production, which favours an allo-reactive process by limiting the effect of T-regs. 
Conversely, during intense allo-reactivity, the KIR2DS2/DL2 negative T-cell population is 
essential in maintaining homeostasis via the up-regulation of IL-2 and local T-reg expansion. 
This latter activity may be especially relevant at the site of ongoing tissue damage in aGvHD.  
 
T-regs also express surface CCR5 (the ligand for MIP-1  - see later). This interaction may 
maintain T-regs at the site of injury in a homeostatic interplay. The concept of localised T-
reg generation is supported by studies in murine diabetes where T-regs prevent the intra-
islet differentiation of specific anti-islet CD8+ T-cells into cytotoxic effectors. Such T-regs are 
restricted to pancreatic tissue and are specific (Green 2002).  Infusion of pancreatic derived 
T-regs can be shown to significantly reduce development of diabetes mellitus whereas non-
pancreatic derived T-regs infusions have no effect (Green 2002)373. Similarly, KIR2DS2/DL2 
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negative cell IL-2 maybe essential for local T-reg generation at the site of GvHD. This in part 
may explain the difference in GvHD rates we describe in patients receiving SC grafts from 
KIR2DS2/DL2 positive and negative donors.   
 
 
 
 
MIP1 proteins and GvHD Pathogenesis 
 
Introduction 
 
The combination of increased production of the pro-GvHD cytokines IFN-  and TNF-  
together with a relative reduction in IL-2 production in KIR2DS2/2DL2 expressing T and NK 
cells, as described above, suggests that these cells are likely to be implicated in aGvHD 
pathophysiology. This effect is likely to be mediated by both the induction of allo-reactivity 
and by a concomitant reduction of its homeostatic T-reg mediated control. This led us to 
investigate the capability of KIR2DS2/2DL2 positive cells in producing other cytokines 
implicated in aGvHD.  
 
Among other proteins, these include the Macrophage Inflammatory Proteins (MIP1) MIP1-α 
and MIP-β (also known as chemokine (C-C motif) ligand 3 (CCL3) and 4 (CCL4), respectively). 
Both these proteins have been demonstrated to be produced by NK and T-cells and have 
also been implicated in the pathogenesis of aGvHD. Therefore, we sought to determine if 
KIR2DS2/2DL2 positive T and NK cells also had increased propensity to MIP-1 protein up-
regulation following stimulation which would further delineate them as skewed toward a 
pro-GvHD functional phenotype.  
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To date, only a small number of studies have investigated the role of MIP-1 in the context of 
GvHD, and these have concentrated on MIP-1 α (as this was the first MIP1 protein to be 
identified). To our knowledge, to date, no investigators have looked at MIP-1β. Nevertheless 
MIP-β and MIP-1-α show high structural similarity and act on the same cellular receptors 
resulting in the same pro-inflammatory effector mechanisms.  
 
The first study to suggest such a role in aGvHD, was the demonstration that MIP-1α mRNA is 
increased in the spleen of mice with aGvHD (Baker et al 1995)374. This was subsequently 
confirmed in a follow-up study by Serody et al (2000)375, who further demonstrated that this 
increased mRNA occurs following transfer of allo-reactive splenocytes into irradiated mice. 
However, transfer of splenocytes from MIP-1α knockout mice (MIP-1 α-/α-) resulted in a 
comparatively reduced donor CD8+ T-cell infiltration of recipient spleen (and liver) with 
subsequent reduction in aGvHD. This reduced inflammatory response was seen in the 
context of allo-transplants mismatched at either MHC class I or class II loci. These data 
suggest a role for donor derived MIP-1α in the recruitment of effector T-cells into GvHD-
targeted organs.   
 
These findings are strengthened by studies demonstrating that MIP-1α blockade 
ameliorates GvHD. In mismatched murine allo-transplants (C57BL/6J into B6D2F1 mice), 
infusion of evasin-1 (a chemokine binding protein isolated from ticks, which binds and 
inactivates MIP-1α) resulted in significantly improved rates of clinical aGvHD and mortality 
(Castor 2010)376. Mice treated with evasin-1 had reduced effector cell infiltration (CD8+ and 
CD4+ T-cells) into intestinal and hepatic tissue with concomitantly reduced levels of tissue 
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IFN-γ. MIP-1α and MIP-1β have been demonstrated to be co-secreted with IFN-γ by 
activated NK and T-cells and co-operate in IFN-γ mediated up-regulation of CD40 (a co-
stimulatory protein on APC required for their activation) (Blazar 1997 and 1998)377,8. 
 
The ligand for both MIP-1α and  is CCR5. Allo-reactive infiltrating effector cells in human 
cutaneous aGvHD, have been shown to be CCR5 positive and produce TNF-α and IFN-γ 
(Palmer 2010)379. This further strengthens the hypothesis that MIP1 recruits effector cells at 
the tissue level. Together these data suggest a possible mechanism by which activated T-
cells secrete MIP-1, which further recruits allo-reactive GvHD inducing T-cells to the target 
tissue. Interestingly Bougina-Kubik et al demonstrated (2006)380 that allo-SCT recipients with 
a mutated CCR5 gene had reduced rates of aGvHD and that both homo and heterozygotes 
for CCR5 δ32 (a 32 base pair deletion found in between 10-13% of North Europeans 
resulting in a truncated non-functional protein) recipients had significantly less aGvHD 
(grade II-IV), and no aGvHD was seen if the donor was δ32.   
 
Results 
PBMC from a total of 17 individuals were analysed with respect to MIP-  production 
following stimulation with PMA and ionomycin (as described in chapter 2). We were able to 
demonstrate that consistent with our findings for the pro-GvHD cytokines TNF-  and IFN- , 
the pro-inflammatory cytokine MIP-  is preferentially expressed by KIR2DS2/2DL2 positive 
T-cells. The mean percentage of KIR2DS2/2DL2 positive and negative T-cells expressing MIP-
 was 60.39% (range: 18.7% – 92.4%; 95% CI 49.024 – 71.640) and 20.26% (range: 6.63% - 
43.7%; 95% CI: 14.993 – 25.539) respectively (P <0.0001) (Figure 5.18 and Table 5.10). An 
example of T-cell expression of MIP-1  in one individual is shown in Figure 5.17.  
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Figure 5.17: Example of the intracellular expression of MIP-1  in T-cells following 
stimulation with PMA and Ionomycin according to KIR2DS2/DL2 expression status. 
KIR2DS2/DL2 positive and negative T-cells were determined by surface staining with anti- 
KIR2DS2/DL2/DL3 (A). KIR2DS2/DL2 positive cells (B) produced significantly more MIP-1  
than KIR2DS2/DL2 expressing cells (C).  
 
 
 
Figure 5.18 and Table 5.10: The percentages of T-cells expressing intracellular MIP-1  in 
healthy controls according to KIR2DS2/DL2 surface expression status. KIR2DS2/DL2 
surface positive and negative cells within each individual (n=15) are compared. 
KIR2DS2/DL2 positive cells (KIR2+) express significantly more MIP-1  than KIR2DS2/DL2 
negative cells (KIR2-).  
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Chemokines such as MIP-  and MIP-  are stored in granules within T and NK cells 
(Stelegmann 2005). Therefore, we analysed the two T-cell fractions (KIR2DS2/DL2 positive 
and negative) to determine if in the unstimulated state there is a difference in baseline MIP-
 levels.  
 
We were able to determine that KIR2DS2/DL2 positive T-cells have intrinsically increased 
MIP1-  expression as compared to the KIR2DS2/DL2 negative fraction. We showed that 
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KIR2DS2/DL2 positive T-cells (n=11) have greater levels of pre-formed MIP-  than 
KIR2DS2/DL2 negative cells: the mean percentage of T-cells with intrinsic MIP1-  expression 
in KIR2DS2/DL2 positive and negative cells was 5.08% (range 95%CI: 3.16 – 6.99) and 0.41% 
(range 95% CI: 0.29 – 0.51) (P=0.001) (An exmple is shown in Figure 5.19). Data was only 
included if MIP1-  in the KIR2DS2/DL2 negative T-cells was clearly greater than background 
staining by >1 log. In 6 controls, this could not be conclusively demonstrated and as such 
these were excluded from the analysis (data not shown).  
 
Figure 5.19: Example of T-cell MIP-1  baseline expression (unstimulated) in a healthy volunteer 
control. T-cells have intrinsic MIP-1  expression (A). T-cells were gated according to their surface 
expression of KIR2D2DS2/DL2 and MIP-1  expression determined: KIR2D2DS2/DL2 positive T-cells 
expressed greater amounts of MIP-1  (B) as compared to KIR2D2DS2/DL2 negative T-cells (C).   
 
 
 
Following the determination that KIR2DS2/DL2 positive T-cells have increased capability for 
MIP-  production, we investigated whether the presence of KIR2DS2/DL2 also conferred an 
advantage for greater MIP-  expression in NK cells. We were unable to demonstrate a 
difference in the relative expression of MIP-  following stimulation (n=12) between 
KIR2DS2/DL2 positive and negative NK cells. The mean percentage of KIR2DS2/DL2 positive 
and negative NK cells expressing MIP-1  was 81.0% (range: 95%CI: 60.103 – 103.580) and 
79.83% (range: 95%CI 9.70 – 58.430), respectively (P=0.092). An example of MIP-1  
expression in Nk cells is shown in Figure 5.20. As two of the subjects (subjects 7 and 11) had 
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considerably lower levels of MIP-  expression than the other 9 subjects, re-analysis was 
performed following their removal from the dataset. Even allowing for exclusion of these 
two data, we were still unable find any difference between these two groups; mean 96.0% 
(range 95%CI: 93.081 – 98.964) versus 93.51% (range: 95%CI: 89.375 – 93.647) (P=0.07). No 
difference was found with respect to pre-formed MIP-  between KIR2DS2/DL2 positive and 
negative NK cells (P=0.2031) (Table 5.11) 
 
Figure 5.20: Example of MIP-1  expression in NK cells of a healthy volunteer following stimulation 
with PMA and ionomycin. MIP-1  expression within NK cells was determined (A). NK-cells were 
gated according to their expression of KIR2DS2/DL2, NK cell expression of MIP-1  was not 
significantly different between KIR2DS2/DL2 positive (B) and negative (C) NK cells.  
 
Table 5.11. The percentage of MIP-1  expression in NK cells following stimulation with 
PMA and Ionomycin. KIR2DS2/DL2 positive and negative NK did not differ with respect to 
MIP-1  expression. 
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As we had demonstrated that KIR2DS2/DL2 positive T-cells produced more MIP-  we also 
looked to determine if this is also the case for MIP- .  
 
KIR2DS2/DL2 positive T-cells were seen to produce significantly more MIP-  than their 
KIR2DS2/DL2 negative counterparts of this MIP1 protein also (n=6). An example is shown in 
Figure 5.21)The mean percentage of KIR2DS2/DL2 positive and negative T-cells expressing 
MIP-  following stimulation was 47.13% (range: 11.68% – 70%; 95%CI: 16.294 – 77.966) and 
19.34% (range: 11.2% – 42.1%; 95%CI 7.0264 – 31.670) (P=0.03) (Figure 5.22).  
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Figure 5.21: Example of the intracellular expression of MIP-1  in T-cells following 
stimulation with PMA and Ionomycin according to KIR2DS2/DL2 expression status in a 
healthy volunteer donor. Total MIP-1  in T-cells was determined (A). Gating on 
KIR2DS2/DL2 expression revealed that KIR2DS2/DL2 positive cells (B) produced 
significantly more MIP-1  than KIR2DS2/DL2 negative cells (C).  
 
 
 
 
 
 
 
 
 
 
Figure 5.22. Comparison of the percentage MIP-1  expression between the KIR2DS2/DL2 
positive and negative T-cells within healthy volunteers (n=6). KIR2DS2/DL2 positive cells 
produced significantly more MIP-1  than KIR2DS2/DL2 negative (P=0.003). 
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Similar to the findings for MIP-β expression, we were unable to detect any difference for 
MIP1-α expression in NK cells between the KIR2DS2/DL2 positive and negative fractions. The 
mean percentages of MIP1-α expressing NK cells were 28.5% (range 17.1% – 50.4%; 95%CI 
8.664 - 48.336) and 26.38% (range: 20.1% – 44.4%; 95%CI: 13.712 – 39.048) for 
KIR2DS2/DL2 positive and negative cells respectively. We were unable to accurately 
determine whether any difference in pre-formed MIP1-α was evident between KIR 
expressing T and NK cells. This is the subject of ongoing work.  
 
Conclusion  
 
We have demonstrated that in T-cells, the primary effectors of aGvHD, that KIR2DS2/DL2 
expression is associated with an increase in the ability to up-regulate MIP1 (MIP-β and 
MIP1-α) proteins, which have been linked to GvHD pathophysiology.  
 
Interestingly the factors which induce MIP-1 up-regulation are those same molecules which 
are implicated in the pathogenesis of aGvHD (LPS, TNF-α, IL-1, IFN-γ and substance P) and, 
conversely, molecules associated with ameliorating aGvHD (IL-4 and IL-10) downregulate 
MIP-1 expression. Corticosteroids, the standard first line treatment for aGvHD has also been 
demonstrated to reduce MIP-1 expression.  
 
It is possible that KIR2DS2/DL2 positive cells induce GvHD by the secretion of pro-
inflammatory cytokines (discussed above) and that in addition, their increased secretion of 
MIP-1 proteins early in the GvHD reaction, recruits further effector cells to the affected 
tissue. Such an action is likely to result in an amplification of the GvHD process. If this were 
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confirmed, this would place these proteins as important mediators in aGvHD. Indeed, in this 
way MIP-1 proteins have been implicated in other immune mediated diseases in humans 
including, rheumatoid arthritis, allergic asthma, atopic dermatitis, multiple sclerosis, and 
psoriasis.  
 
Consistent with their role in inflammation, MIP-1 may itself lead to a negative feedback loop 
to maintain homeostasis in order to limit tissue inflammation. CCR5, the ligand for MIP1 
also appears to be expressed on T-regs and important in their recruitment to sites of aGvHD. 
In severe aGvHD T-regs have been shown to have reduced expression of both CCR5 and 
CCR1 and infusion of T-regs from CCR5+ knockout mice resulted in no amelioration of GvHD 
or reduced mortality as compared to substantial improvements following wild type T-reg 
(Wysocki 2005)381. T-regs have high expression of CCR5, allowing direct migration to GvHD 
target tissues reducing the numbers of activated T and B lymphocytes (Zhao 2008)382.  
 
In summary, we have shown that KIR2DS2/DL2 expressing cells have an increased ability, on 
activation, to produce those cytokines (namely TNF-α and IFN-γ), which are highly 
associated with aGvHD. These cells also demonstrate a reduced ability to produce the 
cytokine associated with T-reg development (IL-2). In the data above, we further show that 
such cells also express increased amounts of MIP-1 protein; a molecule that has been 
demonstrated to be elevated in tissues affected with aGvHD and thus may have a critical 
role in the localisation of effector cells to such tissues. This increased expression of MIP-1 in 
KIR2DS2/DL2 producing cells, therefore suggests another mechanism to explain the finding 
that KIR2DS2/DL2 positive SC donors are associated with increased aGvHD.  
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Table 5.13  Summary of the differential cytokine production of both KIR2DS2 positive and  
negative T-cell subsets . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heat shock protein and GvHD 
 
 
 
CD4+ and CD8+ lymphocytes can be subdivided according to their co-expression of the 
surface molecule CD28. CD28 provides a potent co-stimulatory signal to T-cells, after 
interaction with MHC expressed antigen, for the production of certain cytokines and is an 
essential molecule in T-cell activation. However, data suggests that the CD28null (CD28 
negative) subset, may have important clinical considerations.  
 
In patients with acute coronary syndrome (ACS), expanded numbers of CD4+CD28null cells 
have demonstrated within the atherosclerotic plaque (such cells have also been 
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demonstrated in small vessel biopsies in patients with rheumatoid vasculitis) (Wagner, 
2000)383. CD4+CD28null T-cells have also been shown to produce more IFN-γ than their 
CD4+CD28+ counterparts (Liuzzo 199,200 and Zal 2004)384-386 and with other pro-
inflammatory cells play an important role in atherosclerotic plaque destabilization 
(Nakajima 2002) 387. CD4+CD28null T-cells have been shown to have increased expression 
(by mRNA quantification) of KIR molecules in patients with ACS. Importantly, Nakajima and 
colleagues (2002)387 demonstrated that CD4+CD28null cells have a specifically increased 
expression of KIR2DS2. Further, CD28null cells acquire de-novo expression of DAP-12, the 
downstream protein, which transmits KIR2DS2 pro-effector signals in the absence of the T-
cell receptor (Nakajima Cir Res 2003)388. Therefore, the activation of CD4+ CD28null cells is 
governed by both TCR and KIR mechanisms.  
 
This interesting data has lead investigators to attempt to determine the ligand for T-cell 
KIR2DS2 in patients with ACS. One candidate ligand, is heat shock protein (HSP-60) (see 
below), which under physiological conditions is not expressed by vascular endothelial cells. 
However, classical risk factors for atherosclerosis such as hypertension, act as endothelial 
stressors inducing surface expression of HSP. Zal and colleagues (2004)386 demonstrated 
that in patients with ACS, 54% of CD4+,CD28null T-cells were reactive to this autologous 
HSP-60 producing increased amounts of IFN- . The majority of these cells expressed 
KIR2DS2 (in the absence of KIR2DL2 and KIR2DL3). Eloquent blocking experiments provided 
conclusive evidence of an interaction between KIR2DS2 and MHC class-1 presented HSP-60, 
which generated a cytotoxic response (Zal 2008)389. CD4+CD28null T-cells have been shown 
to correlate with a more severe form of rheumatoid arthritis (RA), which is also associated 
with a KIR2DS2 positive genotype. Increased expression of KIR2DS2 mRNA was recently 
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shown following exercise in both athletes and healthy controls and is associated with a 
reciprocal increase in serum concentrations of HSP-70 (Shleptsova 2010)390.      
 
This led us to consider whether HSP maybe an important molecule in the generation of 
aGvHD.  Heat shock protein is a ubiquitous protein found both in eukaryotic and prokaryotic 
cells, important in both intra-cellular and inter-cellular pathways (Quintana 2011)391. HSP is 
expressed in the mitochondria and translocated to the cytoplasm, where it acts as an 
important chaperone molecule; in addition it is also transported to the cell surface and shed 
to the extra-cellular environment. Translocation to the cell surface is a significant stress 
response, capable of activating both innate (via toll-like receptor 4) and adaptive immune 
responses.  
 
HSP can activate both B and T lymphocytes, and anti-HSP-60 antibodies are found in all 
healthy individuals with significantly increased titres seen following bacterial infection and 
vaccination391. However, the presence of antibodies directed against self HSP-60 has also 
been associated with autoimmune diseases (including diabetes, multiple sclerosis, 
inflammatory bowel disease, lupus and rheumatoid arthritis) 392.  
 
Significant T-cell responses to bacterial infections are seen following exposure to HSP such 
as Mycobacterial HSP-65, identical to human HSP-60, foreign HSP-60 is a dominant T-cell 
antigen. HSP-60 expressed on the surface of activated T-cells has also been shown to be 
associated with increased pro-inflammatory CK production. High concentrations of HSP-60 
suppress regulatory T-cells391.  
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Therefore, as HSP has been associated with T-cell mediated disease, foreign HSP can act as 
T-cell stimuli, and HSP may have an impact on T-regs, it is possible that foreign (allo) HSP 
may act as a minor histocompatibility antigen.  As we have demonstrated that KIR2DS2 is 
associated with GvHD a T-cell mediated disease and there is data, which suggests that HSP-
60 is a ligand for this molecule, it is possible that donor KIR2DS2 positive cells react against 
HSP-60 and that this may be involved in GvHD pathogenesis.    
 
Whilst there is no published data on the role of HSP-60 in GvHD, there is preliminary data to 
suggest that HSP plays a role in the GvHD process. HSP-70 has been shown to correlate with 
severe aGVHD in both animal and human models (Goral 1998, Jarvis 2003)401-3. In a human 
skin explant GvHD prediction model, inducible expression of HSP-70 was associated with 
GvHD (both acute and chronic) and was independent of GVHD prophylaxis. Importantly, HSP 
expression preceded tissue damage, suggest a role for HSP-70 in inducing or facilitating 
GVHD. HSP-70 stimulates pro-inflammatory cytokine release from monocytes including IL-1-
β, TNF-α, and IL-6 (Asea)404 . It is possible that HSP-70 may form HSP-MHC complexes which 
directly stimulate cytotoxic T-cell responses or indirectly by chaperoning foreign peptides to 
antigen presenting cells (APC). An alternative explanation is that HSP-70 may bind cellular 
receptors on T cells such as KIR molecules as has been described for HSP-60. Antibodies 
directed against HSP-70 (anti-hsp70) and HSP-90 (anti-hsp90) have been demonstrated in 
patients with acute and chronic GVHD (Goral 2000)484. 
 
 
 
Therefore, we sought to determine if the increased mRNA expression seen in the data 
discussed predicted for increased KIR2DS2 expression at the cell surface, and to attempt to 
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determine if this preferential KIR2DS2 expression on CD4+ CD28 null cells is also applicable 
to CD8+ CD28null T-cells.  
 
 
 
Fresh PBMC from 12 KIR2DS2 positive (KIR2DL3 negative) individuals were isolated (as 
described in chapter 2) and surface staining for anti-CD56 and anti-CD3 performed in order 
to identify the T-cell population. Co-staining with anti-CD4 and anti-KIR2DS2/DL2 was also 
performed concomitantly. CD8+ T-cells were derived by the subtraction of the CD4+ T-cell 
population from the total T-cell subset.  
 
The mean percentage of CD4+ T-cells co-expressing CD28 and which were CD28 null were 
97.47% (range: 92.6 – 99.9; 95% CI:  95.78 – 99.15) and 2.53% (range: 0.08 – 7.4; 95% CI:  
0.84 – 4.21), respectively. The mean percentage of cells positive and negative for CD28 in 
the CD8+ T-cell fraction were 65.12% (range: 44.7 – 81.8; 95% CI:  58.39 – 71.84) and 
10.59% (range: 18.20 – 53.50; 95% CI:  28.14 – 41.61) respectively. The mean percentage of 
CD4+ CD28null cells expressing KIR2DS2/DL2 was 9.64% (range: 1.8 – 29.8; 95% CI:  3.82– 
15.46) as compared to 0.40% (range: 0.2 – 0.83; 95% CI:  0.27 – 0.53) in cells co-expressing 
CD28 (P=0.0048). Similarly, as significant difference was also found with regard to 
KIR2DS2/DL2 expression between CD8+ T-cells dependent upon CD28 expression status; the 
mean percentages of KIR2DS2/DL2 expressing cells in the CD8+ CD28null and CD8+ 
CD28positive fractions were 11.69% (range: 3.5 – 35.8; 95% CI:  5.86 – 17.50) and 1.71% 
(range: 0.42 – 2.5; 95% CI:  0.74 – 01.59) respectively (P=0.0019). This data confirmed that 
CD28 null cells produce more KIR2DS2/DL2 than CD28+ T-cells. (Figure 5.23 and Table 5.12) 
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Table 5.12: The percentage of both CD4+ and CD8+ T-cells co-expressing CD28 and 
CD28null were determined using surface staining in 12 KIR2DS2 positive individuals. For 
both subsets the percentage of cells also surface positive for KIR2DS2/DL2 was 
determined. CD4+ and CD8+ cells null for CD28 expressed significantly more KIR2DS2/DL2 
than their CD28 expressing counterparts.  Figure 5.23: T-cells negative for CD28 express 
significantly less KIR2DS2/DL2/ than CD28 positive T-cells.  
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We then compared IFN-  production in KIR2DS2/DL2 positive T-cells directly with that of 
their KIR2DS2/DL2 negative counterparts following stimulation with human HSP-60.  In total 
fresh T-cells from 5 healthy controls were evaluated for IFN-  production capacity. The 
percentage of IFN-  producing T-cells KIR2DS2/DL2 positive and negative cells was 
determined: The mean percentage of KIR2DS2/DL2 positive T-cells expressing IFN-  was 
0.85% (range 0.6% – 11.2%; 95% CI: -2.0 – 6.9) as compared to 0.39% (range 0.18% – 0.90%; 
95% CI: 0.40 - 0.70) in KIR2DS2/DL2 negative cell (P=0.0313). An individual example is shown 
in 5.24). Work is underway to expand these numbers further and to determine if this 
difference seen in ‘bulk’ T-cells is also evident in both CD4+ and CD8+ T-cells. Further 
experiments using human HSP-70 stimulation are also planned.  
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Figure 5.24: Example of the intracellular expression of IFN-  in T-cells following 
stimulation with heat shock protein 60KDa (HSP-60) in a KIR2DS2/DL2 positive healthy 
control. A: Negative control B: T-cells express following incubation with purified human 
HSP-60. C: KIR2DS2/DL2 (B) expressing cells produce more IFN-  than KIR2DS2/DL2 
negative T-cells(C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion  
 
These data confirm the existence of a subset of T-cells, determined by a lack of co-
expression of CD28, that have increased KIR2DS2/DL2 expression. Previous data have 
described this phenomenon using quantification of KIR2DS2 mRNA in CD4+ T-cells. Here we 
further describe that CD28null T-cells do have significantly increased KIR2DS2 cell surface 
expression on CD4+ but also on CD8+ T-cells as compared to the corresponding CD28+ cell 
population. Earlier in this chapter we described a more pro-inflammatory cytokine profile 
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for KIR2DS2/DL2 expressing T-cells (and NK cells) with respect to IFN- , TNF- , MIP1 
proteins together with a reduction in IL-2 required for the generation of T-regs. It is possible 
that the relative increased expression of KIR2DS2/DL2 on CD28 null T-cells defines them as 
deleterious pro-inflammatory subset. Data suggest this from studies in both ACS and 
rheumatoid arthritis. With this in mind and our clinical data on KIR2DS2 (above), CD28null 
KIR2DS2/DL2 positive T-cells may play an important role in the generation of aGvHD 
following stem cell transplantation. As KIR2DS2/DL2 (molecularly) positive T-cells have been 
shown to interact with HSP-60, implicates this protein in GvHD. It is possible that transplant 
conditioning results up-regulation of HSP which stimulates KIR2DS2 positive T-cells directly 
to produce pro-inflammatory cytokines which are important in aGvHD pathogenesis, or 
alternatively that recipient APCs present host HSP, which has subtle differences to donor 
HSP, thus generating an allo-reactive process.  
 
 
 
Conclusion  
In this chapter we have described the association of KIR2DS2/DL2 genotype with the 
increased incidence and severity of acute graft versus host disease, the major cause of 
mortality following an allogeneic stem cell transplant. This genotype association was 
however lost following T-cell depletion using in-vivo anti-CD52 (Campath 1-H). The use of 
Campath 1-H is also likely to significantly reduce the NK cell population in the incoming stem 
cell graft. These data suggest that T-cells and / or NK cells, which express KIR2DS2/DL2 on 
their surface, are more adept at inducing a GvHD process than corresponding non-
KIR2DS2/DL2 expressing cell populations. Further, the demonstration that a donor 
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KIR2DS2/DL2 positive genotype is not associated with improved disease free survival 
suggests the possibility that KIR2DS2/DL2 positive cells may be specific effectors of GvHD 
but are not involved in the GvL effect. This would suggest that such cells are purely 
deleterious in the post transplant setting.  
 
This hypothesis is further supported by our laboratory determination that KIR2DS2/DL2 
positive T-cells and NK cells have a significantly greater capacity for the production of 
cytokines namely IFN-  and TNF-  following activation, cytokines which are directly 
associated with aGvHD. In addition, these cells also produce significantly more MIP1-  and 
MIP-1  proteins, which also have been linked to aGvHD. This also suggests the possibility of 
an amplification loop by which KIR2DS2/DL2 cell derived TNF-α, and IFN-γ induce MIP-1 up-
regulation by the same cells. This would form the basis for further investigation. The fact 
that IL-4 and IL-10, which are associated with reduced GvHD down regulate MIP-1 
expression is also interesting.  
 
This would imply that the action of KIR2DS2/DL2 positive cells in inducing inflammation is 
important at the tissue level. The discovery that KIR2DS2/DL2 cells produce less IL-2 than 
their negative counterparts supports such a theory. Whilst IL-2 has a known pro-
inflammatory role, it also is essential for the generation of regulator T-cells. The role of 
these T-regs is the amelioration and limitation of the allo-reactive process. Therefore the 
relative lack of KIR2DS2/DL2 positive T-cell IL-2 favours a skewing toward the generation of 
an aGvHD process. We have also shown that KIR2DS2/DL2 is found expressed at the cell 
surface significantly more frequently on CD28null T-cells, which have previously been 
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described to have a more pro-inflammatory phenotype (with respect to IFN-  production). 
This may further define the specific KIR2DS2/DL2 positive cell phenotype.  
 
Finally if KIR2DS2/DL2 cells are GvHD effectors the question arises as to what is the 
potential (allo) antigen, which activates them? Here we confirm the previous finding that 
KIR2DS2/DL2 positive cells are stimulated to produce IFN-  by exposure to HSP, a protein 
which is potentially increased following transplant conditioning and has previously been 
suggested to be involved aGvHD. Further work is required to evaluate all the different 
cytokine productions following HSP stimulation of KIR2DS2/DL2 positive cells. These 
however data all support the further investigation of the role of KIR2DS2/DL2 in GvHD.  
 
However, there are a number of limitations to this study. The first is that the only available 
Mab for detecting KIR2DS2/DL2, which does not recognise pan-KIR molecules, unfortunately 
cannot distinguish KIR2DS2/DL2 from KIR2DL3. This confounder was eliminated by selecting 
KIR2DS2/DL2 positive, KIR2DL3 negative healthy controls. However whilst the clinical data 
suggests only KIR2DS2/DL2 is involved in aGvHD, all KIR molecules should be evaluated for 
cytokine production as more than one KIR molecule exists on the surface of NK and T-cells. 
This will need to be approached by the selection and evaluation of specific KIR positive 
clones (by mRNA detection) as the current Mab technology is not specific enough. In the 
same way, whilst we investigated KIR2DS2/DL2 positive KIR2DL3 negative individuals we 
were unable to establish if the effect we have demonstrated is related to KIR2DS2 or 
KIR2DL2. Although as these molecules have significant linkage disequilibrium it would be 
expected that lymphocytes are highly likely to express both molecules and as such depletion 
technology would remove both cell surface molecules. The selection of NK clones on the 
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basis of mRNA expression and subsequent expansion prior to investigation has lead to 
preliminary work on the expansion of NK cells as described later. Investigation on a larger 
cohort of patients to confirm these findings is also required. In order to prove the 
hypothesis that KIR2DS2/DL2 cells are present at the site of GvHD, their in-situ 
histochemical demonstration is required. We have identified and retrieved from an 
independent pathology bank GvHD biopsy samples from the patients described in our 
cohort above. Initial staining experiments performed by Dr James Carton (Consultant 
histoptahologist at Imperial College Healthcare Trust, St Mary’s Hospital campus) have 
validated the Mab antibody against KIR2DS2/DL2, which is applicable for histochemistry. 
Discussions are underway with Professor K Naresh to evaluate in-situ expression of 
KIR2DS2/DL2 in patient samples. 
 
In summary, this work suggests that the role of KIR2DS2/DL2 in aGvHD induction is 
interesting and that such cells may be the basis of GvHD and GvL separation. This work, will 
be carried on by the research group.  
 
  
 
Chapter 6.  
Conclusions and future directions  
 
Natural killer cells (NK) cells are a crucial subset of human peripheral blood mononuclear 
cells consequent to their role as an important component of the innate immune system in 
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humans. As NK cells have been demonstrated to play an important role in innate immune 
responses against cancer, we were particularly interested to further investigate their role in 
determining the outcome of haematological malignancies. The demonstration that NK cells 
are crucial in the elimination and control of tumour metastases, suggests that they may be 
important in the control of circulating leukaemic cells. These data led us to consider whether 
differences in human NK cells might explain differences within humans with apparently 
identical haematological cancers, with respect to outcome following similar therapies. 
 
 One way, in which human NK cells differ between individuals, is the expression of cell 
surface receptors the down stream signals of which control their cytotoxic response to 
targets. NK cell activity is determined by the net balance of the transmitted intracellular 
signals of both activating (pro-cytotoxic) and inhibitory (anti-cytotoxicity) cell surface 
receptors. One major class of such receptor is the Killer immunoglobulin-like receptors 
(KIRs), which are found expressed on both NK cells and a subset of T-cells. The KIR gene 
cluster shows extreme polymorphism and structural diversity resulting in considerable 
diversity in the number or KIR phenotypes observed within a population. The ability of NK 
cells to kill targets appears to be at least partly dependent upon the outcome of these 
counter-balancing signals generated by KIRs.  
 
 
A number of studies have suggested a role for KIR immunogenetics in determining the risk of 
leukaemogenesis. To date, the mechanism for this remains unclear. However, such data 
suggested to us, the possibility that certain NK cells expressing certain KIR molecules maybe 
more adept at recognizing and eliminating early transformed malignant cells than other NK 
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sub clones lacking such receptors. With this in mind, we decided to determine if KIR 
immunogenetics could predict the outcome of patients with CML treated with tyrosine 
kinase inhibitors (TKI), as differing responses might be consequent on divergent KIR 
genotypes. The choice of CML as the malignant disease of investigation resulted from two 
important findings. Firstly that NK cells have the capability for killing CML progenitor cells, 
and in certain circumstances quiescent CD34+ Philadelphia (Ph) positive cells, and secondly 
the finding that NK cells are expanded in patients treated with tyrosine kinase inhibitors 
(TKI). It is possible that effector actions of NK cells maybe be important in determining the 
outcome of patients with CML treated with TKI in addition to the direct inhibition of BCR-Abl.  
 
Whilst TKI (Imatinib) has shown considerable success in CML, its use does not result in long-
term disease control in all patients.  The 5-year cumulative incidence of CCyR and MMR 
being just 82.7% and 50.1%, suggestive that despite its efficacy in a majority of patients, 
approximately a third will have a sub-optimal response. Whilst drug intolerance and BCR-Abl 
mutations explain a proportion of these treatment failures, a significant number remain 
unexplained. It is possible that differences in NK cell mediated killing might be an important 
contributing factor.  
 
Using KIR genotype and HLA typing technique, and combining this data with outcome data 
on 166 consecutive adult patients with CML in first chronic phase, who received Imatinib 
(IM) as first line therapy, we demonstrated the presence of KIR2DS1 (RR=1.51, p=0.03) and 
Sokal risk score (low risk RR=1, intermediate risk RR= 1.53, p=0.04 and high risk RR=1.69, 
p=0.034) were the only independent predictors for failure to achieve cytogenetic response 
CCyR.  Furthermore, the presence of KIR2DS1 alleles within a patient’s KIR repertoire was the 
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only independent predictor for shorter PFS (RR=3.1, p=0.03) and OS (RR=2.6, p=0.04). This 
important finding was then validated in a further 174 CML-CP patients treated in a multi-
centre IM trial, this also demonstrated highly significant inferior CCyR PFS, and OS rates in 
KIR2DS1 positive as compared to KIR2DS1 negative patients: 76.9% vs 87.9% (therapy 
stratified log-rank test =0.003), 85.3% vs 98.1% (P=0.007) and 94.4% vs 100% (P=0.015) 
respectively. Again KIR2DS1 positivity remained the only independent predictor for all three 
outcomes. The impact of KIR2DS1 on CCyR was more significant when the ligand for the 
corresponding inhibitory receptor, KIR2DL1, was absent.  
 
We believe, that these findings demonstrate that KIR-HLA immunogenetics are a novel 
prognostic tool for patients with CML-CP on IM, and it is possible that KIR2DS1 positivity 
may identify patients at greater risk for treatment failure. This may have an important 
clinical relevance in that such patients may benefit from more frequent monitoring and an 
early change to a different TKI. 
 
 
 
The relevance of this data can be seen to be important in the light of additional work done 
by a colleague on the background of the above work (S Ali, Blood 2012). In her follow up 
study, she Investigated 130 patients with CML in CP treated with first-line Dasatinib on the 
UK multi-centre trial (SPIRIT 2), with the aim to determine whether KIR2DS1 also predicted 
response to treatment this second generation TKI. No significant impact of KIR genotype on 
outcome was demonstrated suggesting that Dasatinib may overcome the negative 
prognostic impact of KIR2DS1 in newly diagnosed patients with CML in CP. Taken together 
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these data provide a rationale for genotyping CML patients at diagnosis, to identify KIR2DS1 
positive patients at greater risk of treatment failure with IM. These patients who constitute 
nearly 30% of the CML patient population may benefit from upfront treatment with 
Dasatinib.  
 
The mechanism by which KIR2DS1 predicts for inferior outcome is unclear; these have been 
discussed in the relevant chapter (Chapter 3). The elucidation of potential mechanisms will 
be the basis for ongoing work. Due to the changing referral patterns of patients with CML, 
tertiary centres do not routinely see patients failing first line therapy. However we have 
instigated a collection of PBMC from such patients to evaluate if KIR2DS1 positive cells are 
in fact expanded in patients who do not respond to IM relative to good responders. This 
work remains ongoing with a prospective collection of patient PMBC. Sample size at present 
is limited and no conclusions can be drawn, however we have demonstrated a number of 
patients with sub-optimal response to IM with increased KIR2DS1 sub-clones. An example of 
one such patient is shown below.  
 
Figure 6.1. An example of KIR2DS1 positive NK cells (CD56+, CD3-) in a patient with CML in 
CP with sub-optimal response to Imatinib. The KIR2DS1 fraction is (circled red) is 30%, 
which is elevated compared to the published normal range of 7 – 15%.  
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Following our findings in the context of CML, we believe that KIR immunogenetics are 
important in the outcome of haematological (non-solid) tumours. These data together with 
the knowledge that the NK cell is the most predominant cell type early in haematopoeitic 
reconstitution following both autologous and allogeneic stem cell transplantation, we 
postulated that KIR immunogenetics might exert even greater influence on outcome 
following SCT when their effector function predominates. Indeed, KIR immunogenetics have 
been previously been shown to be significantly associated with disease outcome in the 
context of both haplo-identical and HLA identical SCT (see chapter 1). However, there was a 
paucity of data regarding KIR in the context of autologous stem cell transplant.  
 
Therefore, we chose to investigate the influence of KIR / HLA immunogenetics on the 
outcome of a haematological malignancy following ASCT. This malignancy we selected was 
multiple myeloma (MM). MM was selected for investigating the role of KIR / HLA 
immunogenetics in ASCT for a number of reason. ASCT is not routinely performed for CML 
but is standard consolidation therapy for patients with MM. Further, MM is similarly to CML 
very sensitive to immunological attack as evidenced by the effectiveness of a graft versus 
myeloma effect following allo-SCT, autologous NK cells have been shown by a number of 
investigators to be able to kill malignant plasma cells. 
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Therefore, we investigated 182 patients with multiple myeloma MM with respect to KIR and 
HLA repertoire. On a multivariate analysis, we demonstrated that KIR3DS1 positivity was the 
most significant factor for PFS in patients with good risk disease (GR; complete or partial 
remission at ASCT) but not in those with poor-risk disease. We showed that GR patients who 
are KIR3DS1 negative have a median PFS of 24 months compared with 15.3 months for 
those who are KIR3DS1 positive (P=0.003). Importantly, the median PFS for patients with GR 
disease who were KIR3DS1 positive was not significantly different from those with PD (15.4 
months) or chemo- refractory disease (11.1 months) (P=0.061) These findings highlighted 
the importance of the predictive value of KIR3DS1 in determining outcome following ASCT. 
Following this data we subdivided the patients into 3 groups on the basis of on KIR3DS1 and 
KIR3DL1 genotype and HLA-Bw4 status, and subsequently we determined that the most 
significant difference in PFS was seen in GR KIR3DS1+ patients in whom HLA-Bw4, the ligand 
for the corresponding inhibitory receptor KIR3DL1, was missing such that KIR3DS1+ 
KIR3DL1+ HLA- Bw4- patients had a significantly shorter PFS compared to patients who were 
KIR3DS1 negative. This translated to a highly significant difference in median PFS of 12 
months.  
 
This data demonstrate that the presence of KIR3DS1 a gene with a frequency of greater than 
30% in the general population may identify patients at greater risk of progression following 
ASCT. This may have an important clinical relevance in that KIR3DS1 positive individuals may 
benefit from different transplant strategies such as the incorporation of never novel anti-
MM agents into transplant conditioning regimens and early consideration of younger 
KIR3DS1 positive patients for allo-SCT in the context of a clinical trial.  
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The mechanism by which the KIR gene products exert their effect is not yet clear, Individual 
NK clones expressing a specific array of receptors have been shown to respond differently to 
diverse viral infections, therefore it is conceivable that in myeloma, depending on receptor 
expression and ligand engagement, different NK clones may exert divergent responses 
against the tumour including those which promote tumour cell survival. The interaction of 
specific KIR with myeloma derived epitopes is interesting concept and is a potential avenue 
for further work. Further, whilst adoptive NK therapy following ASCT is under evaluation in 
the context of a number of ongoing clinical trials, it may be that the negative selection of 
specific NK, relevant to the malignancy for which the patient being transplanted, may allow 
for a more effective use of this approach.  
 
Our demonstration that divergent KIR genotype is associated with divergent responses to 
tumour, together with previous data suggesting that KIR genotype can predict disease 
response post allo-SCT, we surmised that such findings may in part be due to divergent 
responses following interaction with tumour antigens. With this in mind, it is also possible 
that certain KIR molecules on donor T and NK cells might also interact with allogeneic 
antigens in the recipient after SCT, and that this might potentially result in the generation of 
a graft versus host disease type response. We therefore went on to analyse donor KIR 
repertoire and acute graft versus host disease association (aGvHD).  
 
We described a significant association of KIR2DS2/DL2 genotype with the increased 
incidence and severity of aGvHD, the major cause of mortality following an allogeneic stem 
cell transplant. Furthermore, we found that this genotype association was lost following T-
cell (and NK cell) depletion using in-vivo anti-CD52 (Campath 1-H) which further 
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strengthened the hypothesis that KIR expressing T and / or NK cells are directly involved in 
the GvHD process. Further, the demonstration that a donor KIR2DS2/DL2 positive genotype 
is not associated with improved DFS, suggests the possibility that KIR2DS2/DL2 positive cells 
may be specific effectors of GvHD but not involved in a graft versus leukaemia (GvL) effect. 
This would suggest that such cells are purely deleterious in the post transplant setting 
 
Therefore, we attempted to demonstrate that KIR2DS2/DL2 expressing T-cells and / or NK 
cells had a more pro-GvHD effector phenotype than their corresponding non-KIR2DS2/DL2 
expressing cell populations. Using intracellular cytokine (ICC) staining techniques following 
the stimulation of T and NK cells, we demonstrate that such cells (KIR2DS2/DL2 positive) 
have a significantly greater capacity for the production of cytokines, namely IFN-  and TNF- , 
which are directly associated with aGvHD. We further demonstrated that the same cells 
produce significantly more MIP1-  and MIP-1 , proteins, also linked to aGvHD. As MIP-1 
proteins are known to be chemotactic for effector T-cells, this suggested the possibility of an 
amplification loop by which KIR2DS2/DL2 cell derived TNF-α, and IFN-γ induce MIP-1 up-
regulation by the same cells attracting more effector cells to the site of the GvH reaction 
 
These data suggested that cells expressing KIR2DS2/DL2 were important at the tissue level. 
Further data was able to strengthen this hypothesis as we showed that KIR2DS2/DL2 
expressing T-cells produce less interleukin-2 (IL-2) than their negative counterparts. IL-2 is 
essential for the generation of regulator T-cells (T-regs). The role of these T-regs is the 
amelioration and limitation of the allo-reactive process. Therefore, the relative lack of 
KIR2DS2/DL2 positive T-cell derived IL-2 favours a skewing toward the generation of an 
aGvHD process. We also strengthened previous findings of increased KIR2DS2/DL2 mRNA in 
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CD28null T-cells by the determination of the protein at the cellular level, which may further 
define the specific KIR2DS2/DL2 positive cell phenotype. Finally we suggested a potential 
(allo), which may activate these KIR2DS2/DL2 cells by the demonstration that KIR2DS2/DL2 
positive T-cells preferentially express IFN-  after interaction with HSP-60, which is known to 
be elevated in the immediate post transplant setting. These data all support the further 
investigation of the role of KIR2DS2/DL2 in GvHD. In summary, this work suggests that the 
role of KIR2DS2/DL2 in aGvHD induction is interesting and that such cells may be the basis of 
GvHD and GvL separation. This work, will be carried on by the research group. We have an 
ongoing prospective collection of PBMC from KIR2DS2/DL2 positive patients diagnosed with 
aGvHD in order to evaluate the expansion of donor KIR2DS2/DL2 NK and T-cells relative to 
baseline at the time of a GvH response. Accrual is slow and this remains ongoing.  
 
 
 
 
In summary, we demonstrate that KIR genotype predict both the response to targeted 
therapy in CML, that the role of KIR is also important in disease control during 
haematopoeitic reconstitution following ASCT. Finally we demonstrate certain KIR molecules 
associate with increased incidence and severity of aGvHD, this association is dependent on 
the lymphocyte population, and is mediated by the increased propensity to produce TNF-α, 
IFN-γ, MIP1- , and MIP-1  and a reduction in IL-2 (an important regulator anti-GvHD T-regs).  
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